<SEC-DOCUMENT>0001178913-23-002834.txt : 20230811
<SEC-HEADER>0001178913-23-002834.hdr.sgml : 20230811
<ACCEPTANCE-DATETIME>20230811161939
ACCESSION NUMBER:		0001178913-23-002834
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		41
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230811
DATE AS OF CHANGE:		20230811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		231164415

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>zk2330106.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:entx="http://www.enterabio.com/20230630" xmlns:ecd="http://xbrl.sec.gov/ecd/2023"  >
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
  <title>Entera Bio Ltd. - 1638097 - 2023</title>
</head>
<body><div style="font-size: 10pt;">

<div style="display:none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="C_20230101to20230630" id="F20230807213857684_19" >00-0000000</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808213523162" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808214535386" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20220808214614689" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230430155759086" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731140510423_xbrl_20220808213523162" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141710655_xbrl_20220808214535386" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141713727_xbrl_20220808214535386" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141740672_xbrl_20230430155759086" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141742631_xbrl_20230430155759086" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:footnote id="FN20230430155729802" xml:lang="en-US">Represents an amount less than one thousand U.S. dollars.</ix:footnote>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20230630" id="Fxbrl_20220808213249447" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="C_20221231" id="Fxbrl_20220808214617486" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="C_20230630" id="Fxbrl_20230426051024328" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" id="Fxbrl_20230426051028683" unitRef="USD" xsi:nil="true"></ix:nonFraction>
    <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20230101to20230630" id="Fdei_EntityCentralIndexKey20220219150840900" >0001638097</ix:nonNumeric>
    <ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20230101to20230630" id="Fdei_AmendmentFlag20220219150858854" >false</ix:nonNumeric>
    <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20230101to20230630" id="Fdei_DocumentFiscalPeriodFocus20220219151109286" >Q2</ix:nonNumeric>
    <ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="C_20230101to20230630" id="Fdei_CurrentFiscalYearEndDate20220506104715921" >--12-31</ix:nonNumeric>
    </ix:hidden>
  <ix:references> <link:schemaRef xlink:type="simple" xlink:href="entx-20230630.xsd"/>
    </ix:references>
  <ix:resources>
    <xbrli:context id="C_20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">entx:OfficeLeaseAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-04-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">entx:OfficeLeaseAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">entx:OfficeLeaseAgreementMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-04</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:SixNonExecutiveBoardMembersMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-02</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230807">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-08-07</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220630">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period> <xbrli:instant>2018-07-31</xbrli:instant>
        </xbrli:period>
      </xbrli:context>
    <xbrli:context id="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001638097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          </xbrli:segment>
        </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-07-31</xbrli:endDate>
        </xbrli:period>
      </xbrli:context>
    <xbrli:unit id="NIS_per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unit>
    <xbrli:unit id="USD_per_Share"><xbrli:divide>
      <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator>
      <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide>
      </xbrli:unit>
    <xbrli:unit id="shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unit>
    <ix:relationship fromRefs="Fxbrl_20220808213523162" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20220808214535386" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20220808214614689" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230430155759086" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731140510423_xbrl_20220808213523162" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141710655_xbrl_20220808214535386" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141713727_xbrl_20220808214535386" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141740672_xbrl_20230430155759086" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141742631_xbrl_20230430155759086" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162" toRefs="FN20230430155729802"/>
    <ix:relationship fromRefs="Fxbrl_20220808213249447" toRefs="FN20220809041142326"/>
    <ix:relationship fromRefs="Fxbrl_20220808214617486" toRefs="FN20220809041142326"/>
    </ix:resources>
  </ix:header></div>

<div>

<div style="">

<div>

<div>

<div>

<div style="line-height:1.25;font-family:'Times New Roman'"> <hr style="border:none;border-bottom:1px solid black;border-top:4px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" />

<div style="text-align:justify;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25">

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span><span style="font-family:Times New Roman,Times,serif">UNITED
STATES</span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span><span style="font-family:Times New Roman,Times,serif">SECURITIES
AND EXCHANGE COMMISSION</span></span></span></div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">WASHINGTON,
D.C. 20549</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:14pt;font-weight:bold"><span style="font-size:14pt"><span><span style="font-family:Times New Roman,Times,serif">FORM
<ix:nonNumeric id="F20230807213857678_0" name="dei:DocumentType" contextRef="C_20230101to20230630">10-Q</ix:nonNumeric></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><ix:nonNumeric id="F20230807213857678_1" name="dei:DocumentQuarterlyReport" contextRef="C_20230101to20230630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></strong>&#160;<span style="font-weight:bold">QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
the quarterly period ended <span style="text-decoration:underline"><ix:nonNumeric id="F20230807213857685_25" name="dei:DocumentPeriodEndDate" contextRef="C_20230101to20230630" format="ixt:date-monthname-day-year-en">June
30, <ix:nonNumeric id="F20230807213857685_26" name="dei:DocumentFiscalYearFocus" contextRef="C_20230101to20230630">2023</ix:nonNumeric></ix:nonNumeric></span></span></span>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div> </div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">OR</span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span><ix:nonNumeric id="F20230807213857679_2" name="dei:DocumentTransitionReport" contextRef="C_20230101to20230630" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></strong>&#160;<span style="font-weight:bold">TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For
the transition period from </span></span><span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">to
</span></span><span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Commission
file number: <ix:nonNumeric id="F20230807213857679_3" name="dei:EntityFileNumber" contextRef="C_20230101to20230630">001-38556</ix:nonNumeric></span></span></div>

<div style="line-height:1.25;font-weight:bold">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-size:16pt;font-weight:bold"><span style="font-size:16pt"><span><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857684_20" name="dei:EntityRegistrantName" contextRef="C_20230101to20230630">ENTERA
BIO LTD.</ix:nonNumeric></span></span></span></div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Exact
name of Registrant as specified in its charter)</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:49.01%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857684_18" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20230101to20230630" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:49%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:F20230807213857684_19">Not
        applicable</span></span></span></div> </td> </tr>
  <tr>
    <td style="width:49.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(State
        or other jurisdiction of</span></span></div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:49%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(I.R.S.
        Employer</span></span></div> </td> </tr>
  <tr>
    <td style="width:49.01%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">incorporation
        or organization)</span></span></div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:49%;vertical-align:top">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Identification
        No.)</span></span></div> </td> </tr>
  </table>

<div style="text-align:left;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:49.01%;vertical-align:bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857679_4" name="dei:EntityAddressAddressLine1" contextRef="C_20230101to20230630">Kiryat
        Hadassah</ix:nonNumeric></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857679_5" name="dei:EntityAddressAddressLine2" contextRef="C_20230101to20230630">Minrav
        Building &#8211; Fifth Floor</ix:nonNumeric></span></span></div> </div> </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:49%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25">&#160;</div> </td> </tr>
  <tr>
    <td style="width:49.01%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857680_6" name="dei:EntityAddressCityOrTown" contextRef="C_20230101to20230630">Jerusalem</ix:nonNumeric>,
        <ix:nonNumeric id="F20230807213857683_17" name="dei:EntityAddressCountry" contextRef="C_20230101to20230630" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:49%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857680_7" name="dei:EntityAddressPostalZipCode" contextRef="C_20230101to20230630">9112002</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:49.01%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Address
        of principal executive offices)</span></span></div> </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:49%;vertical-align:bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Zip
        Code)</span></span></div> </td> </tr>
  </table>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Registrant&#8217;s
telephone number, including area code: <ix:nonNumeric id="F20230807213857681_8" name="dei:CityAreaCode" contextRef="C_20230101to20230630">972</ix:nonNumeric>-<ix:nonNumeric id="F20230807213857682_9" name="dei:LocalPhoneNumber" contextRef="C_20230101to20230630">2-532-7151</ix:nonNumeric></span></span></div>

<div style="line-height:1.25;text-align:left">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Securities
registered pursuant to Section 12(b) of the Act:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:32.01%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Title
        of Each Class</span></span></div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:32%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trading
        Symbol</span></span></div> </td>
    <td style="width:2%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Name
        of Each Exchange on Which Registered</span></span></div> </td> </tr>
  <tr>
    <td style="width:32.01%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857682_10" name="dei:Security12bTitle" contextRef="C_20230101to20230630">Ordinary
        Shares</ix:nonNumeric>, par value NIS 0.0000769 per share</span></span></div> </td>
    <td style="width:2%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857682_11" name="dei:TradingSymbol" contextRef="C_20230101to20230630">ENTX</ix:nonNumeric></span></span></div>
        </td>
    <td style="width:2%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:32%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857683_14" name="dei:SecurityExchangeName" contextRef="C_20230101to20230630" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric>
        Capital Market</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. </span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857685_24" name="dei:EntityCurrentReportingStatus" contextRef="C_20230101to20230630">Yes</ix:nonNumeric>&#160;<span>&#9746;</span>&#160;
&#160;No&#160;&#160;<span>&#9744;</span></span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). </span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857682_12" name="dei:EntityInteractiveDataCurrent" contextRef="C_20230101to20230630">Yes</ix:nonNumeric>&#160;<span>&#9746;&#160;&#160;</span>
No&#160;&#160;<span>&#9744;</span></span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></span></div>

<div style="text-align:left;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Large accelerated filer</span></span></div>
        </td>
    <td style="width:45%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
        </td>
    <td style="width:33%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accelerated filer</span></span></div>
        </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9744;</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857685_23" name="dei:EntityFilerCategory" contextRef="C_20230101to20230630" format="ixt-sec:entityfilercategoryen">Non-Accelerated
        filer</ix:nonNumeric></span></span></div> </td>
    <td style="width:45%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#9746;</span></span></div>
        </td>
    <td style="width:33%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Smaller reporting company</span></span></div>
        </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857682_13" name="dei:EntitySmallBusiness" contextRef="C_20230101to20230630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:20%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:45%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:33%;vertical-align:bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Emerging growth company</span></span></div>
        </td>
    <td style="width:2%;vertical-align:bottom">
        <div style="line-height:1.25;font-family:'Segoe UI Symbol', sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="F20230807213857683_16" name="dei:EntityEmergingGrowthCompany" contextRef="C_20230101to20230630" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span></span></div>
        </td> </tr>
  </table>

<div style="text-align:left;line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span><ix:nonNumeric id="F20230807213857684_21" name="dei:EntityExTransitionPeriod" contextRef="C_20230101to20230630" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span></span></span></div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) </span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Yes&#160;<span>&#9744;&#160;</span>
No <span><ix:nonNumeric id="F20230807213857685_22" name="dei:EntityShellCompany" contextRef="C_20230101to20230630" format="ixt:fixed-false">&#9746;</ix:nonNumeric></span></span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">&#160;</div>

<div style="text-align:left;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:normal">

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of August 7, 2023, the registrant had <ix:nonFraction id="F20230807213857683_15" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20230807" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,813,952</ix:nonFraction>
ordinary shares, par value NIS 0.0000769 per share (&#8220;Ordinary Shares&#8221;) outstanding. </span></span><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal">&#160;</span></span></span></div>
</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div> </div>

<div style="line-height:1.25;font-weight:bold">

<div style="line-height:1.25;font-weight:bold;text-align:center"><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Table
of Contents</span></span></span></div>

<div>&#160;</div>

<div>

<table border="0" cellpadding="1" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:8%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:84%;vertical-align:bottom">
        <div style="text-align:justify;line-height:1.25">&#160;</div> </td>
    <td style="width:8%;vertical-align:bottom;border-bottom:#000000 2px solid">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div>
        </td> </tr>
  <tr>
    <td colspan="2" rowspan="1" style="width:8%;vertical-align:middle">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CAUTIONARYSTATEMENTREGARD_integixAnchor">CAUTIONARY
        STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></span></span></div> </td>
    <td rowspan="1" style="width:8%;vertical-align:middle;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1</span></span></td>
        </tr>
  <tr>
    <td colspan="2" rowspan="1" style="width:8%;vertical-align:middle">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTI_integixAnchor"><span style="font-weight:bold">PART
        I &#8211; FINANCIAL INFORMATION</span>&#160;</a></span></span></div> </td>
    <td rowspan="1" style="width:8%;vertical-align:middle;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></td>
        </tr>
  <tr>
    <td style="width:8%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="width:84%;vertical-align:middle">
        <div style="text-align:justify;line-height:1.25">&#160;</div> </td>
    <td style="width:8%;vertical-align:middle">
        <div style="line-height:1.25;text-align:center">&#160;</div> </td> </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTI_integixAnchor">Item
        1.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTI_integixAnchor">Financial
        Statements</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS_integixAnchor">Condensed
        Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FOPERATIONS_integixAnchor">Condensed
        Consolidated Statements of Operations for the three and six months ended June 30, 2023 and 2022 (unaudited)</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ERSEQUITY_integixAnchor">Condensed
        Consolidated Statement of Changes in Shareholders&#8217; Equity for the three and six months ended June 30, 2023 and 2022 (unaudited)</a></span></span></div>
        </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS_integixAnchor">Condensed
        Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022 (unaudited)</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25">&#160;</div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#NOTE1_integixAnchor">Notes
        to Condensed Consolidated Financial Statements (unaudited)</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">8</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ITEM2MAN_integixAnchor">Item
        2.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ITEM2MAN_integixAnchor">Management's
        Discussion and Analysis of Financial Condition and Results of Operations</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#TEM3_integixAnchor">Item
        3.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#TEM3_integixAnchor">Quantitative
        and Qualitative Disclosures About Market Risk</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#TEM3_integixAnchor">Item
        4.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#TEM3_integixAnchor">Controls
        and Procedures</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">24</span></span></td>
        </tr>
  <tr>
    <td colspan="3" style="background-color:#FFFFFF;vertical-align:middle;width:100%">
        <div style="line-height:1.25">&#160;</div> </td> </tr>
  <tr>
    <td colspan="2" rowspan="1" style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor"><span style="font-weight:bold">PART
        II &#8211; OTHER INFORMATION</span>&#160;</a></span></span></div> </td>
    <td rowspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25
        </span></span></td> </tr>
  <tr>
    <td rowspan="1" style="background-color:#FFFFFF;vertical-align:top;width:8%">&#160;</td>
    <td rowspan="1" style="background-color:#FFFFFF;vertical-align:bottom;width:84%">&#160;</td>
    <td rowspan="1" style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center">&#160;</td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Item
        1.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Legal
        Proceedings</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25
        </span></span></td> </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Item
        1A.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Risk
        Factors</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Item
        2.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Unregistered
        Sales of Equity Securities and Use of Proceeds</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Item
        3.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Defaults
        Upon Senior Securities</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Item
        4.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Mine
        Safety Disclosures</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Item
        5.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#PARTII_integixAnchor">Other
        Information</a></span></span></div> </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></td>
        </tr>
  <tr>
    <td style="background-color:#FFFFFF;vertical-align:top;width:8%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ITEM6E_integixAnchor">Item
        6.</a></span></span></div> </td>
    <td style="background-color:#FFFFFF;vertical-align:bottom;width:84%">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#ITEM6E_integixAnchor">Exhibits</a></span></span></div>
        </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">25</span></span></td>
        </tr>
  <tr>
    <td colspan="3" style="background-color:#FFFFFF;vertical-align:middle;width:100%">&#160;</td> </tr>
  <tr>
    <td colspan="2" style="background-color:#FFFFFF;vertical-align:top;width:92%">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SIGNATURES_integixAnchor">SIGNATURES</a></span></span></div>
        </td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">26</span></span></td>
        </tr>
  <tr>
    <td colspan="2" style="background-color:#FFFFFF;vertical-align:top;width:92%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);vertical-align:bottom;white-space:nowrap;width:8%;text-align:center">&#160;</td> </tr>
  </table> </div> </div> </div>

<div style="clear:both;margin-top:0pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div>

<div style="line-height:1.25;font-family:'Times New Roman'">

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="CAUTIONARYSTATEMENTREGARD_integixAnchor"></span>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:24.5pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>This
Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking statements,&#8221; as that term is
defined under the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section 27A of the Securities Act of 1933, as
amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
Various statements in this Quarterly Report are &#8220;forward-looking statements&#8221; within the meaning of the PSLRA and other U.S.
Federal securities laws. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that
the conclusions of future research or trials would not be different, and historic results referred to in this Quarterly Report may be
interpreted differently in light of additional research and clinical and preclinical trial results. Forward-looking statements include
all statements that are not historical facts. We have based these forward-looking statements largely on our management&#8217;s current
expectations and future events and financial trends that we believe may affect our financial condition, results of operations, business
strategy and financial needs. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements
of historical facts, included in this Quarterly Report regarding our strategy, future operations, future financial position, projected
costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties
and are based on information currently available to our management. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221;
&#8220;contemplates,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; or the
negative of these terms and similar expressions or words, identify forward-looking statements. The events and circumstances reflected
in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking
statements. These factors include those described in &#8220;Item 1A-Risk Factors&#8221; of this Quarterly Report and in &#8220;Item 1A-Risk
Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;2022 Annual Report&#8221;). Meaningful
factors which could cause actual results to differ include, but are not limited to:<br />&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Clinical development involves a lengthy and expensive
        process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to
        develop or commercialize our current and future product candidates;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The regulatory approval processes of the U.S.
        Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable,
        and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed;</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Preclinical development is uncertain. Our preclinical
        programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory
        approvals or commercialize these programs on a timely basis or at all;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Positive results from preclinical studies and
        early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be
        indicative of results obtained when the trial is completed or in later stage trials;</span></span></div> </td> </tr>
  </table> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The scope, progress and costs of developing our
        product candidates such as EB613 for Osteoporosis and EB612 for Hypoparathyroidism may alter over time based on various factors such as
        regulatory requirements, the competitive environment and new data from pre-clinical and clinical studies;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accuracy of our estimates regarding expenses,
        capital requirements, the sufficiency of our cash resources and the need for additional financing;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to continue as a going concern absent
        access to sources of liquidity;</span></span></div> </td> </tr>
  </table>&#160;

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to raise additional funds or consummate
        strategic partnerships to offset additional required capital to pursue our business objectives, which may not be available on acceptable
        terms or at all. A failure to obtain this additional capital when needed, or failure to consummate strategic partnerships, could delay,
        limit or reduce our product development, and other operations;</span></span></div> </td> </tr>
  </table> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Even if a current or future product candidate
        receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others
        in the medical community necessary for commercial success;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The successful commercialization of our product
        candidates, if approved, will depend in part on the extent to which governmental authorities and third-party payors establish adequate
        coverage and reimbursement levels and pricing policies;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div> </div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">1</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div>&#160;

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Failure to obtain or maintain coverage and adequate
        reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate
        revenue;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">If we are unable to obtain and maintain patent
        protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors
        could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates
        may be adversely affected;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We are an emerging growth company, and we cannot
        be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to
        investors;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because we do not anticipate paying any cash dividends
        on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain;</span></span></div> </td>
        </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our reliance on third parties to conduct our clinical
        trials and on third-party suppliers to supply or produce our product candidates;</span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our interpretation of FDA feedback and guidance
        and how such guidance may impact our clinical development plan;</span></span></div> </td> </tr>
  </table> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to use and expand our drug delivery
        technology to additional product candidates;</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our operation as a development stage company with
        limited operating history and a history of operating losses and our ability to fund our operations going forward;</span></span></div>
        </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our competitive position with respect to other
        products on the market or in development for the treatment of osteoporosis and hypoparathyroidism and other disease categories we pursue;</span></span></div>
        </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to establish and maintain development
        and commercialization collaborations;</span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to manufacture and supply enough material
        to support our clinical trials and any potential future commercial requirements;</span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The size of any market we may target and the adoption
        of our product candidates, if approved, by physicians and patients;</span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to obtain, maintain and protect our
        intellectual property and operate our business without infringing misappropriating or otherwise violating any intellectual property rights
        of others;</span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to retain key personnel and recruit
        additional qualified personnel;</span></span></div> </td> </tr>
  </table> </div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The possibility that competing products or technologies
        may make any product candidates we may develop and commercialize or our oral delivery technology obsolete;</span></span></div> </td> </tr>
  </table> </div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to comply with laws and regulations
        that currently apply or become applicable to our business in Israel, the United States and internationally; and</span></span></div> </td>
        </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our ability to manage growth.</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:18pt">&#160;</td>
    <td style="width:18pt;vertical-align:top">&#160;</td>
    <td style="width:auto;vertical-align:top">&#160;</td> </tr>
  </table> </div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;text-indent:24.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">All
forward-looking statements contained in this Quarterly Report are expressly qualified in their entirety by the cautionary statements contained
or referred to in this section. We caution investors not to rely heavily on the forward-looking statements we make. Except as required
by applicable law, we are under no duty, and expressly disclaim any obligation, to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make
on related subjects in any annual, quarterly or current reports that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:24.5pt;line-height:1.25;font-family:Times New Roman, Times, serif;margin-bottom:5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
encourage you to read Part II, Item 1A of this Quarterly Report and Item 1A of our 2022 Annual Report, each entitled &#8220;Risk Factors,&#8221;
and Part I, Item 2 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation&#8212;Liquidity and
Capital Resources&#8221; of this Quarterly Report for additional discussion of the risks and uncertainties associated with our business.
There can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized,
that they will have the expected consequences to, or effects on, us. Therefore, no assurance can be given that the outcomes stated in
such forward-looking statements and estimates will be achieved.</span></span></div>

<div style="text-align:justify;text-indent:24.5pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-indent:24.5pt;line-height:1.25;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">2</span></span></span></div>

<div style="clear:both;margin-top:4pt;margin-bottom:10pt">

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" />
</div> </div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div> </div> </div>
</div> </div> </div>

<div style="">

<div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span id="PARTI_integixAnchor"></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART
I.</span></span></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
1. FINANCIAL STATEMENTS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;

<div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA
BIO LTD.</span></span></div>

<div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">UNAUDITED
CONDENSED</span></span></div>

<div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED
FINANCIAL STATEMENTS</span></span></div>

<div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">AS
OF JUNE 30, 2023</span></span><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>&#160;</span></span></span></div>

<div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-family:'Times New Roman'"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">TABLE
OF CONTENTS</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:92.42%;vertical-align:top;font-family:'Times New Roman'">&#160;</td>
    <td style="width:7.58%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);font-family:'Times New Roman'">
        <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0);font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Page</span></span></div></td></tr>
  <tr>
    <td style="width:92.42%;vertical-align:top;font-family:'Times New Roman'">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONDENSED
        CONSOLIDATED FINANCIAL STATEMENTS:</span></span></div></td>
    <td style="width:7.58%;vertical-align:top;font-family:'Times New Roman'">&#160;</td></tr>
  <tr>
    <td style="width:92.42%;vertical-align:top">
        <div style="margin-left:9pt;line-height:1.25;font-family:Georgia,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#BALANCESHEETS_integixAnchor"><span>Condensed
        Consolidated Balance Sheets (unaudited)</span></a></span></span></div></td>
    <td style="width:7.58%;vertical-align:top;font-family:'Times New Roman'">
        <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div></td></tr>
  <tr>
    <td style="width:92.42%;vertical-align:top">
        <div style="margin-left:9pt;line-height:1.25;font-family:Georgia,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#OPERATIONS_integixAnchor"><span>Condensed
        Consolidated Statements of Operations (unaudited)</span></a></span></span></div></td>
    <td style="width:7.58%;vertical-align:top;font-family:'Times New Roman'">
        <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></div></td></tr>
  <tr>
    <td style="width:92.42%;vertical-align:top">
        <div style="margin-left:9pt;line-height:1.25;font-family:Georgia,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#SHAREHOLDERSEQUITY_integixAnchor"><span>Condensed
        Consolidated Statements of Changes in Shareholders' Equity (unaudited)</span></a></span></span></div></td>
    <td style="width:7.58%;vertical-align:top;font-family:'Times New Roman'">
        <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></div></td></tr>
  <tr>
    <td style="width:92.42%;vertical-align:top">
        <div style="margin-left:9pt;line-height:1.25;font-family:Georgia,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#CASHFLOWS_integixAnchor"><span>Condensed
        Consolidated Statements of Cash Flows (unaudited)</span></a></span></span></div></td>
    <td style="width:7.58%;vertical-align:top;font-family:'Times New Roman'">
        <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div></td></tr>
  <tr>
    <td style="width:92.42%;vertical-align:top">
        <div style="margin-left:9pt;line-height:1.25;font-family:Georgia,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="#FINANCIALSTATEMENTS_integixAnchor"><span>Notes
        to the Condensed Consolidated Financial Statements (unaudited)</span></a></span></span></div></td>
    <td style="width:7.58%;vertical-align:top;font-family:'Times New Roman'">
        <div style="text-align:center;line-height:1.25;color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6</span></span></div></td></tr>
  </table>

<div style="text-align:justify;line-height:1.25;font-family:Times New Roman;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">3</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div></div></div></div>

<div style="">

<div style="margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ENTERA
BIO LTD.</span></span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span id="BALANCESHEETS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span id="SHEETS_integixAnchor"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">CONDENSED
CONSOLIDATED BALANCE SHEETS</span></span></span></span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">(U.S.
dollars in thousands, except share data)</span></span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">(Unaudited)</span></span></span></span></span></span></div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;color:rgb(0, 0, 0);width:100%;margin-top:0pt;margin-bottom:0pt">
  <tr style="margin-top:0pt;margin-bottom:0pt">
    <td colspan="1" style="padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;vertical-align:bottom" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">A
        s s e t s</span></p> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">June&#160;30,</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">December
        31,</span></span></span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt">
    <td colspan="1" style="vertical-align:top;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <div style="line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2023</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">2022</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" rowspan="1" style="vertical-align:top;font-weight:bold;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">CURRENT
        ASSETS:</span></span></span></span></span></span></td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:top;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:bottom;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Cash
        and cash equivalents</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_33" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,135</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_37" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,309</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Accounts
        receivable</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_43" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_47" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Prepaid
        expenses and other current assets</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_53" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_57" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        CURRENT ASSETS</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_63" name="us-gaap:AssetsCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,814</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_67" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,849</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">NON-CURRENT
        ASSETS:</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Property
        and equipment, net</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_83" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_87" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Operating
        lease right-of-use assets</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_93" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">460</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_97" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Deferred
        income taxes</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_93" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_97" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:15pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Funds
        in respect of employee rights upon retirement</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_103" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_107" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        NON-CURRENT ASSETS</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_113" name="us-gaap:AssetsNoncurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">631</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_117" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:4px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        ASSETS</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_123" name="us-gaap:Assets" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,445</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_127" name="us-gaap:Assets" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,127</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Liabilities
        and shareholders' equity</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">CURRENT
        LIABILITIES:</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.65pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Accounts
        payable</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_153" name="us-gaap:AccountsPayableCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_157" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.65pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Accrued
        expenses and other payables</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_163" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,485</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_167" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.65pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Current
        maturities of operating lease</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_173" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_177" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        CURRENT LIABILITIES</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_193" name="us-gaap:LiabilitiesCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,865</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_197" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,341</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">NON-CURRENT
        LIABILITIES</span>:</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;<span style="line-height:107%">Operating
        lease liabilities</span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731132348860_xbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_223" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731132348860_xbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_227" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Liability
        for employee rights upon retirement</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_223" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_227" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        NON-CURRENT LIABILITIES</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_233" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">348</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_237" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        LIABILITIES</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_243" name="us-gaap:Liabilities" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,213</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_247" name="us-gaap:Liabilities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">COMMITMENTS
        AND<span style="-sec-ix-hidden:Fxbrl_20230426051028683"><span style="-sec-ix-hidden:Fxbrl_20230426051024328"> </span></span>CONTINGENCIES</span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">SHAREHOLDERS'
        EQUITY:</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Ordinary
        Shares, NIS <ix:nonFraction id="Fxbrl_20220809034950441" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="NIS_per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808214817829" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20230630" unitRef="NIS_per_Share" decimals="INF" format="ixt:num-dot-decimal">0.0000769</ix:nonFraction></ix:nonFraction>
        par value: Authorized - as of June&#160;30, 2023 and December 31, 2022, <ix:nonFraction id="Fxbrl_20220809035007189" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808214936276" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">140,010,000</ix:nonFraction></ix:nonFraction>
        shares; issued and outstanding - as of June&#160;30, 2023 and December 31, 2022, <ix:nonFraction id="Fxbrl_20220809035046498" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20220808215259598" name="us-gaap:CommonStockSharesIssued" contextRef="C_20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,813,952</ix:nonFraction></ix:nonFraction></span></span></span></span><span style="line-height:107%">&#160;and
        <ix:nonFraction id="Fxbrl_20230731132500229" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731132441499" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></ix:nonFraction>
        shares, respectively</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20220808213249447">*</span></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="-sec-ix-hidden:Fxbrl_20220808214617486">*</span></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Additional
        paid-in capital</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_283" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,203</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_287" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,210</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Accumulated
        other comprehensive income</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_293" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_297" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;margin-left:15.55pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Accumulated
        deficit</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <p style="margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="Fxbrl_20230731132604195" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">100,012</ix:nonFraction></span></span></span></span></span></span></p>
        </div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">)</span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="Fxbrl_20220808213205318_xbrl_20220802012334047_xbrl_20220505162133476_xbrl_20220219060830028_307" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">95,497</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">)</span></span></span></span></span></span></div>
        </div> </td> </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        SHAREHOLDERS' EQUITY</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_313" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,232</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_317" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,754</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:top;width:76%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">TOTAL
        LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_323" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,445</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">
        <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_327" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,127</ix:nonFraction></span></span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;margin-top:0pt;margin-bottom:0pt;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">*

    <ix:footnote id="FN20220809041142326" xml:lang="en-US">Represents an amount less than one thousand US dollars</ix:footnote></span></span></span></span></span></span></div>

                    <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">The
                    accompanying notes are an integral part of the</span>&#160;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">unaudited condensed
                    consolidated financial statements.</span></span></span></span></span></span></span></div>

                    <div style="clear:both;margin-top:0pt;margin-bottom:0pt">

                    <div style="text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</div>

                    <div style="text-align:center;margin-top:8pt;margin-bottom:0pt"><span style="color:#000000;font-family:Times New Roman, Times, serif"><span style="font-size:13.3333px">4</span></span></div>
                    </div> </div> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:20pt" />
                    </div>

                    <div style="">

                    <div style="margin-top:0pt;margin-bottom:0pt">

                    <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">ENTERA
                    BIO LTD.</span></span></span></span></div>

                    <div style="text-align:center;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span id="FOPERATIONS_integixAnchor"><span id="OPERATIONS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">CONDENSED
                    CONSOLIDATED STATEMENTS OF OPERATIONS</span></span></span></span></span></span></span></div>

                    <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

                    <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">(U.S.
                    dollars in thousands, except share and per share data)</span></span></span></span></div>

                    <div style="text-align:center;line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">(Unaudited)</span></span></span></span></div>

                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

                    <div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">

                    <table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="padding-top:0px;padding-bottom:0px;height:18px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="bottom">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="6" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <p style="margin-top:0pt;margin-bottom:0pt;border:none;padding-top:0cm;padding-bottom:0cm;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>Six
        Months Ended </span></strong></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;border:none;padding-top:0cm;padding-bottom:0cm;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>June
        30,</span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="6" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <p style="margin-top:0pt;margin-bottom:0pt;border:none;padding-top:0cm;padding-bottom:0cm;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>Three
        Months Ended </span></strong></span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;border:none;padding-top:0cm;padding-bottom:0cm;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>June
        30,</span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr>
    <td style="padding-top:0px;padding-bottom:0px;height:18px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="bottom">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>2023</span></strong></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>2022</span></strong></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>2023</span></strong></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span>2022</span></strong></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="padding-top:0px;padding-bottom:0px;height:18px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left" valign="bottom">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p> </td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>REVENUES</span></span></strong></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133138310" name="us-gaap:Revenues" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133144933" name="us-gaap:Revenues" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132401520_xbrl_20220218235908029_33" name="us-gaap:Revenues" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132401520_xbrl_20220218235908029_37" name="us-gaap:Revenues" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>COST
        OF REVENUES</span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133155581" name="us-gaap:CostOfRevenue" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133201241" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132409409_xbrl_20220218235908029_43" name="us-gaap:CostOfRevenue" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132409409_xbrl_20220218235908029_47" name="us-gaap:CostOfRevenue" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>GROSS
        PROFIT</span></span></strong><strong> </strong></span></span></span></p> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133206777" name="us-gaap:GrossProfit" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133209449" name="us-gaap:GrossProfit" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132417008_xbrl_20220218235908029_53" name="us-gaap:GrossProfit" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;border-bottom:2px solid black" valign="bottom">
        <div style="padding-top:0cm;padding-bottom:0cm;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132417008_xbrl_20220218235908029_57" name="us-gaap:GrossProfit" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>OPERATING
        EXPENSES:</span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td colspan="2" style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%;margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;margin-left:14pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="line-height:normal;margin-top:0pt;margin-bottom:0pt">Research
        and development </span></span></span></p> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133215930" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,140</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133218473" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,084</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132429369_xbrl_20220218235908029_73" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,209</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132429369_xbrl_20220218235908029_77" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,394</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%;margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;margin-left:14pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="line-height:normal;margin-top:0pt;margin-bottom:0pt">General
        and administrative </span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133222993" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,429</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133225481" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,052</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132437400_xbrl_20220218235908029_83" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,135</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132437400_xbrl_20220218235908029_87" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%;margin-top:0pt;margin-bottom:0pt" valign="bottom">
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;margin-left:14pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="line-height:normal;margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Other
        income</span></span></span></span></span></p> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731133230777" name="us-gaap:OtherNonrecurringIncome" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731133233321" name="us-gaap:OtherNonrecurringIncome" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731132445367_xbrl_20220218235908029_93" name="us-gaap:OtherNonrecurringIncome" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731132445367_xbrl_20220218235908029_97" name="us-gaap:OtherNonrecurringIncome" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>TOTAL
        OPERATING EXPENSES</span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133239257" name="us-gaap:OperatingExpenses" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,542</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133242049" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,109</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132456989_xbrl_20230426024644129" name="us-gaap:OperatingExpenses" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,330</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132456989_xbrl_20230426024649896" name="us-gaap:OperatingExpenses" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,260</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>OPERATING
        LOSS</span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133248337" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,542</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133250874" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,084</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132513429_xbrl_20230426024657072" name="us-gaap:OperatingIncomeLoss" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,330</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:2px solid black">&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <div style="border-bottom:2px solid black;padding-top:0cm;padding-bottom:1pt;text-align:right;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0pt;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132513429_xbrl_20230426024704447" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,249</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px">&#160;</p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>FINANCIAL
        INCOME, NET</span></span></strong><span><span> </span></span></span></span></span></p> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731133257321" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731133301376" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731132528780_xbrl_20220505170035707" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731132528780_xbrl_20220505170041902" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="border-bottom:0px;padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px;border-top:0px">
        <p style="margin-top:0px;margin-bottom:0px;border:none;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>LOSS
        BEFORE INCOME TAX </span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133306248" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,515</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731133309217" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,980</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132538804_xbrl_20220218235908029_143" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,325</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%" valign="top">
        <p style="margin-top:0px;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal;text-align:right"><ix:nonFraction id="Fxbrl_20230731132538804_xbrl_20220218235908029_147" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,189</ix:nonFraction></span></span></span></p>
        </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>INCOME
        TAX BENEFIT</span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731133319816" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731133316065" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">11</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px">
        <p style="margin-top:0px;margin-bottom:0px;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132548997_xbrl_20230426025507535" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:2px solid black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:2px solid black">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">(<ix:nonFraction id="Fxbrl_20230731132548997_xbrl_20220218235908029_157" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:baseline;padding-top:0px;padding-bottom:0px;width:1%">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:left;margin-top:0px;margin-bottom:0px">
        <p style="margin-top:0px;margin-bottom:0px;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal">)</span></span></span></p>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>NET
        LOSS</span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;text-align:right;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731134159798" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,515</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731134202640" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,969</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><ix:nonFraction id="Fxbrl_20230731132558977_xbrl_20230426024625121" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,325</ix:nonFraction></span></span></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_20230731132558977_xbrl_20230426024631752" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,185</ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px">&#160;</p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><strong><span><span>LOSS
        PER SHARE BASIC AND DILUTED </span></span></strong></span></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_s_20230731133332051" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230101to20230630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731133332051" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230101to20230630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.16</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><ix:nonFraction id="Fxbrl_s_20230731133334601" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20220630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731133334601" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20220630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.24</ix:nonFraction></ix:nonFraction></span></span></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><ix:nonFraction id="Fxbrl_20220809001710649" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20230401to20230630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731132606945_xbrl_20220218235908029_183" name="us-gaap:EarningsPerShareBasic" contextRef="C_20230401to20230630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.08</ix:nonFraction></ix:nonFraction></span></span></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><span><span><ix:nonFraction id="Fxbrl_20220809001731689" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220401to20220630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731132606945_xbrl_20220218235908029_187" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220401to20220630" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></span></span></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255);height:15px">
    <td style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="margin-top:0px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif;padding-top:0px">&#160;</p>
        </td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;text-align:right">&#160;</td>
    <td style="background-color:rgb(204, 238, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255);height:15px">
    <td style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:52%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:18pt;text-indent:-18pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>WEIGHTED
        AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE</strong></span></span></p> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_s_20230731133341737" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230101to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731133341738" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230101to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,811,162</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_s_20230731133344049" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20220630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731133344049" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20220630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,806,217</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_s_20230426024815480" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20230401to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731132614577_xbrl_20230426024815480" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20230401to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,812,375</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;text-align:right">&#160;</td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%;border-bottom:4px double black">
        <div>&#160;</div> </td>
    <td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:9%;border-bottom:4px double black" valign="top">
        <div style="padding-top:0cm;padding-bottom:1pt;text-align:right">
        <p style="margin-top:0px;margin-bottom:0pt;padding-top:0px;padding-bottom:0cm;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="line-height:normal"><ix:nonFraction id="Fxbrl_s_20230426024821824" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220401to20220630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230731132614577_xbrl_20230426024821824" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220401to20220630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,808,023</ix:nonFraction></ix:nonFraction></span></span></span></p>
        </div> </td>
    <td style="background-color:rgb(255, 255, 255);font-size:10pt;height:15px;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;padding-top:0px;padding-bottom:0px;width:1%">&#160;</td>
        </tr>
  </table> </div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">The
accompanying notes are an integral part of the</span>&#160;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">unaudited condensed
consolidated financial statements.</span></span></span></span></span></div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:8pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal;margin-top:0pt;margin-bottom:0pt">5</span></span></span></div>
</div> </div> <hr style="border-width:0px;clear:both;margin-top:4px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);page-break-after:always;margin-bottom:20pt" />
</div>

<div style="">

<div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span style="font-weight:bold">ENTERA
BIO LTD</span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span id="ERSEQUITY_integixAnchor"><span id="SHAREHOLDERSEQUITY_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></span></span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S.
dollars in thousands, except share and per share data)</span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary
        shares</span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="14" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Number
        of </span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>shares
        issued</span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Amounts</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">Additional</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">paid-in</span></span></span></span></span></div>
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="font-weight:bold">capital</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated
        </span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>other
        </span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Comprehensive
        </span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>income</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated
        </span></span></span></span></div>
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>deficit</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE
        AT JANUARY 1, 2023</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50" name="us-gaap:SharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220808213523162">*</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,210</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">95,497</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,754</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:34%" valign="bottom">
        <div style="line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        loss</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010392_20220801223211740_10" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010392_20220801223211740_9" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010392_20220801223211739_8" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010392_20220801223211739_7" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,515</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010392_20220801223211738_6" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,515</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance
        of shares under the ATM program, net of issuance costs</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,030
        </ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731140510423_xbrl_20220808213523162">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <div style="line-height:1.25;margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Share-based
        compensation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010428_20220801223211758_33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010428_20220801223211758_32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">988</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010428_20220801223211757_31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010428_20220801223211757_30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010428_20220801223211756_29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">988</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>BALANCE
        AT JUNE&#160;30, 2023</span></span></span></p> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010611_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,813,952</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220808214535386">*</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010611_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,203</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010611_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010611_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">100,012</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:3pt;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010611_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,232</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:34%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>BALANCE
        AT APRIL 1, 2023</strong></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141710655_xbrl_20220808214535386">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,726</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">97,687</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20230331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,080</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211805_56" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211798_55" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211791_54" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211791_53" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,325</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211791_52" name="us-gaap:NetIncomeLoss" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,325</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Issuance
        of shares under the ATM program, net of issuance costs</span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">4,030
        </ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211758_33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211758_32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211757_31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211757_30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211756_29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20230401to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>BALANCE
        AT JUNE 30, 2023</strong></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,813,952</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141713727_xbrl_20220808214535386">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,203</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">100,012</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%;padding-bottom:3pt" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);border-bottom:4px double black;border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,232</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:34%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE
        AT JANUARY 1, 2022</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010482_20220801223211790_50" name="us-gaap:SharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,804,411</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20220808214614689">*</span></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010482_20220801223211790_49" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,950</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010482_20220801223211789_48" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010482_20220801223211789_47" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">82,426</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010482_20220801223211788_46" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,565</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <div style="line-height:1.25;margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Net
        loss</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010516_20220801223211805_56" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010516_20220801223211798_55" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213010516_20220801223211791_54" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010516_20220801223211791_53" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,969</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213010516_20220801223211791_52" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,969</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        of options to ordinary shares</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,511</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <div style="line-height:1.25;margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt">Share-based
        compensation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>-</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211758_33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211758_32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,660</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211757_31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211757_30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211756_29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,660</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>BALANCE
        AT JUNE 30, 2022</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213412916_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="-sec-ix-hidden:Fxbrl_20230430155759086">*</span></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213412916_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,623</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213412916_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220808213412916_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,395</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808213412916_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,269</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:34%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>BALANCE
        AT APRIL 1, 2022</strong></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,804,411</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141740672_xbrl_20230430155759086">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,914</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">86,210</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:0px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20220331" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,745</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss&#160;</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211740_10" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211740_9" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211739_8" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211739_7" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,185</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:0px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211738_6" name="us-gaap:NetIncomeLoss" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,185</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:0px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise
        of options to ordinary shares</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">5,511</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);margin-top:0pt;margin-bottom:0pt;width:34%" valign="bottom">
        <p style="margin-left:16pt;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Share-based
        compensation</span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211758_33" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211758_32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211757_31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211757_30" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;white-space:nowrap;background-color:rgb(255, 255, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211756_29" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_20220401to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(255, 255, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:34%" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>BALANCE
        AT JUNE 30, 2022</strong></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;border-top:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;border-top:2px solid black;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211822_66" name="us-gaap:SharesOutstanding" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">28,809,922</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);border-top:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);border-top:2px solid black;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="-sec-ix-hidden:Fxbrl_20230731141742631_xbrl_20230430155759086">*</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;border-top:2px solid black;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;border-top:2px solid black;background-color:rgb(204, 238, 255);width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211822_65" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,623</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211822_64" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255);border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double black;background-color:rgb(204, 238, 255);border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211821_63" name="us-gaap:StockholdersEquity" contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">89,395</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:3pt;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);border-top:2px solid black;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);white-space:nowrap;background-color:rgb(204, 238, 255);border-top:2px solid black;width:8%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211821_62" name="us-gaap:StockholdersEquity" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,269</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;background-color:rgb(204, 238, 255);width:1%" valign="bottom">&#160;</td>
        </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">* Represents an amount
less than one thousand U.S. dollars.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">The
accompanying notes are an integral part of the</span>&#160;<span style="font-weight:bold">unaudited condensed consolidated financial statements.</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-weight:normal;font-style:normal">6</span></span></span></div>

<div style="page-break-after:always"> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;margin-bottom:20pt" />
</div> </div> </div> </div>

<div style="">

<div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ENTERA
BIO LTD.</span></span></span></span></div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span id="CASHFLOWS_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span></span></span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(U.S.
dollars in thousands, except share and per share data)</span></span></span></span></div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(Unaudited)</span></span></span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Six
        months<br />ended June&#160;30,</span></span></span></span></div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25;font-weight:bold;text-indent:1pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">CASH
        FLOWS FROM OPERATING ACTIVITIES:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        loss</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_33" name="us-gaap:NetIncomeLoss" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">4,515</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_37" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,969</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Adjustments
        required to reconcile net loss to net cash used in operating activities:</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Depreciation</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_63" name="us-gaap:Depreciation" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_67" name="us-gaap:Depreciation" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Deferred
        income taxes</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220305111909474_xbrl_20220219041121835_63" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220305111909474_xbrl_20220219041121835_67" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">63</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share-based
        compensation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_83" name="us-gaap:ShareBasedCompensation" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">988</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_87" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,660</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Finance
        income, net</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_103" name="entx:FinanceExpensesNet" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_107" name="entx:FinanceExpensesNet" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">71</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Changes
        in operating asset and liabilities:</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Decrease
        (increase) in accounts receivable</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_123" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">217</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_127" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Increase
        in other current assets</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_133" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">356</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_137" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span>Increase
        (decrease) in accounts payable</span></span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220802102026794" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20230731140959224" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">57</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Increase
        (decrease) in accrued expenses and other payables</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_153" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_157" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,390</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;padding-bottom:2px;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:0.4pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Decrease
        in contract liabilities</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220219041121835_163" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_167" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">15</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        cash used in operating activities</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_173" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,168</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220305111416980" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,619</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CASH
        FLOWS FROM INVESTING ACTIVITIES:</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Purchase
        of property and equipment</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20221030215719839_xbrl_20220219041121835_203" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20221030215719839_xbrl_20220219041121835_207" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Net
        cash used in investing activities</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20221030215741538" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20221030215753542" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">42</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong><span style="line-height:107%">CASH
        FLOWS FROM FINANCING ACTIVITIES:</span></strong></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Proceeds
        from issuance of shares under the ATM program, net of issuance costs</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_203" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_207" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Exercise
        of options and warrants into shares </span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid black;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140301139_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_203" name="entx:ProceedsFromOptionsAndWarrantExercises" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid black;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid black;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140301139_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_207" name="entx:ProceedsFromOptionsAndWarrantExercises" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td> </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-14.2pt;margin-left:30.15pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Net
        cash provided by financing activities</span></span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731140302926_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_203" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230731140302926_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_207" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25">&#160;</div> </div> </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>DECREASE
        IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_313" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,175</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="Fxbrl_20220219041121835_317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">7,648</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
        </td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:bottom;padding-bottom:2px;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CASH,
        CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE PERIOD</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031113662" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,376</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031120293" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,964</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:4px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CASH,
        CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE PERIOD</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031130941" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,201</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031137438" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,316</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Reconciliation
        in amounts on consolidated balance sheets:</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash
        and cash equivalents</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220505171612811" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,135</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220505171631694" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,279</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:middle;padding-bottom:4px;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Restricted
        deposits included in other current assets</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031237262" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031246543" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:4px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-indent:-15.95pt;margin-left:15.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Total
        cash and cash equivalents and restricted deposits</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031145133" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,201</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20230426031152246" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,316</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong><span style="line-height:107%">SUPPLEMENTARY
        INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS</span><span style="line-height:107%">:</span></strong></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:bottom;padding-bottom:4px;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:107%">Operating
        lease right of use assets obtained in exchange for new operating lease liabilities&#160; </span></span></span></span></span></p> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140755339_xbrl_20230426031237262" name="entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" contextRef="C_20230101to20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">449</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:4px double rgb(0, 0, 0);width:9%;background-color:rgb(255, 255, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731140755339_xbrl_20230426031246543" name="entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" contextRef="C_20220101to20220630" unitRef="USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:4px;white-space:nowrap;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  </table>

<div style="text-align:center;line-height:1.25">&#160;</div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="margin-top:0pt;margin-bottom:0pt"><span style="margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">The
accompanying notes are an integral part of the</span>&#160;<span style="font-weight:bold;margin-top:0pt;margin-bottom:0pt">unaudited condensed
consolidated financial statements.</span></span></span></span></span></div>

<div style="line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div> </div>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0pt;margin-bottom:0pt">

<p style="margin:8pt 0pt 0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">7</span></span></p>
</div> </div> </div> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always;margin-bottom:20pt" />
</div>

<div style="">

<div>

<div>

<div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA
BIO LTD.</span></span></div>

<div style="text-align:center;line-height:1.25"><span id="FINANCIALSTATEMENTS_integixAnchor"><span id="NOTE1_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></span></span></span></span>

<p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(U.S. dollars in thousands,
except share and per share data)</span></span> </div>

<div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Unaudited)</span></span></div>

<div style="text-align:center;line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20230430182140649" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
1 - DESCRIPTION OF BUSINESS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera Bio Ltd. (collectively with its subsidiary,
        the "Company") was incorporated on September 30, 2009 under the laws of the State of Israel and commenced operation on June 1, 2010. On
        January 8, 2018, the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware United States. The Company
        is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant
        unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
        The Company&#8217;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism,
        are based on its proprietary technology platform and are both in clinical development. Additionally, the Company intends to license its
        oral delivery technology to biopharmaceutical companies for use with their proprietary compounds. &#160;&#160; &#160;</span></span></div>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's ordinary shares, NIS <ix:nonFraction id="Fxbrl_20230731131108454" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20230630" unitRef="NIS_per_Share" scale="0" decimals="7" format="ixt:num-dot-decimal">0.0000769</ix:nonFraction>
        par value per share (&#8220;ordinary shares&#8221;), have been listed on the Nasdaq Capital Market since July 2018 under the symbol &#8220;ENTX&#8221;.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because the Company is engaged in research and
        development activities, it has not derived significant income from its activities and has incurred an accumulated deficit in the amount
        of $<ix:nonFraction id="Fxbrl_20230807123800537" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20230630" unitRef="USD" scale="6" decimals="-6" format="ixt:num-dot-decimal" sign="-">100</ix:nonFraction>.0
        million as of June 30, 2023 and negative cash flows from operating activities. The Company's management is of the opinion that its available
        funds as of June 30, 2023 will allow the Company to operate under its current plans into the third quarter of 2024. This assumes the use
        of the Company&#8217;s capital to fund its ongoing operations, including R&#38;D and the completion of the Phase 1 study related to the
        new formulation EB612. This does not include the capital required to fund the Company's proposed Phase 3 study for EB613 in osteoporosis
        and the related comparative study. These factors raise substantial doubt as to the Company's ability to continue as a going concern. Management
        is in the process of evaluating various financing alternatives in the public or private equity markets, debt financing and strategic collaborations,
        as the Company will need to finance future research and development activities, general and administrative expenses and working capital
        through fund raising. However, there is no certainty about the Company's ability to obtain such funding. These condensed consolidated
        financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></span></div>
        <div>&#160;</div> </td> </tr>
  </table> </div> </ix:nonNumeric>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0pt;margin-bottom:0pt">

<p style="margin:10pt 0pt 3pt"><span style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt">8</span></p></div>

<div style="break-after:page;margin-top:0pt;margin-bottom:0pt"><hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:20pt" /></div></div>

<p style="text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">ENTERA
BIO LTD.<br />NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">

<p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share data)</span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:10pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(Unaudited)</span></span></span></span></span></p></div>
</div> </div> </div>

<div style="">

<div>

<div> <ix:nonNumeric id="Fxbrl_20230430182410304" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES</span></span></div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold">&#160;</div> <ix:nonNumeric id="Fxbrl_20230426050128144" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis
        of presentation of the financial statements</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:44pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These
unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all the information and
notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial
statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s
consolidated financial position as of June 30, 2023, the consolidated results of operations and statements of changes in shareholders'
equity for the three and six-month periods ended June 30, 2023 and 2022 and cash flows for the six-month periods ended June 30, 2023 and
2022.<br />&#160;</span></span></span></div>

<div style="margin-right:1.95pt;margin-left:44pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
consolidated results for the three and six-month periods ended June 30, 2023 are not necessarily indicative of the results to be expected
for the year ending December 31, 2023.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:44pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the
Company for the year ended December 31, 2022, as filed with the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March 31, 2023. The comparative balance sheet at December 31, 2022 has been derived
from the audited annual financial statements at that date but does not include all disclosures required by U.S. GAAP for annual financial
statements.</span></span></div> </div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20230426050145564" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        per share</span></span></div> </td> </tr>
  </table>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic
loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares
during the period.</span></span></span></span></div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:36pt;text-align:justify">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-align:justify"><span><span><span>Diluted
loss per share is based upon the weighted average number of ordinary shares and outstanding stock options and warrants, which are included
under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants, exercisable
into <ix:nonFraction id="Fxbrl_20230807124230923" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230101to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,360,374</ix:nonFraction>
shares and <ix:nonFraction id="Fxbrl_20230807124240532" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20220630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">6,326,180</ix:nonFraction>
shares for the six months ended June 30, 2023 and 2022, respectively and <ix:nonFraction id="Fxbrl_20230807124247875" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20230401to20230630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">7,604,195</ix:nonFraction>
shares and <ix:nonFraction id="Fxbrl_20230807124253627" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220401to20220630" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">6,473,863</ix:nonFraction>
shares for the three months ended June 30, 2023 and 2022, respectively, because the effect would have been anti-dilutive.</span></span></span></span></span></span></span></div>
</div> </ix:nonNumeric>

<div style="line-height:1.25">&#160;</div> <ix:nonNumeric id="Fxbrl_20230426050204421" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Newly
        issued and recently adopted accounting pronouncements:</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:44pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently
issued accounting pronouncements adopted</span></span></div>

<div style="margin-left:72pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:44pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2016, the FASB issued ASU 2016-13 &#8220;Financial
        Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current
        incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range
        of reasonable and supportable information to inform credit loss estimates. The guidance is effective for smaller reporting companies (as
        defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The adoption of this
        guidance did not have material impact on the Company&#8217;s consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p> </div> </td> </tr>
  </table> </div> </ix:nonNumeric> </div> </ix:nonNumeric>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0pt;margin-bottom:0pt">

<p style="margin:10pt 0pt 3pt"><span style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt">9</span></p></div>

<div style="break-after:page;margin-top:0pt;margin-bottom:0pt"><hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:20pt" /></div></div>

<p style="text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">ENTERA
BIO LTD.<br />NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">

<p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share data)</span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:10pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(Unaudited)</span></span></span></span></span></p></div>
</div> </div> </div>

<div style="">

<div> <ix:nonNumeric id="Fxbrl_20230807093050751" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
3 - SHARE-BASED COMPENSATION</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 2, 2023,
        options to purchase an aggregate of <ix:nonFraction id="Fxbrl_20230731165113188" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">534,246</ix:nonFraction>
        ordinary shares were granted to six non-executive board members with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230731165125485" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.73</ix:nonFraction>
        per share which was the share price on the grant date. <ix:nonNumeric id="Fxbrl_20230731165150349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember">The
        options vest over <ix:nonNumeric id="Fxbrl_20230731165418549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember" format="ixt-sec:durwordsen">one
        year</ix:nonNumeric> in four equal quarterly installments starting on the date of grant. This grant was approved by the shareholders of
        the Company on October 4, 2021.</ix:nonNumeric> The fair value of the options at January 2, 2023 was $<ix:nonFraction id="Fxbrl_20230731165202399" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction>.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 24, 2023<span style="font-weight:bold">,
        </span>options to purchase an aggregate of<span style="font-weight:bold">&#160;</span><ix:nonFraction id="Fxbrl_20230731142759231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">881,000</ix:nonFraction>
        ordinary shares were granted to employees, executive officers and service providers with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230731143006520" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.795</ix:nonFraction>
        per share which was the share price on the grant date. <ix:nonNumeric id="Fxbrl_20230731142842080" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">These
        options vest over <ix:nonNumeric id="Fxbrl_20230731142910794" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; <ix:nonFraction id="Fxbrl_20230731143031369" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%
        vest on the first anniversary of the date of grant and the remaining <ix:nonFraction id="Fxbrl_20230731143046023" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction>%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date.</ix:nonNumeric> The
        fair value of the options at the date of grant was $<ix:nonFraction id="Fxbrl_20230731172321185" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">485</ix:nonFraction>.</span></span></div>
        <div>&#160;</div>
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of each
        option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following assumptions:</span></span></div>
        </td> </tr>
  </table>

<div>

<div style="margin-left:63.8pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="margin-left:54pt"> <ix:nonNumeric id="Fxbrl_20230807093025632" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_20230101to20230630" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td style="vertical-align:top;font-family:'Times New Roman';border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-indent:0.05pt;line-height:1.25;font-weight:bold;text-align:center">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>Six months</strong></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>ended June 30, 2023</strong></p>
        </div> </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$<ix:nonFraction id="Fxbrl_20230731142418037" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20230630_srtRangeAxis_srtMinimumMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.73</ix:nonFraction>-$<ix:nonFraction id="Fxbrl_20230731143106069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="C_20230630_srtRangeAxis_srtMaximumMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.79</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20220808220724198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20230101to20230630" unitRef="Percent" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility </span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731142428702" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">74</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230731143116693" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">76</ix:nonFraction>%</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate
        </span></span></div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230731142434996" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.58</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230731143130366" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.98</ix:nonFraction>%</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life - in years
        </span></span></div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="Fxbrl_20230731142443738" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember" format="ixt-sec:duryear">5.3</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230731143137595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember" format="ixt-sec:duryear">6.11</ix:nonNumeric></span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div> </div>

<div style="line-height:1.25;font-family:'Times New Roman';clear:both">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        April 24, 2023<span style="font-weight:bold">, </span>options to purchase an aggregate of<span style="font-weight:bold">&#160;</span><ix:nonFraction id="Fxbrl_20230731142052683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">350,000</ix:nonFraction>
        ordinary shares were granted to the Company&#8217;s Chief Executive Officer with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230731142104791" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" unitRef="USD_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">0.795</ix:nonFraction>
        per share which was the share price on that day. <ix:nonNumeric id="Fxbrl_20230731142815988" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">These
        options vest over <ix:nonNumeric id="Fxbrl_20230731142214458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember" format="ixt-sec:durwordsen">four
        years</ix:nonNumeric> from the date of grant; <ix:nonFraction id="Fxbrl_20230731142113252" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>%
        vest on the first anniversary of the date of grant and the remaining <ix:nonFraction id="Fxbrl_20230731142136564" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" unitRef="Percent" scale="-2" decimals="2" format="ixt:num-dot-decimal">75</ix:nonFraction>%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date.</ix:nonNumeric> This
        grant is subject to the Company's shareholders' approval.</span></span></div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        June 4, 2023, options to purchase an aggregate of <ix:nonFraction id="Fxbrl_20230731142803880" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">33,638</ix:nonFraction>
        ordinary shares were granted to non-executive board member with an exercise price of&#8201;$<ix:nonFraction id="Fxbrl_20230731143000644" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" unitRef="USD_per_Share" scale="0" decimals="2" format="ixt:num-dot-decimal">0.89</ix:nonFraction>
        per share which was the share price on that day. Th<ix:nonNumeric id="Fxbrl_20230731142348247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember">e
        options will vest over <ix:nonNumeric id="Fxbrl_20230731142856445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember" format="ixt-sec:durwordsen">three
        years</ix:nonNumeric> in 12 equal quarterly installments starting on the date of grant.</ix:nonNumeric> This grant is subject to the Company's
        shareholders' approval.</span></span></div> </div> </td> </tr>
  </table> </div> </ix:nonNumeric>

<p style="margin:0pt">&#160;</p>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0pt;margin-bottom:0pt">

<p style="margin:10pt 0pt 3pt"><span style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt">10</span></p></div>

<div style="break-after:page;margin-top:0pt;margin-bottom:0pt"><hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:20pt" /></div></div>

<p style="text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">ENTERA
BIO LTD.<br />NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">

<p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share data)</span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:10pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(Unaudited)</span></span></span></span></span></p></div>
</div> </div>

<div style="">

<div> <ix:nonNumeric id="Fxbrl_20230430182915089" name="entx:SupplementaryFinancialStatementInformationTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
4 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</span></span></span></span></strong></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance
sheets:</span></span></span></span></strong></div>

<div>

<div style="line-height:1.25">

<div style="margin-left:31.2pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt">

<div> <ix:nonNumeric id="Fxbrl_20230731134500300" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" contextRef="C_20230101to20230630" escape="true">

<table border="0" cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June&#160;30,</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>December&#160;31,</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2023</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2022</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Prepaid
        expenses and other current assets:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="margin-left:16pt;text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Prepaid
        expenses</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230731132636236_xbrl_20220808200953075_xbrl_20220510112546992" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230731132636236_xbrl_20220808200953075_xbrl_20220510112707928" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-left:16pt;text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Other
        current assets</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230731132644516_xbrl_20220808200953081_xbrl_20220510112644305" name="us-gaap:OtherAssetsCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230731132644516_xbrl_20220808200953081_xbrl_20220510112742136" name="us-gaap:OtherAssetsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230731132628506_xbrl_20220808200953083_xbrl_20220510112657784" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">650</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230731132628506_xbrl_20220808200953083_xbrl_20220510112751072" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">294</ix:nonFraction></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> </ix:nonNumeric> </div> </div> </div>

<div>

<div style="margin-left:31.2pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt"> <ix:nonNumeric id="Fxbrl_20230731144057802" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_20230101to20230630" escape="true">

<div style="margin-bottom:10pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June&#160;30,</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Accrued
        expenses and other payables:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees
        and employees related</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953075_xbrl_20220510112546992" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953075_xbrl_20220510112707928" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Provision
        for vacation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953079_xbrl_20220510112621448" name="us-gaap:AccruedVacationCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953079_xbrl_20220510112732615" name="us-gaap:AccruedVacationCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued
        expenses</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953081_xbrl_20220510112644305" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,122</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953081_xbrl_20220510112742136" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">933</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953083_xbrl_20220510112657784" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,485</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="Fxbrl_20220808200953083_xbrl_20220510112751072" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_20221231" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> </div> </ix:nonNumeric> </div> </div> </div> </div> </ix:nonNumeric> </div> </div>

<div style="">

<div> <ix:nonNumeric id="Fxbrl_20230807100531482" name="entx:EventsDuringPeriodTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
5 - EVENTS DURING THE PERIOD</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In April 2023, the
        Company entered into an amendment to its office lease agreement from 2014 to extend the period of the lease agreement for additional <ix:nonNumeric id="Fxbrl_20230731135831949" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember" format="ixt-sec:durwordsen">five
        years</ix:nonNumeric>, expiring on <ix:nonNumeric id="Fxbrl_20230731135844020" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">June
        30, 2028</ix:nonNumeric>, with <ix:nonNumeric id="Fxbrl_20230806152330316" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" contextRef="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">two
        options for early termination by the Company</ix:nonNumeric> subject to a notice period. The monthly lease fee is a total of $<ix:nonFraction id="Fxbrl_20230731135918668" name="us-gaap:OperatingLeaseExpense" contextRef="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction>.<br />&#160;<br />As
        of June 30,2023, the Company recorded the related asset and obligation at the present value of lease payments over the expected terms,
        discounted using the lessee&#8217;s incremental borrowing rate, which was <ix:nonFraction id="Fxbrl_20230731143936543" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_20230630_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember" unitRef="Percent" scale="-2" decimals="4" format="ixt:num-dot-decimal">13.84</ix:nonFraction>%.
        The Company lease agreements do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing
        rate to discount the lease payments based on information available at lease commencement.</span></span></div>
        <div>&#160;</div>
        <div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
        of June 30, 2023, the maturity of lease liabilities under our non-cancelable operating leases were as follows:</span></span></div> </div>
        </td> </tr>
  </table>

<p>&#160;</p> </div> <ix:nonNumeric id="Fxbrl_20230807100517778" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="line-height:1.25">

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230807095051830" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230807095101583" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230807095103582" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230807095105670" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        future minimum lease payments</span></span></div> </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230807095107790" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">542</ix:nonFraction></span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less:
        interest</span></span></div> </td>
    <td style="width:10%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230807095109959" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction>)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present
        value of operating lease liabilities</span></span></div> </td>
    <td style="width:10%;vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230807095112103" name="us-gaap:OperatingLeaseLiability" contextRef="C_20230630" unitRef="USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">456</ix:nonFraction></span></span></div>
        </div> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric> </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 10, 2018,
        the Company entered into a research collaboration and license agreement with Amgen (the &#8220;Amgen Agreement&#8221;) for the use of
        the Company&#8217;s oral delivery platform in the field of inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement,
        the Company and Amgen had agreed to use the Company&#8217;s proprietary drug delivery platform to develop oral formulations for one preclinical
        large molecule program that Amgen had selected. Additionally, the Company had granted Amgen an exclusive, worldwide, sublicensable license
        under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable
        products.</span></span></div>
        <div>&#160;</div>
        <div>
        <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        May 2, 2023, the Company and Amgen agreed to terminate the Amgen Agreement in accordance with its terms, effective on such date. Neither
        party incurred any termination penalty or fees in connection with the termination of the Amgen Agreement.</span></span></div> </div> </td>
        </tr>
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">&#160;</td> </tr>
  </table> </div> </ix:nonNumeric>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0pt;margin-bottom:0pt">

<p style="margin:10pt 0pt 3pt"><span style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;margin-bottom:0pt">11</span></p></div>

<div style="break-after:page;margin-top:0pt;margin-bottom:0pt"><hr style="border-width:0px;clear:both;margin:0pt 0px;width:100%;height:2px;color:rgb(0, 0, 0);background-color:rgb(0, 0, 0);margin-bottom:20pt" /></div></div>

<p style="text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong style="margin-top:0pt;margin-bottom:0pt">ENTERA
BIO LTD.<br />NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</strong></span></span></p>

<div style="text-align:center;line-height:1.25">

<div style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center">

<p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(U.S.
dollars in thousands, except share and per share data)</span></span></span></span></span></div>

<p style="margin-top:0pt;margin-bottom:10pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="line-height:normal">(Unaudited)</span></span></span></span></span></p></div>
</div> </div>

<div style=""> <ix:nonNumeric id="Fxbrl_20230731153001919" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20230101to20230630" escape="true">

<div>

<div style="margin-right:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
6 - SUBSEQUENT EVENTS</span></span></div>

<div>

<div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-family:'Times New Roman'">a.</span></td>
    <td style="vertical-align:top;text-align:justify;font-family:Times New Roman;width:auto">
        <div>In connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in July 2018, the Company issued <ix:nonFraction id="Fxbrl_20230731152514160" name="entx:ClassOfWarrantOrRightIssued" contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">1,400,000
        </ix:nonFraction>IPO warrants to purchase <ix:nonFraction id="Fxbrl_20230731152519079" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="shares" decimals="INF" format="ixt:num-dot-decimal">700,000
        </ix:nonFraction>ordinary shares, and these warrants were listed for trading on Nasdaq Capital Market (&#8220;Nasdaq&#8221;) since August
        12, 2018. The IPO warrants were immediately exercisable at an initial exercise price of $<ix:nonFraction id="Fxbrl_20230731152524576" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" unitRef="NIS_per_Share" scale="0" decimals="3" format="ixt:num-dot-decimal">8.40
        </ix:nonFraction>per ordinary share for a period of <ix:nonNumeric id="Fxbrl_20230731152529808" name="entx:ClassOfWarrantOrRightExerciseTerm" contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" format="ixt-sec:durwordsen">five
        years</ix:nonNumeric>, unless earlier repurchased by the Company as described in the warrant agreement. These IPO warrants expired on
        July 2, 2023, in accordance with their original terms, and Nasdaq removed them from listing.</div> </td> </tr>
  </table> </div> </div> </div> </ix:nonNumeric>

<div style="clear:both;margin-top:0pt;margin-bottom:0pt">

<div style="text-align:center;margin-top:0px">&#160;</div>

<div style="text-align:center;margin-top:8pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#000000;font-weight:normal;font-style:normal">12</span></span></span></div>

<div> <hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000;page-break-after:always" />
</div> </div> </div>

<div style="">

<div>

<div>

<div style="line-height:1.25;font-family:'Times New Roman'">

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
2. MAN<span id="ITEM2MAN_integixAnchor"></span>AGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations,
financial condition, liquidity and cash flows for the periods presented below. This discussion should be read in conjunction with the
interim unaudited condensed consolidated financial statements and related notes contained elsewhere in this Quarterly Report, Part II,
Item 1A-Risk Factors in this Quarterly Report, and Item 1A-Risk Factors in our 2022 Annual Report. As discussed in the section above titled
&#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; the following discussion contains forward-looking statements that
are based upon our current expectations, including with respect to our future operations, revenues and operating results. Our actual results
may differ materially from those anticipated in such forward-looking statements as a result of various factors. Factors that could cause
or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled &#8220;Risk
Factors&#8221; included under Part II, Item 1A below, as well as in Item 1A-Risk Factors in our 2022 Annual Report.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unless
otherwise provided, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Entera
Bio Ltd. and its consolidated subsidiary.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Overview</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-align:justify;text-indent:18.9333px;color:rgb(0, 0, 0);font-style:normal;font-weight:400">Entera
is a clinical stage biopharmaceutical company and a leader in the development of orally delivered macromolecule therapeutics, including
peptides and therapeutic proteins. Currently, most protein therapies are administered via frequent intravenous, subcutaneous, or intramuscular
injections. In chronic diseases where patients require persistent management, these cumbersome, often painful and high-priced injections
can create a major treatment gap. Furthermore, from a technical standpoint, oral delivery of therapeutic proteins has historically been
challenging due to enzymatic degradation within the gastrointestinal tract, poor absorption into the blood stream and variable drug exposures.
Entera&#8217;s proprietary technology is designed to deliver orally administered proteins with sufficient bioavailability&#160;</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;font-weight:400;text-align:justify;text-indent:18.9333px;white-space:normal;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;background-color:#ffffff">to
meet treatment goals, in a simple tablet format (around 6mm in diameter).</span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
strategically focus on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement
therapy has the potential to significantly shift a treatment paradigm.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
currently have two product candidates in the clinical stage of development: EB613 and EB612. Both candidates are first-in-class daily
mini tablets of human parathyroid hormone (hPTH (1-34), teriparatide). To date, Entera&#8217;s proprietary PTH tablets have been safely
administered to a total of 72 healthy subjects in Phase 1 studies and 153 patients across Phase 2 studies in osteoporosis and hypoparathyroidism,
two diseases that remain underserved with the current standard of care and which disproportionately affect women.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
addition to these product candidates, we have various internal early-stage research programs targeting GLP-2, kappa opioid receptors and
hGH, among other peptides. On May 2, 2023, the results from our oral GLP-2 program were published in the International Journal of Peptide
Research and Therapeutics, &#8220;Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (Teduglutide)
- A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome.&#8221; We believe GLP-2 represents a strong candidate for our
oral delivery platform and warrants further development as an injection -free alternative to patients suffering from short bowel syndrome
and other disorders requiring parenteral nutrition.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">13</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Osteoporosis</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Osteoporosis
is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility of bones and
an increase in fracture risk. Osteoporosis is most frequently associated with menopause in women, aging in both women and men and glucocorticoid
steroid use (greater than three months). The bone remodeling cycle can be separated into two distinct processes: (i) bone resorption,
where cells called osteoclasts function in the resorption of mineralized tissue; and (ii) bone formation, where cells called osteoblasts
are responsible for bone matrix synthesis and subsequent mineralization of the bone. In healthy individuals, bone resorption is matched
by new bone formation. Osteoporosis develops as the balance between bone resorption by osteoclasts and bone formation by osteoblasts is
not maintained, and not enough bone tissue is formed, leading to frail and fracture-prone bones.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="text-align:justify;text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25">Osteoporosis
is a significant health issue facing our aging population. In the United States, with respect to hip fractures alone, 21% of women who
suffer a hip fracture do not survive beyond one year, even after it is surgically repaired. Without surgery, the one-year mortality rate
is approximately 70%. Post-menopausal osteoporosis afflicts more women globally than cancer and cardiovascular disease .</span></span></span></div>

<div style="text-align:left">&#160;</div>

<div style="text-align:justify;text-indent:36pt">

<div style="text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25"><span style="line-height:1.25">Current
osteoporosis drugs may be divided into two categories: antiresorptive and anabolic. Drugs that inhibit bone resorption include oral and
injectable options such as estrogen (for postmenopausal women), oral and intravenous bisphosphonates, selective estrogen receptor modulators
(SERMs), the RANK-ligand inhibitor (denosumab) and (salmon) calcitonin. The three currently approved osteoanabolic drugs that stimulate
bone formation all require daily or monthly subcutaneous injections: teriparatide (hPTH[1-34]); abaloparatide (a PTH-related protein analog);
and romosozumab (an antibody that inhibits sclerostin and also inhibits bone resorption).&#160; It is estimated that less than 10% of
currently treated osteoporosis patients agree to injectable osteoanabolic treatment despite guideline recommendations and the approval
of generics. There are currently no FDA-approved oral anabolic treatments for osteoporosis. EB613 is positioned to potentially be the
first, once daily osteoanabolic mini tablet treatment for women with high risk post-menopausal osteoporosis and no prior fractures.</span></span></span></span></div></div>

<div style="text-align:left">&#160;</div>

<div style="text-align:justify;text-indent:36pt">

<div style="text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25"><span style="line-height:1.25">To
date, we have completed two Phase 1 clinical trials and a phase 2, 6-month, 161-patient, placebo-controlled study in which daily oral
EB613 tablets produced rapid dose-proportional increases in biochemical markers of bone formation (primary endpoint), reductions in markers
of bone resorption, and increased lumbar spine, total hip, and femoral neck Bone Mineral Density (BMD, key secondary endpoint) in postmenopausal
women with low BMD or osteoporosis. Results were reported at ASBMR 2021 as a LB oral presentation.</span></span></span></span></div></div>

<div style="text-align:left">&#160;</div>

<div style="text-align:justify;text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25">In
November 2018, we had a Pre-Investigational New Drug meeting with the FDA to discuss our EB613 program for the treatment of osteoporosis.
In December 2020, we announced that the FDA had approved our 2020 IND Application.</span></span></span></div>

<div style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25">&#160;</span></span></span></div>

<div style="text-align:justify;text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25">In
December 2021, we held an end-of-Phase 2 meeting (EOP2) with the FDA to review the six-month phase 2 results and a proposed Head-to-Head,
Non-Inferiority (NI) Phase 3 study design vs. Forteo&#174; , using BMD as the primary endpoint to support an NDA submission under the
505(b)2 pathway. In the minutes from our EOP2 meeting, which we received in January 2022, the FDA agreed that the use of BMD as a primary
endpoint in our proposed phase 3 study could support an NDA and that a new fracture study would not be required. However, the FDA expressed
concern that a NI Head-to-Head phase 3 study design vs. Forteo&#174; may not be favorable. The FDA also remarked that the ASBMR-FNIH SABRE<sup style="vertical-align:text-top;line-height:1;font-size:smaller">1</sup>&#160;program
was evaluating BMD as a surrogate endpoint for fracture risk reduction across placebo-controlled studies; and that the FNIH framework
could provide another approach to support a potential NDA for EB613.</span></span></span></div>

<div style="text-align:left"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25">&#160;</span></span></span></div>

<div style="text-align:justify;text-indent:36pt">

<div style="text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25"><span style="line-height:1.25">In
early 2022, we redesigned our pivotal phase 3 study for EB613 as a placebo-controlled study with a total hip (TH) BMD primary endpoint,
following the FDA&#8217;s EOP2 remarks and emerging data from the ASBMR-FNIH SABRE program. In August 2022, we held a Type C meeting with
the FDA, and in October 2022, we announced the FDA&#8217;s concurrence on the major design elements of the protocol; and that (1) a single
Phase 3&#160;<span style="font-style:italic">placebo-controlled</span>&#160;study with a TH BMD primary endpoint along with (2) a comparative
PK study vs. Forteo&#174; could support a NDA submission of EB613 under the 505(b)(2) regulatory pathway.</span></span></span></span></div>

<div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25"><span style="line-height:1.25">&#160;</span></span></span></span></div></div>

<div style="text-align:left">

<div style="text-align:justify;text-indent:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:rgb(0, 0, 0);font-style:normal;font-weight:400;line-height:1.25"><span style="line-height:1.25"><span>In
February 2023, we submitted a revised phase 3 protocol for EB613 as part of a Type D meeting with the FDA with further detail on the statistical
evaluation of our TH BMD endpoint. On April 3, 2023, we reported that the FDA would not be opposed to Entera initiating the Phase 3 study
under the proposed FNIH BQP pathway and that the Company&#8217;s proposed PK sampling scheme seemed reasonable. Also on April 3, 2023,
we announced that we plan to continue our dialogue with the FDA and await the final qualification of the FNIH-BQP criteria and their guidance
on the statistical evaluation of our BMD endpoint before initiating a phase 3 study for EB613.</span></span></span></span></span></div></div></div>

<div style="line-height:1.25">

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25"><span style="text-decoration:underline">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;
&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</span>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><sup style="font-family:'Times Roman', serif;vertical-align:text-top;line-height:1;font-size:smaller">1</sup>&#160;FNIH
BQP is also known as the ASBMR FNIH-SABRE, American Society for Bone and Mineral Research-Foundation for the National Institutes of Health
(FNIH) Strategy to Advance BMD as a Regulatory Endpoint (SABRE);</span></span></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">14</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div></div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hypoparathyroidism</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Hypoparathyroidism
is a rare condition in which the body either fails to produce sufficient amounts of endogenous PTH or the PTH produced lacks normal biologic
activity. Individuals with a deficiency of PTH may exhibit hypocalcemia and hyperphosphatemia. Hypocalcemia can cause weakness, muscle
cramps, excessive nervousness, headaches and uncontrollable twitching and tetany. Hyperphosphatemia can result in soft tissue calcium
deposition, which may lead to severe issues, including damage to the circulatory and central nervous systems. The most common cause of
hypoparathyroidism is damage to, or removal of, the parathyroid glands due to surgery for another condition.</span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
product candidate for hypoparathyroidism, EB612, is the first oral formulation of PTH (1-34, teriparatide) hormone replacement treatment
developed in a mini tablet form. The FDA and the European Medicines Agency have granted EB612 orphan drug designation for the treatment
of hypoparathyroidism. We believe that EB612 may have inherent advantages compared to experimental daily injectable treatments, including
convenience of administration, storage, and the potential for a flexible titration schedule. In 2015, we successfully completed a Phase
2a trial for EB612, which was an open-label, multicenter pilot study, evaluating the safety, tolerability and PK of EB612 in 19 patients
who had been diagnosed with hypoparathyroidism for at least a year and were taking &#8805;1gr/day of calcium and alfa-calcidol 25(OH)D
20ng/ml supplementation. Patients received PTH (1-34) 0.75 mg/dose tablets qid for 4 months (NCT02152228). The study achieved its primary
and secondary endpoints, including a significant reduction in calcium supplementation (42% reduction from baseline, (p=0.001), a decline
of 23% (p=0.0003) in median serum phosphate levels two hours following the first dose that was maintained for the duration of the study,
improvement in quality of life score and maintenance of median calcium levels above the lower target level for hypoparathyroidism patients
(&gt;7.5 mg/dL) throughout the study. There were no treatment emergent adverse events of hypercalcemia reported and no treatment-emergent
serious adverse events.</span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
have since developed what we believe could be an improved formulation of EB612 based on new intellectual property, tailored to optimize
its PK profile and the potential for reduced daily dosing. We initiated a PK study in May 2023, which is testing various potential drug
candidates based on our new platform, including several which could be developed for the treatment of hypoparathyroidism. We expect to
begin reporting our results from this study during the second half of 2023.</span></span></p></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">15</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Patent
Transfer, Licensing Agreements and Grant Funding</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Oramed
Patent Transfer Agreement</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
2011, we entered into a patent transfer agreement with Oramed, or the Patent Transfer Agreement, pursuant to which Oramed assigned to
us all of its rights, title and interest in the patent rights Oramed licensed to us when we were originally organized, subject to a worldwide,
royalty-free, exclusive, irrevocable, perpetual and sub-licensable license granted to Oramed under the assigned patent rights to develop,
manufacture and commercialize products or otherwise exploit such patent rights in the fields of diabetes and influenza. Additionally,
we agreed not to engage, directly or indirectly, in any activities in the fields of diabetes and influenza. Under the terms of the Patent
Transfer Agreement, we agreed to pay Oramed royalties equal to 3% of our net revenues generated, directly or indirectly, from exploitation
of the assigned patent rights, including the sale, lease or transfer of the assigned patent rights or sales of products or services covered
by the assigned patent rights.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Israeli Innovation Authority Grants</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
have received grants of approximately $0.5 million from the Israeli Innovation Authority (&#8220;IIA&#8221;) to partially fund our research
and development. The grants are subject to certain requirements and restrictions under the Israeli Encouragement of Research, Development
and Technological Innovation in Industry Law 5477-1984, or the Research Law. In general, until the grants are repaid with interest, royalties
are payable to the Israeli government in the amount of 3% on revenues derived from sales of products or services developed in whole or
in part using the IIA grants, including EB613, EB612 and any other oral PTH product candidates we may develop. The royalty rate may increase
to 5%, with respect to approved applications filed following any year in which we achieve sales of over $70 million.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The
rate of royalties may be accelerated and the royalty liability may increase (up to three times the amount of the grant amount and the
interest), if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. Moreover, a
payment of up to 600% of the grant received may be required upon the transfer of any IIA-funded know-how to a non-Israeli entity. We signed
a contract with a global contract manufacturing organization to produce and supply pills for trials performed worldwide. We believe that,
because this production is not for commercial purposes, it will not affect the royalty rates to be paid to the IIA. Should the IIA successfully
take a contrary position, the maximum royalties to be paid to the IIA will be approximately $1.5 million, which is three times the amount
of the original grant plus interest thereon. Following the signing of the Amgen Agreement, we were required to pay 5.38% of each payment
by Amgen and up to 600% of the grant received plus interest. Through June 30, 2023, we had paid royalties to the IIA in the amount of
$95 thousand related to our former research collaboration and license agreement with Amgen (the &#8220;Amgen Agreement&#8221;) and other
master service agreements.</span></span></span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
addition to paying any royalties due, we must abide by other restrictions associated with receiving such grants under the Research Law
that continue to apply following repayment to the IIA.<br />&#160;</span></span></div>

<div style="text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
Overview</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25">

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since
our inception, we have raised a total of $84.7 million from a combination of public and private equity offerings, IIA grants and the exercise
of options and warrants. Since inception, we have incurred significant losses. For the three months ended June 30, 2023 and 2022, our
operating losses were $2.3 million and $3.3 million, respectively. For the six months ended June 30, 2023 and 2022, our operating losses
were $4.5 million and $7.1 million, respectively, and we expect to continue to incur significant expenses and losses for the foreseeable
future.</span></span></p></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of June 30, 2023, we had an accumulated deficit of $100.0 million. Our losses may fluctuate significantly from quarter to quarter and
year to year, depending on the timing of our clinical trials, our expenditures on research and development activities and any third-party
collaborations into which we may enter.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
a result of our recurring losses from operations, negative cash flows and lack of liquidity, management is of the opinion that there is
substantial doubt as to the Company's ability to continue as a going concern. Our independent registered public accounting firm included
an explanatory paragraph in its report on our financial statements as of, and for the year ended, December 31, 2022, expressing the existence
of substantial doubt about our ability to continue as a going concern. The unaudited condensed consolidated financial statements included
herein have been prepared assuming that we will continue as a going concern and do not include adjustments that might result from the
outcome of this uncertainty. If we are unable to raise the requisite funds, we will need to delay the initiation of certain programs and
otherwise curtail or cease operations. See &#8220;Item 1A-Risk Factors-Risks Related to Our Financial Position and Need for Additional
Capital&#8221; contained in our 2022 Annual Report.</span></span></div>

<div style="line-height:1.25">&#160;</div></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">16</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">

<p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of June 30, 2023, we had cash and cash equivalents of&#8201;$9.1 million. We believe that our existing cash resources will be sufficient
to meet our projected operating requirements into the third quarter of 2024, which includes the capital required to fund our ongoing operations,
including R&#38;D and the completion of the Phase 1 PK study related to our new generation platform and new formulations for EB612. However,
this does not include the capital required to fund our proposed Phase 3 pivotal study for EB613 in osteoporosis and comparative PK study
of EB613 and Forteo&#174;. Our ability to commence such studies will depend on finalizing discussions with the FDA and will require additional
funding, which may not be available on reasonable terms, or at all.&#160; Any delay or our inability to secure such funding will delay
or prevent the commencement of these studies.</span></span></p></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In
order to fund further operations, we will need to raise additional capital. We may raise these funds through a variety of means, including
private or public equity offerings, debt financings, strategic collaborations and licensing arrangements. Additional financing may not
be available when we need it or may not be available on terms that are favorable to us.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
of June 30 2023, we had 19 full-time employees, two part-time employees and five consultants who provide services to us on a part-time
basis. Our operations are located in Jerusalem, Israel.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To
date, we have not generated any revenue from sales of our products, and we do not expect to receive any revenue from our product candidates
unless and until we obtain regulatory approval and successfully commercialize our products.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under
the Amgen Agreement, from 2019 through March 31, 2023, we recognized an aggregate amount of $1.7 million in accordance with ASC 606, "Revenues
from Contracts with Customers&#8221;. As previously reported, we and Amgen mutually terminated the Amgen Agreement in May 2023.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
and Development Expenses</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Research
and development expenses consist of costs incurred for the development of our drug delivery technology and our product candidates. Those
expenses include:<br />&#160;</span></span></span></div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">employee-related expenses, including salaries,
        bonuses and share-based compensation expenses for employees and service providers in the research and development function;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">expenses incurred in operating our laboratories
        including our small-scale manufacturing facility;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">expenses incurred under agreements with CROs,
        and investigative sites that conduct our clinical trials;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">expenses related to outsourced and contracted
        services, such as external laboratories, consulting and advisory services;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">supply, development and manufacturing costs relating
        to clinical trial materials; and</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.7pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">other costs associated with pre-clinical and clinical
        activities.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">17</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
and development activities are the primary focus of our business. Product candidates in later stages of clinical development generally
have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of
later-stage clinical trials. We expect that our research and development expenses will increase significantly in future periods as we
advance EB613 and EB612 into later stages of clinical development and invest in additional preclinical candidates.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
research and development expenses may vary substantially from period to period based on the timing of our research and development activities,
including due to the timing of initiation of clinical trials and the enrollment of patients in clinical trials. For the three months ended
June 30, 2023 and 2022, our research and development expenses were $1.2 million and $1.4 million, respectively. For the six months ended
June 30, 2023 and 2022, our research and development expenses were $2.1 million and $3.1 million, respectively. Research and development
expenses for the three and six months ended June 30, 2023 and 2022 were primarily for the development of EB613 and EB612. The successful
development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and estimated
costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows
may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the uncertainty of the scope, rate of progress,
        results and cost of our clinical trials, nonclinical testing and other related activities;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the cost of manufacturing clinical supplies and
        establishing commercial supplies of our product candidates and any products that we may develop;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the number and characteristics of product candidates
        that we pursue;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the cost, timing and outcomes of regulatory approvals;</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the cost and timing of establishing any sales,
        marketing, and distribution capabilities; and</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:20.9pt">&#160;</td>
    <td style="width:18pt;vertical-align:top"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8226;</span></span></td>
    <td style="width:auto;vertical-align:top;text-align:justify">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">the terms and timing of any collaborative, licensing
        and other arrangements that we may establish, including any milestone and royalty payments thereunder.</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A
change in the outcome of any of these variables with respect to the development of EB613, EB612 or any other product candidate that we
may develop could mean a significant change in the costs and timing associated with the development of such product candidate. For example,
if the FDA or other regulatory authority were to require us to conduct preclinical and/or clinical studies beyond those which we currently
anticipate will be required for the completion of clinical development, if we experience significant delays in enrollment in any clinical
trials or if we encounter difficulties in manufacturing our clinical supplies, then we could be required to expend significant additional
financial resources and time on the completion of the clinical development.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
and Administrative Expenses</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
and administrative expenses consist primarily of salaries, benefits, share-based compensation and related costs for directors and personnel
in executive and finance functions. Other general and administrative expenses include D&#38;O insurance and other insurance, professional
fees for legal and accounting services, costs associated with maintaining and prosecuting our intellectual property portfolio and business
development expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
Income, Net</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
income, net is composed primarily of exchange rate differences of certain currencies against our functional currency.</span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">18</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes
on Income</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
have not generated taxable income since our inception, and, as of June 30, 2023, we had carry-forward tax losses of $71.3 million. We
anticipate that we will be able to carry forward these tax losses indefinitely to future tax years. Accordingly, we do not expect to pay
taxes in Israel until we have taxable income after the full utilization of our carryforward tax losses. We provided a full valuation allowance
with respect to the deferred tax assets related to these carry-forward losses of the Company.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
Company&#8217;s subsidiary, Entera Bio, Inc., is taxed separately under U.S. tax laws. As of June 30, 2023, Entera Bio Inc. had tax loss
carry-forwards of $26 thousand.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Results
of Operations</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Comparison
of Three Months Ended June 30, 2023 and 2022</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Three
        Months Ended<br />June 30,</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (Decrease)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;<span style="font-weight:bold">$</span></span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="14" style="vertical-align:bottom" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(In
        thousands, except for percentage information)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">44</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(44</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">33</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,209</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,394</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(185</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(13</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
        and administrative expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,135</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,880</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(745</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(40</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        income</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(14</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        loss</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,330</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,249</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(919</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(28</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial income, net</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(5</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(60</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">55</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(92</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax benefit</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(4</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,325</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,185</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(860</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  </table></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues
for the three months ended June 30, 2022 of $44,000 were mainly attributable to pre-clinical R&#38;D services provided to Amgen under
the Amgen Agreement. We did not recognize any revenue for the three months ended June 30, 2023 due to termination of the Amgen Agreement,
effective May 2, 2023, under which we provided no revenue-generating services for 2023. We did not generate any revenues prior to entering
into the Amgen Agreement.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Cost
of Revenues<br />&#160;</span></span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost
of revenues for the three months ended June 30, 2022 of $33,000 were mainly attributable to pre-clinical R&#38;D services provided to
Amgen under the Amgen Agreement. The decrease in cost was due to the lack of revenues under the Amgen Agreement, as described above, for
the three months ended June 30, 2023.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Research
and Development Expenses<br />&#160;</span></span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research
and development expenses for the three months ended June 30, 2023 were $1.2 million, as compared to $1.4 million for the three months
ended June 30, 2022. We reduced pre-clinical costs by $0.2 million, which was offset by an increase of $0.2 million in materials and production
costs in preparation of our Phase 3 clinical trial for EB613. There were no special one-time payments in the current period such as the
$0.2 million payment made to a former employee pursuant to the terms of his separation agreement.</span></span></span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">19</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
and Administrative Expenses</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
and administrative expenses for the three months ended June 30, 2023 were $1.1 million, as compared to $1.9 million for the three months
ended June 30, 2022. The decrease of $0.8 million was mainly attributable to a decrease of $0.2 million in employee compensation, including
share-based compensation, a decrease of $0.3 million in professional fees and other consultants and a decrease of $0.2 million in D&#38;O
insurance costs.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
Income, Net</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
income, net for the three months ended June 30, 2023 and 2022 was $5,000 and $60,000, respectively. Our financial income is composed mainly
of exchange rate differences of certain currencies against our functional currency, which is the U.S. Dollar.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Comparison
of Six Months Ended June 30, 2023 and 2022</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six
        Months Ended<br />June 30,</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase
        (Decrease)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0);text-align:center;font-weight:bold" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold">&#160;</div></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
    <td colspan="14" style="vertical-align:bottom" valign="bottom">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(In
        thousands, except for percentage information)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">112</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(112</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenues</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">87</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(87</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research
        and development expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,140</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,084</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(944</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(31</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:52%" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
        and administrative expenses</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,429</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,052</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(1,623</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(40</span></span></div></td>
    <td colspan="1" style="background-color:rgb(204, 238, 255);vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:2px" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other
        income</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%
        </span></span></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating
        loss</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,542</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">7,084</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,542</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(36</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial income, net</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(27</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(104</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">77</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(74</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Income tax benefit</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(11</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(100</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:bottom;width:52%;padding-bottom:4px" valign="bottom">
        <div style="margin-left:10pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
        loss</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">4,515</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">6,969</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$
        </span></span></td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(2,454</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(35</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)%</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenues
for the six months ended June 30, 2022 of $112,000 were mainly attributable to pre-clinical R&#38;D services provided to Amgen under the
Amgen Agreement. We did not recognize any revenue for the six months ended June 30, 2023 due to finalization of third year pre-clinical
R&#38;D services and termination of the Amgen Agreement, effective May 2, 2023. We did not generate any revenues prior to entering into
the Amgen Agreement.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Cost
of Revenues<br />&#160;</span></span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost
of revenues for the six months ended June 30, 2022 of $87,000 were mainly attributable to pre-clinical R&#38;D services provided to Amgen
under the Amgen Agreement. The decrease in cost was due to the lack of revenues under the Amgen Agreement, as described above, for the
six months ended June 30, 2023.</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">20</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold;font-style:italic">Research
and Development Expenses<br />&#160;</span></span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Research</span></span>&#160;and
development expenses for six months ended June 30, 2023 were $2.1 million, as compared to $3.1 million for the six months ended June 30,
2022. The decrease of $1.0 million was primarily due to a decrease of $0.4 million in pre-clinical activity, a decrease of $0.1 million
in share-based compensation and a decrease of $0.5 million related to a one-time payment made to a former employee pursuant to the terms
of his separation agreement.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
and Administrative Expenses</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General
and administrative expenses for the six months ended June 30, 2023 were $2.4 million, as compared to $4.1 million for the six months ended
June 30, 2022. The decrease of $1.7 million was mainly attributable to a decrease of $0.3 million in employee compensation and $0.5 million
in share-based compensation, a decrease of $0.6 million in professional fees and other consultants and a decrease of $0.3 million in D&#38;O
insurance costs.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
Income, Net</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial
income, net for the six months ended June 30, 2023 and 2022 was $27,000 and $104,000, respectively. Our financial income is composed mainly
of exchange rate differences of certain currencies against our functional currency, which is the U.S. Dollar.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Liquidity
and Capital Resources</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since
inception, we have incurred significant losses. For the three months ended June 30, 2023 and 2022, our operating losses were $2.3 million
and $3.2 million, respectively. For the six months ended June 30, 2023 and 2022, our operating losses were $4.5 million and $7.1 million,
respectively. As of June 30, 2023, we had an accumulated deficit of $100.0 million. We expect to continue to incur significant expenses
and losses for the next several years as we advance our products through development and provide administrative support for our operations.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
a result of our recurring losses from operations, negative cash flows and lack of liquidity, management is of the opinion that there is
substantial doubt as to the Company's ability to continue as a going concern. If we are unable to raise the requisite funds, we will need
to curtail or cease operations. See in &#8220;Item 1A-Risk Factors&#8221; in our 2022 Annual Report.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Since
our inception, we have raised a total of $84.7 million, including $25.3 million through completed or terminated at-the-market-offering
(&#8220;ATM&#8221;) programs, $14.3 million in our December 2019 private placement, $11.2 million in our IPO in 2018 and $33.9 million
in aggregate funding from a combination of grants, exercise of options and warrants and private placements of Ordinary Shares, preferred
shares and debt prior to our IPO. In addition, as of June 30, 2023, we had received approximately $1.7 million under the Amgen Agreement,
which has since been terminated. As of June 30, 2023, we had cash and cash equivalents of $9.1 million. Our primary uses of cash have
been to fund research and development, general and administrative expenses and working capital requirements, and we expect these will
continue to be our primary uses of cash. </span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;text-indent:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On
</span></span>September 2, 2022, we entered into a Sales Agreement with SVB Securities LLC, as sales agent, to implement an at-the-market
offering program, under which we may from time to time offer and sell up to 5,000,000 Ordinary Shares (the &#8220;SVB ATM Program&#8221;)
under our currently effective Registration Statement on Form S-3 and a related prospectus supplement forming a part thereof. The sales
agent is entitled to a fixed commission of 3% of the aggregate gross proceeds as well as reimbursement of expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Funding
Requirements</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
believe that our existing capital resources will be sufficient to meet our projected operating requirements into the third quarter of
2024, which includes the capital required to fund our ongoing operations, including R&#38;D and the completion of the Phase 1 PK study
related to the new formulation EB612. However, this does not include the capital required to fund our proposed Phase 3 pivotal study for
EB613 in osteoporosis and comparative PK study of EB613 and Forteo&#174;. Our ability to commence such studies will depend on finalizing
discussions with the FDA and will require additional funding, which may not be available on reasonable terms, or at all. Any delay or
our inability to secure such funding will delay or prevent the commencement of these studies.</span></span></div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">21</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently
expect. Because of the numerous risks and uncertainties associated with the development of our product candidates, and the extent to which
we may enter into collaborations with third parties for development of these or other product candidates, we are unable to estimate the
amounts of increased capital outlays and operating expenses associated with completing the development of our current and future product
candidates. Our future capital requirements will depend on many factors, including:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">
        <div style="margin:0;padding:0"><span style="font-size:16px;position:relative;top:-4px">&#8226;</span></div></td>
    <td style="vertical-align:top;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>the costs, timing and outcome of clinical
        trials for, and regulatory review of, EB613, EB612 and any other product candidates we may develop;</span></span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">&#160;</td>
    <td style="vertical-align:top;width:auto">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">
        <div style="margin:0;padding:0"><span style="font-size:16px;position:relative;top:-4px">&#8226;</span></div></td>
    <td style="vertical-align:top;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>the costs of development activities for
        any other product candidates we may pursue;</span></span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">&#160;</td>
    <td style="vertical-align:top;width:auto">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">
        <div style="margin:0;padding:0"><span style="font-size:16px;position:relative;top:-4px">&#8226;</span></div></td>
    <td style="vertical-align:top;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>the costs of preparing, filing and prosecuting
        patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">&#160;</td>
    <td style="vertical-align:top;width:auto">&#160;</td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">
        <div style="margin:0;padding:0"><span style="font-size:16px;position:relative;top:-4px">&#8226;</span></div></td>
    <td style="vertical-align:top;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>our ability to establish collaborations
        on favorable terms, if at all.</span></span></span></div></td></tr>
  <tr>
    <td style="vertical-align:top;width:14pt">&#160;</td>
    <td style="vertical-align:top;width:32pt">&#160;</td>
    <td style="vertical-align:top;width:auto">&#160;</td></tr>
  </table>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
do not have any committed external sources of funds. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, the ownership interest of our then-existing shareholders will be diluted, and the terms of these securities may include
liquidation or other preferences that may adversely affect our existing shareholders&#8217; rights as shareholders. Debt financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends and may include requirements to hold minimum levels of funding. If
we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable
to us. If we are unable to raise additional funds through equity or debt financings or collaborations, when needed, we may be required
to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market
our oral PTH product candidates and any other product candidates that we would otherwise prefer to develop and market ourselves.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2023 included elsewhere in
this Quarterly Report note that there is substantial doubt about our ability to continue as a going concern as of such date. This means
that our management has expressed substantial doubt about our ability to continue our operations without an additional infusion of capital
from external sources. The unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not
include any adjustments that may be necessary should we be unable to continue as a going concern. If we are unable to finance our operations,
our business would be in jeopardy, and we might not be able to continue operations and might have to liquidate our assets. In that case,
investors might receive less than the value at which those assets are carried on our financial statements, and it is likely that investors
would lose all or a part of their investment.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">22</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash
Flows</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six
Months Ended June 30, 2023 compared to Six Months Ended June 30, 2022</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
following table sets forth the primary sources and uses of cash for each of the periods set forth below:</span></span></div>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Six
        Months Ended June 30,<br />(unaudited)</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div></td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align:baseline">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8203;</span></span></div></td>
    <td colspan="1" style="vertical-align:baseline">&#160;</td>
    <td colspan="6" style="vertical-align:baseline">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(In
        thousands)</span></span></div></td>
    <td colspan="1" style="vertical-align:baseline;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);width:76%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net Cash used in operating
        activities</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;width:1%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;text-align:right;width:9%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,168</span></span></div></td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;width:1%;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;width:1%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;text-align:right;width:9%">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7,619</span></span></div></td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;width:1%;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td></tr>
  <tr>
    <td style="vertical-align:baseline">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net Cash used in investing
        activities</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:baseline">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12)</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:baseline">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(42)</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:baseline;background-color:rgb(204, 238, 255);padding-bottom:2px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net Cash provided by
        financing activities</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;padding-bottom:2px;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:baseline;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5</span></span></div></td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;padding-bottom:2px;white-space:nowrap">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;padding-bottom:2px;background-color:rgb(204, 238, 255)">&#160;</td>
    <td colspan="2" rowspan="1" style="vertical-align:baseline;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)">
        <div style="text-align:right;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">13</span></span></div></td>
    <td colspan="1" rowspan="1" style="background-color:rgb(204, 238, 255);vertical-align:baseline;padding-bottom:2px;white-space:nowrap">&#160;</td></tr>
  <tr>
    <td style="vertical-align:baseline;width:76%;padding-bottom:4px">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net decrease in cash
        and cash equivalents</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(3,175</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px">&#160;</td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;border-bottom:4px double rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(7,648</span></span></div></td>
    <td colspan="1" rowspan="1" style="vertical-align:baseline;width:1%;padding-bottom:4px;white-space:nowrap">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div></td></tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
Cash Used in Operating Activities</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
cash used in operating activities for the six months ended June 30, 2023 was $3.2 million, consisting primarily of our operating loss
of&#8201;$4.5 million, which was partially offset by an increase of $0.3 million in our working capital and $1.0 million of share-based
compensation and depreciation expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
cash used in operating activities for the six months ended June 30, 2022 was $7.6 million, consisting primarily of our operating loss
of&#8201;$7.1 million and a decrease of $2.2 million in our working capital, which was partially offset by approximately $1.7 million
of share-based compensation and depreciation expenses.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
decrease of $4.4 million in cash used in operating activities for the six months ended June 30, 2023 compared to the same period in 2022
was mainly attributed to a decrease of $2.6 million in our operating loss and an increase of $2.5 million in working capital, primarily
due to a decrease in payments to suppliers and services providers, which were partially offset by a decrease of $0.7 million in share-based
compensation.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
Cash Used in Investing Activities</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
cash used in investing activities for the six months ended June 30, 2023 and 2022 consisted primarily of the purchase of property and
equipment.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
Cash Provided by Financing Activities</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
Cash provided by financing activities for the six months ended June 30, 2023 consisted of the net proceeds of $5 thousand from the issuance
of Ordinary Shares under the SVB ATM Program.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net
Cash provided by financing activities for the six months ended June 30, 2022 consisted of the net proceeds of $13 thousand from the issuance
of Ordinary Shares due to exercise of options .</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Contractual
Obligations</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;text-indent:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>On
</span></span>April 17, 2023, we entered into an amendment to our lease for our principal offices in Israel to extend the lease term by
five years, or through 2028. As amended, the Company has the option to exit the lease earlier, in December 2024 and in June 2026. The
average rent over the new five-year extension is $180 thousand per year.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;text-indent:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Other
than as disclosed above, there have not been any material changes in our assessment of material contractual obligations and commitments
as set forth in Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our
2022 Annual Report.<br />&#160;</span></span></span></div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">23</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">

<p style="margin:0pt">&#160;</p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Critical Accounting
Policies and Estimates</span></span></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">See
Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Critical Accounting
Policies&#8221; and our consolidated financial statements and related notes included in the 2022 Annual Report for accounting policies
and related estimates we believe are the most critical to understanding our consolidated financial statements, financial condition and
results of operations and which require complex management judgment and assumptions, or involve uncertainties. The preparation of consolidated
financial statements also requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue,
expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be
reasonable under the circumstances. There have been no changes to our critical accounting policies or their application since the date
of the 2022 Annual Report.</span></span></div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently
Issued Accounting Pronouncements</span></span></div></div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div></div>

<div style="line-height:1.25">

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain
recently issued accounting pronouncements are discussed in Note 2 to the unaudited condensed consolidated financial statements included
elsewhere in this Quarterly Report.</span></span></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
3<span id="TEM3_integixAnchor"></span>. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></span></div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;text-indent:14.2pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Not
required for smaller reporting companies.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
4. CONTROLS AND PROCEDURES</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="line-height:1.25">

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Evaluation
of Disclosure Controls and Procedures</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div></div>

<div style="line-height:1.25">

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;text-indent:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal financial officer), has evaluated
the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange
Act and regulations promulgated thereunder) as of June 30, 2023, which we refer to as the Evaluation Date. Based on such evaluation, those
officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective.</span></span></div></div>

<div style="line-height:1.25">

<div style="line-height:1.25">&#160;</div></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Changes
in Internal Control over Financial Reporting</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;text-indent:14.2pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There
have been no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">24</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">PART
II &#8211;<span id="PARTII_integixAnchor"></span> OTHER INFORMATION.</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
1. LEGAL PROCEEDINGS</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We
are not currently a party to any material legal proceedings.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
1A. RISK FACTORS</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">There
have been no material changes with respect to the risk factors disclosed in Part I, Item 1A. of our 2022 Annual Report.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
3. DEFAULTS UPON SENIOR SECURITIES</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">None.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
4. MINE SAFETY DISCLOSURES</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Not
applicable.</span></span></div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
5. OTHER INFORMATION</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;text-indent:36pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During
the quarter ended June 30, 2023, none of our officers or directors adopted or terminated any contract, instruction or written plan for
the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange
Act or any &#8220;non-Rule 10b5-1 trading arrangement&#8221;, as defined in Item 408 of Regulation S-K.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ITEM
6. E<span id="ITEM6E_integixAnchor"></span>XHIBITS</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:10.46%;vertical-align:bottom;border-bottom:#000000 2px solid;white-space:nowrap">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exhibit
        No.</span></span></div></td>
    <td style="width:0.77%;vertical-align:bottom">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:bottom;border-bottom:#000000 2px solid;white-space:nowrap">
        <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description
        of Exhibits</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;background-color:#CCEEFF;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-1.htm">31.1</a></span></span></div></td>
    <td style="width:0.77%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top;background-color:#CCEEFF">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-1.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-2.htm">31.2</a></span></span></div></td>
    <td style="width:0.77%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_31-2.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;background-color:#CCEEFF;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-1.htm">32.1*</a></span></span></div></td>
    <td style="width:0.77%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-1.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-2.htm">32.2*</a></span></span></div></td>
    <td style="width:0.77%;vertical-align:top">&#160;</td>
    <td style="width:88.77%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><a href="exhibit_32-2.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;background-color:rgb(204, 238, 255);white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.INS</span></span></div></td>
    <td style="width:0.77%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">XBRL Instance Document.</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.SCH</span></span></div></td>
    <td style="width:0.77%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">XBRL Taxonomy Extension
        Schema Document.</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;background-color:rgb(204, 238, 255);white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.DEF</span></span></div></td>
    <td style="width:0.77%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">XBRL Taxonomy Extension
        Definition Linkbase Document.</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.CAL</span></span></div></td>
    <td style="width:0.77%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">XBRL Taxonomy Extension
        Calculation Linkbase Document.</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;background-color:rgb(204, 238, 255);white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.LAB</span></span></div></td>
    <td style="width:0.77%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">XBRL Taxonomy Extension
        Label Linkbase Document.</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">101.PRE</span></span></div></td>
    <td style="width:0.77%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:88.77%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">XBRL Taxonomy Extension
        Presentation Linkbase Document.</span></span></div></td></tr>
  <tr>
    <td style="width:10.46%;vertical-align:top;background-color:#CCEEFF;white-space:nowrap">
        <div style="text-align:center;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">104</span></span></div></td>
    <td style="width:0.77%;vertical-align:top;background-color:#CCEEFF">&#160;</td>
    <td style="width:88.77%;vertical-align:top;background-color:#CCEEFF">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cover Page Interactive
        Data File (embedded within the Inline XBRL document)</span></span></div></td></tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">*
Furnished herewith.</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="clear:both;margin-top:10pt;margin-bottom:10pt">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">25</span></span></span></div>

<div style="page-break-after:always"><hr style="border-width:0px;clear:both;margin:4px 0px;width:100%;height:2px;color:#000000;background-color:#000000" /></div></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:center;line-height:1.25;font-family:'Times New Roman', Times, serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span id="SIGNATURES_integixAnchor"></span>SIGNATURES</span></span></div>

<div style="text-indent:24.5pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="text-align:justify;text-indent:24.5pt;line-height:1.25;font-family:'Times New Roman', Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.</span></span></div>

<div style="text-indent:24.5pt;line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:middle">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ENTERA BIO LTD.</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:middle">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: August 11, 2023</span></span></div></td>
    <td style="width:50%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Miranda Toledano</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Miranda Toledano<br />Chief
        Executive Officer</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Principal
        Executive Officer)</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Date: August 11, 2023</span></span></div></td>
    <td style="width:50%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">/s/ Dana Yaacov-Garbeli</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dana Yaacov-Garbeli<br />Chief
        Financial Officer</span></span></div></td></tr>
  <tr>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25">&#160;</div></td>
    <td style="width:50%;vertical-align:top">
        <div style="line-height:1.25;font-style:italic"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Principal
        Financial and Accounting Officer)</span></span></div></td></tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">&#160;</div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif">

<div style="text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:normal;font-style:normal">26</span></span></span></div></div>

<div style="line-height:1.25;font-family:'Times New Roman', Times, serif"><hr style="border:none;border-bottom:4px solid black;border-top:1px solid black;height:10px;color:#ffffff;background-color:#ffffff;text-align:center;margin-left:auto;margin-right:auto;text-align:center" /></div></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div></div></div></div></div>

</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit_31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 31.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Miranda Toledano, certify that:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze82ebed0d1544b77960acce1e60324f8">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 of Entera Bio Ltd.;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2a2d83407e774fbe9b51484da39cbb59">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
                misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z07ab97ad0b234e6b88ff54d4b1f0e289">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
                for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca098033bf1543a887113c560a52724b">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z279854fa6bf04351914cf766ff849a0d">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z33c987ada2c74548af3fd51e493856d5">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
                the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z181c3318683945459a33c3cfdb016ef7">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
                this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02235db25566415baeea8eae94efd317">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
                that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d45ef53e089462d98741de0db535bf7">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
                (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2eaa177b74c74d6fa3324d1e41b87dcc">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                report financial information; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8e549ae82494e3fa71cf9cb98d74400">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z4dae558d7d49447da40dd1b7c846f6fa">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Date: August 11, 2023</div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">/s/ Miranda Toledano</div>
            </td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 25%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Miranda Toledano</div>
            </td>
            <td style="width: 25%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chief Executive Officer</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit_31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 31.2</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Dana Yaacov-Garbeli, certify that:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zad70296e4d39450a9279cd767ce5bcc4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 of Entera Bio Ltd.;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z02c88ac741bf4b70aa7f364812e9aa35" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
                light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zce01916ef4624382a03e7393bd6a89d9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
                condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8389c3188dcd40538e3cd50c3218c4bb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
                13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf01c4d946a5a4bcf988585ff1c7164bd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
                information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zea1d9936024e4dc78ffa642e4049f3a2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
                reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z702252c4f0b64dbfa5525df78961c628" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
                disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zae86d942559840239a1f55e2883e55b5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter
                (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3d35d8a7a7314285be8eb9ab7bc28b4c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s
                auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd40064fa09bb4923aa405441039ff078" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
                affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc2aeed8a88f740e69eea23459d3f4436" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial
                reporting.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze11c76558e96497cac3561e93d4f2706" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Date: August 11, 2023</div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; line-height: 1.25;">/s/ Dana Yaacov Garbeli</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Dana Yaacov-Garbeli</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <div> <br>
    </div>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit_32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 32.1</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Miranda Toledano, Chief Executive Officer of Entera Bio Ltd. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the
        Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 that, to the best of my knowledge:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf099a738b0c74ed2bd289ea186983587" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or
                15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z378762f3bf2d4b4ea36dd22024e174bb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z7ebbaf82a8ce4c6eb9a3a0be4bd1e1b6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Date: August 11, 2023</div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: justify; line-height: 1.25;">/s/ Miranda Toledano</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Miranda Toledano</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Chief Executive Officer</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">(Principal Executive Officer)</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">&#160;
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <div> <br>
    </div>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit_32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 32.2</font></u><br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">I, Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the
        Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350 that, to the best of my knowledge:</div>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zbcb001eaa29e433c9712db16e21dbaf3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or
                15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc5df2b0e659741a69b59a40dfc5c3916" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z09d2712b29744334a62bbe1da170b644" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Date: August 11, 2023</div>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">/s/ Dana Yaacov-Garbeli</div>
            </td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Dana Yaacov-Garbeli</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Chief Financial Officer</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 25%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="width: 25%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
    <div> <br>
    </div>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>entx-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:entx="http://www.enterabio.com/20230630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.enterabio.com/20230630" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.enterabio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS" id="CONSOLIDATEDBALANCESHEETS">
        <link:definition>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" id="CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/GENERAL" id="GENERAL">
        <link:definition>0007 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES" id="SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATION" id="SHAREBASEDCOMPENSATION">
        <link:definition>0009 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION">
        <link:definition>0010 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD" id="EVENTSDURINGTHEPERIOD">
        <link:definition>0011 - Disclosure - EVENTS DURING THE PERIOD</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENT" id="SUBSEQUENTEVENT">
        <link:definition>0012 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" id="SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables" id="SHAREBASEDCOMPENSATIONTables">
        <link:definition>0014 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable">
        <link:definition>0015 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables" id="EVENTSDURINGTHEPERIODTables">
        <link:definition>0016 - Disclosure - EVENTS DURING THE PERIOD (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/GENERALDetailTextuals" id="GENERALDetailTextuals">
        <link:definition>0017 - Disclosure - DESCRIPTION OF BUSINESS (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" id="SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
        <link:definition>0018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals" id="SHAREBASEDCOMPENSATIONDetailTextuals">
        <link:definition>0019 - Disclosure - SHARE-BASED COMPENSATION (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails" id="SHAREBASEDCOMPENSATIONDetails">
        <link:definition>0020 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails" id="SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails">
        <link:definition>0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails" id="EVENTSDURINGTHEPERIODNarrativeDetails">
        <link:definition>0022 - Disclosure - EVENTS DURING THE PERIOD (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails" id="EVENTSDURINGTHEPERIODDetails">
        <link:definition>0023 - Disclosure - EVENTS DURING THE PERIOD (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative" id="SUBSEQUENTEVENTSNarrative">
        <link:definition>0024 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="entx-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" id="entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AdditionalAmountPaidForServicesToBeRecognized" id="entx_AdditionalAmountPaidForServicesToBeRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdditionalCashSeparationPayment" id="entx_AdditionalCashSeparationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AdjustedExercisePriceUnderAtMarketEquityProgram" id="entx_AdjustedExercisePriceUnderAtMarketEquityProgram" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementAxis" id="entx_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="AgreementDomain" id="entx_AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementsTypeAxis" id="entx_AgreementsTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="AgreementsTypeDomain" id="entx_AgreementsTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmendmentToBusinessDevelopmentServicesAgreementMember" id="entx_AmendmentToBusinessDevelopmentServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmgenIncMember" id="entx_AmgenIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AtmEquityProgram2020Member" id="entx_AtmEquityProgram2020Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AtmEquityProgram2021Member" id="entx_AtmEquityProgram2021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BankGuarantees" id="entx_BankGuarantees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BoardMembersMember" id="entx_BoardMembersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerWarrantsMember" id="entx_BrokerWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerWarrantsType1Member" id="entx_BrokerWarrantsType1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BrokerWarrantsType2Member" id="entx_BrokerWarrantsType2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashFeesInPercentage" id="entx_CashFeesInPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashlessExerciseOfWarrants" id="entx_CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashSeparationPayment" id="entx_CashSeparationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ChairmanOfBoardAndDnaMember" id="entx_ChairmanOfBoardAndDnaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightExerciseTerm" id="entx_ClassOfWarrantOrRightExerciseTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightIssued" id="entx_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" id="entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightReducedExercisePrice" id="entx_ClassOfWarrantOrRightReducedExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdConsecutiveTradingDays" id="entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" id="entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" id="entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" id="entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommitmentsAndContingenciesTable" id="entx_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="CommitmentsLineItems" id="entx_CommitmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultantMember" id="entx_ConsultantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DecreaseIncreaseInTaxRefundAbstract" id="entx_DecreaseIncreaseInTaxRefundAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DnaBiomedicalSolutionsLtdAndOramedLtdMember" id="entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DnaBiomedicalSolutionsLtdMember" id="entx_DnaBiomedicalSolutionsLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EffectOfDownRoundTriggerAmount" id="entx_EffectOfDownRoundTriggerAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EmployeeMember" id="entx_EmployeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeSeveranceBenefitsPolicyPolicyTextBlock" id="entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesExecutiveOfficersAndServiceProvidersMember" id="entx_EmployeesExecutiveOfficersAndServiceProvidersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesMember" id="entx_EmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EnteraBioLtdMember" id="entx_EnteraBioLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityProgramAxis" id="entx_EquityProgramAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="EquityProgramDomain" id="entx_EquityProgramDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EventsDuringPeriodAbstract" id="entx_EventsDuringPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EventsDuringPeriodLineItems" id="entx_EventsDuringPeriodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EventsDuringPeriodTable" id="entx_EventsDuringPeriodTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="EventsDuringPeriodTextBlock" id="entx_EventsDuringPeriodTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExecutiveOfficerAndServiceProviderMember" id="entx_ExecutiveOfficerAndServiceProviderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfWarrantsShares" id="entx_ExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExerciseOfWarrantsValue" id="entx_ExerciseOfWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ExercisePricePerShareOnePointTwoFourMember" id="entx_ExercisePricePerShareOnePointTwoFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareOnePointZeroSixMember" id="entx_ExercisePricePerShareOnePointZeroSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareSevenPointFiveFourMember" id="entx_ExercisePricePerShareSevenPointFiveFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareSixPointThreeOneMember" id="entx_ExercisePricePerShareSixPointThreeOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointNineSevenMember" id="entx_ExercisePricePerShareThreePointNineSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointOneFiveMember" id="entx_ExercisePricePerShareThreePointOneFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointSixEightMember" id="entx_ExercisePricePerShareThreePointSixEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareThreePointSixOneMember" id="entx_ExercisePricePerShareThreePointSixOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointFiveThreeMember" id="entx_ExercisePricePerShareTwoPointFiveThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareTwoPointOneFourMember" id="entx_ExercisePricePerShareTwoPointOneFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExercisePricePerShareZeroMember" id="entx_ExercisePricePerShareZeroMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinanceExpensesNet" id="entx_FinanceExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FirstAnniversaryMember" id="entx_FirstAnniversaryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FormerChiefExecutiveOfficerMember" id="entx_FormerChiefExecutiveOfficerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FundsInRespectOfEmployeeRightsUponRetirement" id="entx_FundsInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GeneralLineItems" id="entx_GeneralLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GeneralTable" id="entx_GeneralTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="InvestorRelationsServicesAgreementMember" id="entx_InvestorRelationsServicesAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" id="entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" id="entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" id="entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" id="entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="JointVentureAgreementMember" id="entx_JointVentureAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LaboratoryEquipmentMember" id="entx_LaboratoryEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LeaseArrangementAxis" id="entx_LeaseArrangementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="LeaseArrangementDomain" id="entx_LeaseArrangementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LiabilityForEmployeeRightsUponRetirement" id="entx_LiabilityForEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ManagementAndConsultingFees" id="entx_ManagementAndConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NetProceedsFromIssuanceOfCommonStock" id="entx_NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NonExecutiveBoardMember" id="entx_NonExecutiveBoardMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonExecutiveDirectorMember" id="entx_NonExecutiveDirectorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonExecutiveDirectorsMember" id="entx_NonExecutiveDirectorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" id="entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NumberOfNonExecutiveBoardMembers" id="entx_NumberOfNonExecutiveBoardMembers" type="xbrli:integerItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfSharesIssuedUnderPrivatePlacement" id="entx_NumberOfSharesIssuedUnderPrivatePlacement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OfficeLeaseAgreementMember" id="entx_OfficeLeaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OneTimeTerminationPayment" id="entx_OneTimeTerminationPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" id="entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeaseAgreementsForVehiclesForEmployeesMember" id="entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" id="entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionToIssueVestingPercentage" id="entx_OptionToIssueVestingPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OramedLtdMember" id="entx_OramedLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PatentCostsPolicyTextBlock" id="entx_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PatentTransferAgreementMember" id="entx_PatentTransferAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentOfRoyaltyGuaranteesCommitments" id="entx_PaymentOfRoyaltyGuaranteesCommitments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PlacementAgencyAgreementWithGpNumenkariIncMember" id="entx_PlacementAgencyAgreementWithGpNumenkariIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PresidentOfResearchAndDevelopmentMember" id="entx_PresidentOfResearchAndDevelopmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" id="entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" id="entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromOptionsAndWarrantExercises" id="entx_ProceedsFromOptionsAndWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromShortTermBankDeposits" id="entx_ProceedsFromShortTermBankDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" id="entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RelatedPartyTransactionOfCompensationOfExecutiveOfficers" id="entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" id="entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" id="entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" id="entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionWithExecutiveOfficersPayables" id="entx_RelatedPartyTransactionWithExecutiveOfficersPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RelatedPartyTransactionWithNonExecutiveDirectorsPayable" id="entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentServiceExpense" id="entx_ResearchAndDevelopmentServiceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchCollaborationAndLicenseAgreementMember" id="entx_ResearchCollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReversalOfExpensesUponForfeitureOfOptions" id="entx_ReversalOfExpensesUponForfeitureOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" id="entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RightToUseIntellectualProperty" id="entx_RightToUseIntellectualProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" id="entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" id="entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" id="entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" id="entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" id="entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SaleOfStockAmountOfInvestment" id="entx_SaleOfStockAmountOfInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SaleOfStockPercentageOfOwnershipOfEntityAcquired" id="entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfEstimatedUsefulLifeTableTextBlock" id="entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" id="entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" id="entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecondAnniversaryMember" id="entx_SecondAnniversaryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SellingPriceOfPreclinicalResearchAndDevelopmentServices" id="entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ServiceProviderMember" id="entx_ServiceProviderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeveralEmployeesAndServiceProvidersMember" id="entx_SeveralEmployeesAndServiceProvidersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeveranceExpenses" id="entx_SeveranceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayPolicyTextBlock" id="entx_SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheFiveMember" id="entx_ShareBasedPaymentArrangementTrancheFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheFourMember" id="entx_ShareBasedPaymentArrangementTrancheFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheSevenMember" id="entx_ShareBasedPaymentArrangementTrancheSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedPaymentArrangementTrancheSixMember" id="entx_ShareBasedPaymentArrangementTrancheSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIncentivePlan2013Member" id="entx_ShareIncentivePlan2013Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIncentivePlan2018Member" id="entx_ShareIncentivePlan2018Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesGrantedInPercentage" id="entx_SharesGrantedInPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SharesIssuedWeightedAveragePricePerShare" id="entx_SharesIssuedWeightedAveragePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesLineItems" id="entx_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantAccountingPoliciesTable" id="entx_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SixNonExecutiveBoardMembersMember" id="entx_SixNonExecutiveBoardMembersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockholdersEquityNoteLineItems" id="entx_StockholdersEquityNoteLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockholdersEquityNoteTable" id="entx_StockholdersEquityNoteTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="SupplementaryFinancialStatementInformationAbstract" id="entx_SupplementaryFinancialStatementInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementaryFinancialStatementInformationTextBlock" id="entx_SupplementaryFinancialStatementInformationTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TransactionCosts" id="entx_TransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TriggeringEventAxis" id="entx_TriggeringEventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="TriggeringEventDomain" id="entx_TriggeringEventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TriggeringEventMember" id="entx_TriggeringEventMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwentySeventeenMemberMember" id="entx_TwentySeventeenMemberMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwentyTwentyOneGrantMember" id="entx_TwentyTwentyOneGrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="VestedRestrictedSharesUnits" id="entx_VestedRestrictedSharesUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="VestedRestrictedShareUnitsShares" id="entx_VestedRestrictedShareUnitsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantToPurchaseOrdinaryShare" id="entx_WarrantToPurchaseOrdinaryShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>entx-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDBALANCESHEETS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_GrossProfit_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_OtherNonrecurringIncome_6" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_5" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_Liabilities_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_AccountsPayableCurrent_11" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_13" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_15" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_19" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10" xlink:to="loc_us-gaap_StockholdersEquity_20" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_20" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_20" xlink:to="loc_us-gaap_CommonStockValue_23" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionExpenseIncludingAssetRetirementObligations" xlink:label="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xlink:to="loc_entx_ProceedsFromOptionsAndWarrantExercises_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_entx_FinanceExpensesNet_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_Depreciation_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_10" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_AccretionExpenseIncludingAssetRetirementObligations_11" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_12" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_ShareBasedCompensation_13" order="70" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_14" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_16" order="100" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_17" order="110" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_18" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19" order="130" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_22" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_AccruedVacationCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="10" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>entx-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SHAREBASEDCOMPENSATIONDetails" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SHAREBASEDCOMPENSATIONDetailTextuals" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#GENERALDetailTextuals" roleURI="http://www.enterabio.com/role/GENERALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUBSEQUENTEVENTSNarrative" roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#EVENTSDURINGTHEPERIODNarrativeDetails" roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_6"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_7"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_8"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_9"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_SignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_entx_AmgenIncMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_SeveranceExpenses_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_entx_RightToUseIntellectualProperty_10" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SixNonExecutiveBoardMembersMember" xlink:label="loc_entx_SixNonExecutiveBoardMembersMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_entx_SixNonExecutiveBoardMembersMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_entx_NonExecutiveDirectorMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_entx_ExecutiveOfficerAndServiceProviderMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_ExecutiveOfficerMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_VestingAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_8" xlink:to="loc_us-gaap_VestingDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_8" xlink:to="loc_us-gaap_VestingDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_17" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_18" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_19" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/GENERALDetailTextuals">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_entx_GeneralTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_us-gaap_WarrantMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9" xlink:to="loc_us-gaap_CommonStockMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_GeneralLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_12"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_18"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_21"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockholdersEquity_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_SharesOutstanding_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_16" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_ExerciseOfWarrantsValue_18" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_ExerciseOfWarrantsShares_19" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_21" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_entx_VestedRestrictedShareUnitsShares_22" order="130" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_17"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5" xlink:to="loc_us-gaap_WarrantMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9" xlink:to="loc_us-gaap_SubsequentEventMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightIssued_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_entx_ClassOfWarrantOrRightExerciseTerm_17" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodLineItems" xlink:label="loc_entx_EventsDuringPeriodLineItems_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTable" xlink:label="loc_entx_EventsDuringPeriodTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OfficeLeaseAgreementMember" xlink:label="loc_entx_OfficeLeaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_entx_EventsDuringPeriodLineItems_0" xlink:to="loc_entx_EventsDuringPeriodTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_entx_EventsDuringPeriodTable_1" xlink:to="loc_us-gaap_LeaseContractualTermAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_1" xlink:to="loc_us-gaap_LeaseContractualTermDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_1" xlink:to="loc_entx_OfficeLeaseAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_1" xlink:to="loc_us-gaap_LeaseContractualTermDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EventsDuringPeriodLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EventsDuringPeriodLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EventsDuringPeriodLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescription_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EventsDuringPeriodLineItems_0" xlink:to="loc_us-gaap_OperatingLeaseExpense_9" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_entx_EventsDuringPeriodLineItems_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_10" order="50" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>entx-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_42"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_43"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_44"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember" xlink:label="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_45"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_46"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_47"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_48"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_49"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_50"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalCashSeparationPayment" xlink:label="loc_entx_AdditionalCashSeparationPayment_51"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_52"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_53"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdjustedExercisePriceUnderAtMarketEquityProgram" xlink:label="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_54"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementAxis" xlink:label="loc_entx_AgreementAxis_55"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementAxis" xlink:label="loc_entx_AgreementAxis_56"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_57"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementDomain" xlink:label="loc_entx_AgreementDomain_58"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementsTypeAxis" xlink:label="loc_entx_AgreementsTypeAxis_59"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementsTypeAxis" xlink:label="loc_entx_AgreementsTypeAxis_60"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementsTypeDomain" xlink:label="loc_entx_AgreementsTypeDomain_61"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AgreementsTypeDomain" xlink:label="loc_entx_AgreementsTypeDomain_62"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_63"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_64"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmendmentToBusinessDevelopmentServicesAgreementMember" xlink:label="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_65"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_66"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_67"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_68"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_69"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_70"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AtmEquityProgram2020Member" xlink:label="loc_entx_AtmEquityProgram2020Member_71"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_72"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_73"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AtmEquityProgram2021Member" xlink:label="loc_entx_AtmEquityProgram2021Member_74"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_75"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_76"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BankGuarantees" xlink:label="loc_entx_BankGuarantees_77"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BoardMembersMember" xlink:label="loc_entx_BoardMembersMember_78"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BoardMembersMember" xlink:label="loc_entx_BoardMembersMember_79"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_80"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_81"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsMember" xlink:label="loc_entx_BrokerWarrantsMember_82"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_83"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_84"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsType1Member" xlink:label="loc_entx_BrokerWarrantsType1Member_85"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_86"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_87"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_BrokerWarrantsType2Member" xlink:label="loc_entx_BrokerWarrantsType2Member_88"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_89"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_90"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashFeesInPercentage" xlink:label="loc_entx_CashFeesInPercentage_91"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashlessExerciseOfWarrants" xlink:label="loc_entx_CashlessExerciseOfWarrants_92"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashlessExerciseOfWarrants" xlink:label="loc_entx_CashlessExerciseOfWarrants_93"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashlessExerciseOfWarrants" xlink:label="loc_entx_CashlessExerciseOfWarrants_94"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_95"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_96"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CashSeparationPayment" xlink:label="loc_entx_CashSeparationPayment_97"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_98"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_99"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ChairmanOfBoardAndDnaMember" xlink:label="loc_entx_ChairmanOfBoardAndDnaMember_100"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_101"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_102"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_103"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_104"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_105"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_106"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_107"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_108"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit" xlink:label="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_109"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_110"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_111"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightReducedExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_112"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_113"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_114"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_115"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_116"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_117"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_118"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_119"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_120"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_121"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_122"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_123"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice" xlink:label="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_124"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CommitmentsAndContingenciesTable" xlink:label="loc_entx_CommitmentsAndContingenciesTable_125"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CommitmentsAndContingenciesTable" xlink:label="loc_entx_CommitmentsAndContingenciesTable_126"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CommitmentsLineItems" xlink:label="loc_entx_CommitmentsLineItems_127"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_CommitmentsLineItems" xlink:label="loc_entx_CommitmentsLineItems_128"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_129"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_130"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ConsultantMember" xlink:label="loc_entx_ConsultantMember_131"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DecreaseIncreaseInTaxRefundAbstract" xlink:label="loc_entx_DecreaseIncreaseInTaxRefundAbstract_132"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DecreaseIncreaseInTaxRefundAbstract" xlink:label="loc_entx_DecreaseIncreaseInTaxRefundAbstract_133"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DecreaseIncreaseInTaxRefundAbstract" xlink:label="loc_entx_DecreaseIncreaseInTaxRefundAbstract_134"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_135"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_136"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_137"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_138"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_139"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_DnaBiomedicalSolutionsLtdMember" xlink:label="loc_entx_DnaBiomedicalSolutionsLtdMember_140"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_141"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_142"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EffectOfDownRoundTriggerAmount" xlink:label="loc_entx_EffectOfDownRoundTriggerAmount_143"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_144"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_145"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeMember" xlink:label="loc_entx_EmployeeMember_146"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_147"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_148"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_149"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeesExecutiveOfficersAndServiceProvidersMember" xlink:label="loc_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_150"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeesExecutiveOfficersAndServiceProvidersMember" xlink:label="loc_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_151"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_152"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_153"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeesMember" xlink:label="loc_entx_EmployeesMember_154"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_155"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_156"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EnteraBioLtdMember" xlink:label="loc_entx_EnteraBioLtdMember_157"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EquityProgramAxis" xlink:label="loc_entx_EquityProgramAxis_158"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EquityProgramAxis" xlink:label="loc_entx_EquityProgramAxis_159"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_160"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EquityProgramDomain" xlink:label="loc_entx_EquityProgramDomain_161"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodAbstract" xlink:label="loc_entx_EventsDuringPeriodAbstract_162"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodLineItems" xlink:label="loc_entx_EventsDuringPeriodLineItems_163"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodLineItems" xlink:label="loc_entx_EventsDuringPeriodLineItems_164"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTable" xlink:label="loc_entx_EventsDuringPeriodTable_165"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTable" xlink:label="loc_entx_EventsDuringPeriodTable_166"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTextBlock" xlink:label="loc_entx_EventsDuringPeriodTextBlock_167"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTextBlock" xlink:label="loc_entx_EventsDuringPeriodTextBlock_168"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTextBlock" xlink:label="loc_entx_EventsDuringPeriodTextBlock_169"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_170"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_171"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_172"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_173"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_174"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_175"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_176"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_177"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_178"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_179"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_180"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareOnePointTwoFourMember" xlink:label="loc_entx_ExercisePricePerShareOnePointTwoFourMember_181"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_182"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_183"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareOnePointZeroSixMember" xlink:label="loc_entx_ExercisePricePerShareOnePointZeroSixMember_184"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareSevenPointFiveFourMember" xlink:label="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_185"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareSevenPointFiveFourMember" xlink:label="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_186"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareSevenPointFiveFourMember" xlink:label="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_187"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_188"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_189"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareSixPointThreeOneMember" xlink:label="loc_entx_ExercisePricePerShareSixPointThreeOneMember_190"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_191"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_192"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointNineSevenMember" xlink:label="loc_entx_ExercisePricePerShareThreePointNineSevenMember_193"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_194"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_195"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointOneFiveMember" xlink:label="loc_entx_ExercisePricePerShareThreePointOneFiveMember_196"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_197"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_198"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointSixEightMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixEightMember_199"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_200"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_201"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareThreePointSixOneMember" xlink:label="loc_entx_ExercisePricePerShareThreePointSixOneMember_202"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_203"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_204"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareTwoPointFiveThreeMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_205"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_206"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_207"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareTwoPointOneFourMember" xlink:label="loc_entx_ExercisePricePerShareTwoPointOneFourMember_208"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_209"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_210"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExercisePricePerShareZeroMember" xlink:label="loc_entx_ExercisePricePerShareZeroMember_211"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_212"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_213"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_214"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FirstAnniversaryMember" xlink:label="loc_entx_FirstAnniversaryMember_215"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FirstAnniversaryMember" xlink:label="loc_entx_FirstAnniversaryMember_216"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_217"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_218"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FormerChiefExecutiveOfficerMember" xlink:label="loc_entx_FormerChiefExecutiveOfficerMember_219"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_220"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_221"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_222"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FundsInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_223"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_224"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_225"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_226"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_227"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_228"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_229"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_InvestorRelationsServicesAgreementMember" xlink:label="loc_entx_InvestorRelationsServicesAgreementMember_230"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_231"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_232"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_233"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_234"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_235"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_236"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_237"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_238"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_239"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_240"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_241"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue" xlink:label="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_242"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_243"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_244"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_JointVentureAgreementMember" xlink:label="loc_entx_JointVentureAgreementMember_245"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_246"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_247"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LaboratoryEquipmentMember" xlink:label="loc_entx_LaboratoryEquipmentMember_248"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LeaseArrangementAxis" xlink:label="loc_entx_LeaseArrangementAxis_249"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LeaseArrangementAxis" xlink:label="loc_entx_LeaseArrangementAxis_250"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_251"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LeaseArrangementDomain" xlink:label="loc_entx_LeaseArrangementDomain_252"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LiabilityForEmployeeRightsUponRetirement" xlink:label="loc_entx_LiabilityForEmployeeRightsUponRetirement_253"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LiabilityForEmployeeRightsUponRetirement" xlink:label="loc_entx_LiabilityForEmployeeRightsUponRetirement_254"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_LiabilityForEmployeeRightsUponRetirement" xlink:label="loc_entx_LiabilityForEmployeeRightsUponRetirement_255"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ManagementAndConsultingFees" xlink:label="loc_entx_ManagementAndConsultingFees_256"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ManagementAndConsultingFees" xlink:label="loc_entx_ManagementAndConsultingFees_257"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ManagementAndConsultingFees" xlink:label="loc_entx_ManagementAndConsultingFees_258"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_259"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_260"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_entx_NetProceedsFromIssuanceOfCommonStock_261"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveBoardMember" xlink:label="loc_entx_NonExecutiveBoardMember_262"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveBoardMember" xlink:label="loc_entx_NonExecutiveBoardMember_263"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_264"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_265"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_266"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_267"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorsMember" xlink:label="loc_entx_NonExecutiveDirectorsMember_268"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorsMember" xlink:label="loc_entx_NonExecutiveDirectorsMember_269"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorsMember" xlink:label="loc_entx_NonExecutiveDirectorsMember_270"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_271"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_272"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_273"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_274"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_275"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_276"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NumberOfNonExecutiveBoardMembers" xlink:label="loc_entx_NumberOfNonExecutiveBoardMembers_277"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_278"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_279"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NumberOfSharesIssuedUnderPrivatePlacement" xlink:label="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_280"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OfficeLeaseAgreementMember" xlink:label="loc_entx_OfficeLeaseAgreementMember_281"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OfficeLeaseAgreementMember" xlink:label="loc_entx_OfficeLeaseAgreementMember_282"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OneTimeTerminationPayment" xlink:label="loc_entx_OneTimeTerminationPayment_283"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OneTimeTerminationPayment" xlink:label="loc_entx_OneTimeTerminationPayment_284"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OneTimeTerminationPayment" xlink:label="loc_entx_OneTimeTerminationPayment_285"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_286"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_287"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember" xlink:label="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_288"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_289"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_290"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember" xlink:label="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_291"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_292"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_293"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock" xlink:label="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_294"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_295"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_296"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_297"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OptionToIssueVestingPercentage" xlink:label="loc_entx_OptionToIssueVestingPercentage_298"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OptionToIssueVestingPercentage" xlink:label="loc_entx_OptionToIssueVestingPercentage_299"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OptionToIssueVestingPercentage" xlink:label="loc_entx_OptionToIssueVestingPercentage_300"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OramedLtdMember" xlink:label="loc_entx_OramedLtdMember_301"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OramedLtdMember" xlink:label="loc_entx_OramedLtdMember_302"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OramedLtdMember" xlink:label="loc_entx_OramedLtdMember_303"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PatentCostsPolicyTextBlock" xlink:label="loc_entx_PatentCostsPolicyTextBlock_304"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PatentCostsPolicyTextBlock" xlink:label="loc_entx_PatentCostsPolicyTextBlock_305"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PatentCostsPolicyTextBlock" xlink:label="loc_entx_PatentCostsPolicyTextBlock_306"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_307"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_308"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PatentTransferAgreementMember" xlink:label="loc_entx_PatentTransferAgreementMember_309"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_310"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_311"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PaymentOfRoyaltyGuaranteesCommitments" xlink:label="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_312"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_313"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_314"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PlacementAgencyAgreementWithGpNumenkariIncMember" xlink:label="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_315"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_316"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_317"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_PresidentOfResearchAndDevelopmentMember" xlink:label="loc_entx_PresidentOfResearchAndDevelopmentMember_318"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_319"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_320"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_321"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_322"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_323"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts" xlink:label="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_324"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_325"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_326"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_327"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_328"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_329"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_330"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_331"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromShortTermBankDeposits" xlink:label="loc_entx_ProceedsFromShortTermBankDeposits_332"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" xlink:label="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_333"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" xlink:label="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_334"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_335"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_336"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_337"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_338"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_339"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_340"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_341"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_342"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_343"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_344"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_345"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers" xlink:label="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_346"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionWithExecutiveOfficersPayables" xlink:label="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_347"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionWithExecutiveOfficersPayables" xlink:label="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_348"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionWithExecutiveOfficersPayables" xlink:label="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_349"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" xlink:label="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_350"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" xlink:label="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_351"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable" xlink:label="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_352"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ResearchAndDevelopmentServiceExpense" xlink:label="loc_entx_ResearchAndDevelopmentServiceExpense_353"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ResearchAndDevelopmentServiceExpense" xlink:label="loc_entx_ResearchAndDevelopmentServiceExpense_354"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ResearchAndDevelopmentServiceExpense" xlink:label="loc_entx_ResearchAndDevelopmentServiceExpense_355"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_entx_ResearchCollaborationAndLicenseAgreementMember_356"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_entx_ResearchCollaborationAndLicenseAgreementMember_357"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_entx_ResearchCollaborationAndLicenseAgreementMember_358"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_359"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_360"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ReversalOfExpensesUponForfeitureOfOptions" xlink:label="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_361"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_362"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_363"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_364"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_365"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_366"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_367"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_368"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_369"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_370"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_371"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_372"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_373"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_374"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_375"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_376"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_377"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_378"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_379"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_380"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_381"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears" xlink:label="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_382"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_383"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_384"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SaleOfStockAmountOfInvestment" xlink:label="loc_entx_SaleOfStockAmountOfInvestment_385"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_386"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_387"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired" xlink:label="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_388"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_389"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_390"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfEstimatedUsefulLifeTableTextBlock" xlink:label="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_391"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_392"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_393"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_394"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_395"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_396"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_397"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SecondAnniversaryMember" xlink:label="loc_entx_SecondAnniversaryMember_398"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SecondAnniversaryMember" xlink:label="loc_entx_SecondAnniversaryMember_399"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" xlink:label="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_400"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" xlink:label="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_401"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices" xlink:label="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_402"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_403"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_404"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ServiceProviderMember" xlink:label="loc_entx_ServiceProviderMember_405"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_406"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_407"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveralEmployeesAndServiceProvidersMember" xlink:label="loc_entx_SeveralEmployeesAndServiceProvidersMember_408"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_409"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_410"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_411"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeverancePayPolicyTextBlock" xlink:label="loc_entx_SeverancePayPolicyTextBlock_412"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeverancePayPolicyTextBlock" xlink:label="loc_entx_SeverancePayPolicyTextBlock_413"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeverancePayPolicyTextBlock" xlink:label="loc_entx_SeverancePayPolicyTextBlock_414"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_415"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_416"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheFiveMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_417"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_418"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_419"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheFourMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_420"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheSevenMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_421"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheSevenMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_422"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_423"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_424"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareBasedPaymentArrangementTrancheSixMember" xlink:label="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_425"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_426"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_427"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareIncentivePlan2013Member" xlink:label="loc_entx_ShareIncentivePlan2013Member_428"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_429"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_430"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ShareIncentivePlan2018Member" xlink:label="loc_entx_ShareIncentivePlan2018Member_431"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_432"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_433"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SharesGrantedInPercentage" xlink:label="loc_entx_SharesGrantedInPercentage_434"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_435"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_436"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SharesIssuedWeightedAveragePricePerShare" xlink:label="loc_entx_SharesIssuedWeightedAveragePricePerShare_437"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_438"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_439"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_440"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_441"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SixNonExecutiveBoardMembersMember" xlink:label="loc_entx_SixNonExecutiveBoardMembersMember_442"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SixNonExecutiveBoardMembersMember" xlink:label="loc_entx_SixNonExecutiveBoardMembersMember_443"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SixNonExecutiveBoardMembersMember" xlink:label="loc_entx_SixNonExecutiveBoardMembersMember_444"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_StockholdersEquityNoteLineItems" xlink:label="loc_entx_StockholdersEquityNoteLineItems_445"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_StockholdersEquityNoteLineItems" xlink:label="loc_entx_StockholdersEquityNoteLineItems_446"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_StockholdersEquityNoteTable" xlink:label="loc_entx_StockholdersEquityNoteTable_447"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_StockholdersEquityNoteTable" xlink:label="loc_entx_StockholdersEquityNoteTable_448"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_449"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_450"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_451"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_452"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_453"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_454"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TransactionCosts" xlink:label="loc_entx_TransactionCosts_455"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventAxis" xlink:label="loc_entx_TriggeringEventAxis_456"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventAxis" xlink:label="loc_entx_TriggeringEventAxis_457"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventDomain" xlink:label="loc_entx_TriggeringEventDomain_458"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventDomain" xlink:label="loc_entx_TriggeringEventDomain_459"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_460"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_461"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TriggeringEventMember" xlink:label="loc_entx_TriggeringEventMember_462"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_463"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_464"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TwentySeventeenMemberMember" xlink:label="loc_entx_TwentySeventeenMemberMember_465"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_466"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_467"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_TwentyTwentyOneGrantMember" xlink:label="loc_entx_TwentyTwentyOneGrantMember_468"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedSharesUnits" xlink:label="loc_entx_VestedRestrictedSharesUnits_469"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedSharesUnits" xlink:label="loc_entx_VestedRestrictedSharesUnits_470"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedSharesUnits" xlink:label="loc_entx_VestedRestrictedSharesUnits_471"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_472"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_473"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_474"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_475"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_476"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_WarrantToPurchaseOrdinaryShare" xlink:label="loc_entx_WarrantToPurchaseOrdinaryShare_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember" xlink:label="loc_srt_SubsidiariesMember_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="loc_us-gaap_CommonStockValueOutstanding_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:label="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_713"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_714"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_715"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_716"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_717"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_718"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_719"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_720"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_721"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_722"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_723"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_724"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_725"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_726"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_727"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_728"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_729"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_730"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_731"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_732"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_733"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_734"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_735"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_736"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_737"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_738"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_739"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_740"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_741"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_742"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_743"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_744"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_745"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_746"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_747"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_748"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_749"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_750"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_751"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_752"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_753"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_754"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_755"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_756"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_757"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_758"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_759"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_760"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_761"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_762"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_763"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_764"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_765"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_766"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_767"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_768"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_769"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_770"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_771"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_772"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_773"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_774"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_775"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_776"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_777"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_778"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_779"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_780"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_781"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_782"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_784"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_785"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_786"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_787"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_788"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_789"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_790"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_791"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_792"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_793"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_794"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_795"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_796"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_797"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_798"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_799"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_800"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_801"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_802"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_803"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_804"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_805"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_806"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_807"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_808"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_809"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_810"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_811"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_812"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_813"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_814"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_815"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_816"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_817"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_818"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_819"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_820"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_821"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_823"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_824"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_825"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_827"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_828"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_829"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_830"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_831"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_832"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_833"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_834"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_835"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_836"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_837"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_838"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_839"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_840"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_841"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_842"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_843"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_844"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_845"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_846"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_847"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_848"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_849"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_850"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_851"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_852"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_853"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_854"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_855"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_856"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_857"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_858"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_859"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_860"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_861"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_862"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_863"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_864"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_865"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_866"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_867"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_868"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_869"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_870"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_871"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_872"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_873"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_874"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_875"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_876"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_877"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_878"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_879"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_880"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_881"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_882"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_883"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_884"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_885"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_886"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_887"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_888"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_889"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_890"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_891"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_892"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_893"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_894"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_895"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_896"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_897"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_898"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaap_OtherOperatingIncome_899"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaap_OtherOperatingIncome_900"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingIncome" xlink:label="loc_us-gaap_OtherOperatingIncome_901"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_902"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_903"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_904"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_905"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_906"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_907"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_908"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_909"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_910"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_911"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_912"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_913"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_914"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_915"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_916"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_917"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_918"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_919"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_920"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_921"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_922"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_923"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_924"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_925"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_926"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_927"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_929"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_930"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_931"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_932"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_934"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_935"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_936"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_937"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_938"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_939"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_940"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_941"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_942"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_943"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_944"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_945"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_946"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_947"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_948"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_949"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_950"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_951"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_952"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_953"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_954"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_955"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestments" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_956"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_957"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_958"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_959"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_960"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_961"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_962"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_963"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_964"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_965"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_966"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_967"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_968"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_969"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_970"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_971"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_972"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_973"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_974"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_975"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_976"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_977"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_978"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_979"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_980"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_981"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_982"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_983"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_984"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_985"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_986"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_987"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_988"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_989"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_991"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_992"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_993"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_994"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_995"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_996"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_997"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_998"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_999"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1000"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1001"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_1002"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1003"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1004"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1005"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1006"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1007"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1008"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1009"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1010"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1011"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1012"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1013"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1014"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1015"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1016"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1017"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1018"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1019"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1020"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1021"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1022"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1023"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1024"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1025"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1026"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1027"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1028"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1029"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1030"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1031"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1032"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1033"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1034"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1035"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1036"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1037"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1038"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1039"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1040"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1041"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1042"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1043"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1044"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1045"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1046"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1047"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1048"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1049"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1050"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1051"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1052"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1053"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1054"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1055"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1056"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1057"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1058"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1059"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1060"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1061"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1062"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1063"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1064"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1065"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1066"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1067"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1068"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1069"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1070"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1071"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1072"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1073"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1074"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1075"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1076"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1077"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1078"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1079"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1080"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1081"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1082"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1083"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1084"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_1085"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1086"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1087"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1088"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1089"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1090"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1091"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1092"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1093"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1094"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1095"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1096"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1097"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1098"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1099"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1101"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1102"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1103"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1104"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1105"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1106"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1107"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1108"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1109"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1112"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1113"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1114"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1115"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1116"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1117"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1118"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1119"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1123"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1124"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1125"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1126"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1127"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1128"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1129"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1132"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1133"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1134"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1135"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1136"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1137"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1138"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1139"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1141"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1142"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1143"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1144"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1145"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1146"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1147"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract_0" xml:lang="en-US">Cover [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CoverAbstract_1" xml:lang="en-US">CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport_0" xml:lang="en-US">Document Quarterly Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince_0" xml:lang="en-US">Entity Address, State or Province</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat_0" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber_0" xml:lang="en-US">Entity Tax Identification Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_0" xml:lang="en-US">Represents the information regarding accredited investors, including certain board members and their affiliates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_1" xml:lang="en-US">Accredited Investors, Including Certain Board Members And Their Affiliates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_2" xml:lang="en-US">Accredited investors, including certain board members and their affiliates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_0" xml:lang="en-US">Represents the additional amount paid for services to be recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_1" xml:lang="en-US">Additional Amount Paid For Services To Be Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_2" xml:lang="en-US">Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AdditionalCashSeparationPayment_0" xml:lang="en-US">Represents about additional cash separation payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AdditionalCashSeparationPayment_1" xml:lang="en-US">Additional Cash Separation Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AdditionalCashSeparationPayment_2" xml:lang="en-US">Additional cash separation payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_0" xml:lang="en-US">Adjusted Exercise Price under At-the-market equity program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_1" xml:lang="en-US">Adjusted Exercise Price Under At Market Equity Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_2" xml:lang="en-US">Adjusted exercise price under At-the-market equity program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AgreementAxis_0" xml:lang="en-US">Information by the type of agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AgreementAxis_1" xml:lang="en-US">Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AgreementDomain_0" xml:lang="en-US">Name of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AgreementDomain_1" xml:lang="en-US">Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AgreementsTypeAxis_0" xml:lang="en-US">This axis represents about agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AgreementsTypeAxis_1" xml:lang="en-US">Agreements Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AgreementsTypeDomain_0" xml:lang="en-US">Represents about agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AgreementsTypeDomain_1" xml:lang="en-US">Agreements Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_0" xml:lang="en-US">Amendment to business development services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_1" xml:lang="en-US">Amendment To Business Development Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_2" xml:lang="en-US">Amendment to business development services agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AmgenIncMember_0" xml:lang="en-US">Represents one of the related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AmgenIncMember_1" xml:lang="en-US">Amgen Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AmgenIncMember_2" xml:lang="en-US">Amgen Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AtmEquityProgram2020Member_0" xml:lang="en-US">Represents the information related to at-the-market equity program for 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AtmEquityProgram2020Member_1" xml:lang="en-US">Atm Equity Program 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AtmEquityProgram2020Member_2" xml:lang="en-US">ATM Equity Program 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_AtmEquityProgram2021Member_0" xml:lang="en-US">Represents the information related to at-the-market equity program for 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_AtmEquityProgram2021Member_1" xml:lang="en-US">Atm Equity Program 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_AtmEquityProgram2021Member_2" xml:lang="en-US">ATM Equity Program 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BankGuarantees_0" xml:lang="en-US">Represents the value of bank guarantees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BankGuarantees_1" xml:lang="en-US">Bank Guarantees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BankGuarantees_2" xml:lang="en-US">Value of bank guarantees provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BoardMembersMember_0" xml:lang="en-US">Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BoardMembersMember_1" xml:lang="en-US">Board Members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerWarrantsMember_0" xml:lang="en-US">Represents the type of warrants as broker warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerWarrantsMember_1" xml:lang="en-US">Broker Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerWarrantsMember_2" xml:lang="en-US">Broker Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerWarrantsType1Member_0" xml:lang="en-US">Represents the type of warrant as Broker Warrants Type 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerWarrantsType1Member_1" xml:lang="en-US">Broker Warrants Type 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerWarrantsType1Member_2" xml:lang="en-US">Broker Warrants Type 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_BrokerWarrantsType2Member_0" xml:lang="en-US">Represents the type of warrants as Broker Warrants Type 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_BrokerWarrantsType2Member_1" xml:lang="en-US">Broker Warrants Type 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_BrokerWarrantsType2Member_2" xml:lang="en-US">Broker Warrants Type 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CashFeesInPercentage_0" xml:lang="en-US">Represents the cash fees in percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CashFeesInPercentage_1" xml:lang="en-US">Cash Fees In Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_CashFeesInPercentage_2" xml:lang="en-US">Cash fees in percentage of total proceeds paid by subscribers invested through the Broker</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CashlessExerciseOfWarrants_0" xml:lang="en-US">Value of exercise of warrants in noncash transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CashlessExerciseOfWarrants_1" xml:lang="en-US">Cashless Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_CashlessExerciseOfWarrants_2" xml:lang="en-US">Cashless exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CashSeparationPayment_0" xml:lang="en-US">Represents about cash separation payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CashSeparationPayment_1" xml:lang="en-US">Cash Separation Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_CashSeparationPayment_2" xml:lang="en-US">Cash separation payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ChairmanOfBoardAndDnaMember_0" xml:lang="en-US">Represents the information regarding two related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ChairmanOfBoardAndDnaMember_1" xml:lang="en-US">Chairman Of Board And Dna [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ChairmanOfBoardAndDnaMember_2" xml:lang="en-US">Chairman of the board and DNA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightExerciseTerm_0" xml:lang="en-US">Represents the exercise period of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightExerciseTerm_1" xml:lang="en-US">Class Of Warrant Or Right, Exercise Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightExerciseTerm_2" xml:lang="en-US">Term of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightIssued_0" xml:lang="en-US">Represents the number of warrants or rights issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightIssued_1" xml:lang="en-US">Class Of Warrant Or Right, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightIssued_2" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_0" xml:lang="en-US">Represents the percentage of IPO price per unit of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_1" xml:lang="en-US">Class Of Warrant Or Right, Percentage Of Ipo Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_2" xml:lang="en-US">Percentage of IPO price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_0" xml:lang="en-US">Represents the reduced exercise price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_1" xml:lang="en-US">Class Of Warrant Or Right, Reduced Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_2" xml:lang="en-US">Reduced exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_0" xml:lang="en-US">Represents the threshold period of specified consecutive trading days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_1" xml:lang="en-US">Class Of Warrant Or Right, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_2" xml:lang="en-US">Threshold consecutive trading days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_0" xml:lang="en-US">Represents the threshold limit of last reported sale price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_1" xml:lang="en-US">Class Of Warrant Or Right, Threshold Limit Of Last Reported Sale Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_2" xml:lang="en-US">Threshold limit of last reported sale price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_0" xml:lang="en-US">Represents the threshold limit of period for reduction in exercise price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_1" xml:lang="en-US">Class Of Warrant Or Right, Threshold Limit Of Period For Reduction In Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_2" xml:lang="en-US">Threshold limit of period for reduction in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_0" xml:lang="en-US">Represents the threshold limit of reduction in exercise price of warrants or rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_1" xml:lang="en-US">Class Of Warrant Or Right, Threshold Limit Of Reduction In Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_2" xml:lang="en-US">Threshold limit of reduction in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CommitmentsAndContingenciesTable_0" xml:lang="en-US">Information and financial data about the commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CommitmentsAndContingenciesTable_1" xml:lang="en-US">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_CommitmentsLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_CommitmentsLineItems_1" xml:lang="en-US">Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ConsultantMember_0" xml:lang="en-US">Information of consultant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ConsultantMember_1" xml:lang="en-US">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ConsultantMember_2" xml:lang="en-US">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_DecreaseIncreaseInTaxRefundAbstract_0" xml:lang="en-US">Decrease increase in tax refund [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_DecreaseIncreaseInTaxRefundAbstract_1" xml:lang="en-US">Decrease Increase In Tax Refund [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_DecreaseIncreaseInTaxRefundAbstract_2" xml:lang="en-US">Decrease (increase) in tax refund resulting from:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_0" xml:lang="en-US">Represents the information regarding both of the related parties combined.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_1" xml:lang="en-US">Dna Biomedical Solutions Ltd And Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_2" xml:lang="en-US">D. N. A Biomedical Solutions Ltd And Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdMember_0" xml:lang="en-US">Represents the information regarding one of the related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdMember_1" xml:lang="en-US">Dna Biomedical Solutions Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_DnaBiomedicalSolutionsLtdMember_2" xml:lang="en-US">D.N.A Biomedical Solutions Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EffectOfDownRoundTriggerAmount_0" xml:lang="en-US">It represents effect of down round trigger amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EffectOfDownRoundTriggerAmount_1" xml:lang="en-US">Effect Of Down Round Trigger Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_EffectOfDownRoundTriggerAmount_2" xml:lang="en-US">Effect of down round trigger amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeeMember_0" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeeMember_1" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_EmployeeMember_2" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for employee severance benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_1" xml:lang="en-US">Employee Severance Benefits Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_2" xml:lang="en-US">Employee severance benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_0" xml:lang="en-US">This member represents about employees, executive officers and service providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_1" xml:lang="en-US">Employees Executive Officers And Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EmployeesMember_0" xml:lang="en-US">Information of employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EmployeesMember_1" xml:lang="en-US">Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_EmployeesMember_2" xml:lang="en-US">Certain employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EnteraBioLtdMember_0" xml:lang="en-US">This member stands for Entera Bio Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EnteraBioLtdMember_1" xml:lang="en-US">Entera Bio Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_EnteraBioLtdMember_2" xml:lang="en-US">Entera Bio Ltd</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EquityProgramAxis_0" xml:lang="en-US">Information by equity program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EquityProgramAxis_1" xml:lang="en-US">Equity Program [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EquityProgramDomain_0" xml:lang="en-US">Name of the equity program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EquityProgramDomain_1" xml:lang="en-US">Equity Program [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EventsDuringPeriodAbstract_0" xml:lang="en-US">Events During Period [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EventsDuringPeriodLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EventsDuringPeriodLineItems_1" xml:lang="en-US">Events During Period [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EventsDuringPeriodTable_0" xml:lang="en-US">Represents the disclosure of events during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EventsDuringPeriodTable_1" xml:lang="en-US">Events During Period [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_EventsDuringPeriodTextBlock_0" xml:lang="en-US">Represents the entire disclosure for events during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_EventsDuringPeriodTextBlock_1" xml:lang="en-US">Events During Period [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_EventsDuringPeriodTextBlock_2" xml:lang="en-US">EVENTS DURING THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExecutiveOfficerAndServiceProviderMember_0" xml:lang="en-US">Represents about executive officer and service provider.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExecutiveOfficerAndServiceProviderMember_1" xml:lang="en-US">Executive Officer And Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExecutiveOfficerAndServiceProviderMember_2" xml:lang="en-US">Executive Officer and Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExerciseOfWarrantsShares_0" xml:lang="en-US">Number of warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExerciseOfWarrantsShares_1" xml:lang="en-US">Exercise Of Warrants Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExerciseOfWarrantsShares_2" xml:lang="en-US">Exercise of warrants to ordinary shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExerciseOfWarrantsValue_0" xml:lang="en-US">Represents the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExerciseOfWarrantsValue_1" xml:lang="en-US">Exercise Of Warrants Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExerciseOfWarrantsValue_2" xml:lang="en-US">Exercise of warrants to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareOnePointTwoFourMember_0" xml:lang="en-US">Exercise price per share 1.24.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareOnePointTwoFourMember_1" xml:lang="en-US">Exercise Price Per Share One Point Two Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareOnePointTwoFourMember_2" xml:lang="en-US">Exercise Price Per Share - 1.24</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareOnePointZeroSixMember_0" xml:lang="en-US">Exercise Price Per Share 1.06.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareOnePointZeroSixMember_1" xml:lang="en-US">Exercise Price Per Share One Point Zero Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareOnePointZeroSixMember_2" xml:lang="en-US">Exercise Price Per Share - 1.06</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_0" xml:lang="en-US">Exercise Price Per Share 7.54.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_1" xml:lang="en-US">Exercise Price Per Share Seven Point Five Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_2" xml:lang="en-US">Exercise Price Per Share - 7.54</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareSixPointThreeOneMember_0" xml:lang="en-US">Exercise Price Per Share 6.31.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareSixPointThreeOneMember_1" xml:lang="en-US">Exercise Price Per Share Six Point Three One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareSixPointThreeOneMember_2" xml:lang="en-US">Exercise Price Per Share - 6.31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointNineSevenMember_0" xml:lang="en-US">Exercise Price Per Share 3.97.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointNineSevenMember_1" xml:lang="en-US">Exercise Price Per Share Three Point Nine Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointNineSevenMember_2" xml:lang="en-US">Exercise Price Per Share - 3.97</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointOneFiveMember_0" xml:lang="en-US">Exercise Price Per Share 3.15.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointOneFiveMember_1" xml:lang="en-US">Exercise Price Per Share Three Point One Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointOneFiveMember_2" xml:lang="en-US">Exercise Price Per Share - 3.15</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointSixEightMember_0" xml:lang="en-US">Exercise Price Per Share 3.68.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointSixEightMember_1" xml:lang="en-US">Exercise Price Per Share Three Point Six Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointSixEightMember_2" xml:lang="en-US">Exercise Price Per Share - 3.68</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareThreePointSixOneMember_0" xml:lang="en-US">Exercise Price Per Share 3.61.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareThreePointSixOneMember_1" xml:lang="en-US">Exercise Price Per Share Three Point Six One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareThreePointSixOneMember_2" xml:lang="en-US">Exercise Price Per Share - 3.61</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_0" xml:lang="en-US">Exercise Price Per Share 2.53.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_1" xml:lang="en-US">Exercise Price Per Share Two Point Five Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_2" xml:lang="en-US">Exercise Price Per Share - 2.53</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareTwoPointOneFourMember_0" xml:lang="en-US">Exercise Price Per Share 2.14.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareTwoPointOneFourMember_1" xml:lang="en-US">Exercise Price Per Share Two Point One Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareTwoPointOneFourMember_2" xml:lang="en-US">Exercise Price Per Share - 2.14</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ExercisePricePerShareZeroMember_0" xml:lang="en-US">No exercise price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ExercisePricePerShareZeroMember_1" xml:lang="en-US">Exercise Price Per Share Zero [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ExercisePricePerShareZeroMember_2" xml:lang="en-US">Exercise Price Per Share - Zero</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FinanceExpensesNet_0" xml:lang="en-US">The amount of finance expenses, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FinanceExpensesNet_1" xml:lang="en-US">Finance Expenses, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_FinanceExpensesNet_2" xml:lang="en-US">Finance income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FirstAnniversaryMember_0" xml:lang="en-US">This member represents about first anniversary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FirstAnniversaryMember_1" xml:lang="en-US">First Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FormerChiefExecutiveOfficerMember_0" xml:lang="en-US">Former Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FormerChiefExecutiveOfficerMember_1" xml:lang="en-US">Former Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_FormerChiefExecutiveOfficerMember_2" xml:lang="en-US">Former CEO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_0" xml:lang="en-US">Information about funds in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_1" xml:lang="en-US">Funds with respect to employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_2" xml:lang="en-US">Funds In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_3" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_GeneralLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_GeneralLineItems_1" xml:lang="en-US">General [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_GeneralTable_0" xml:lang="en-US">Disclosure of information about general information of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_GeneralTable_1" xml:lang="en-US">General [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_InvestorRelationsServicesAgreementMember_0" xml:lang="en-US">Investor relations services agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_InvestorRelationsServicesAgreementMember_1" xml:lang="en-US">Investor Relations Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_InvestorRelationsServicesAgreementMember_2" xml:lang="en-US">Investor relations services agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_0" xml:lang="en-US">Value of issuance of ordinary shares and warrants due to a private placement net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_1" xml:lang="en-US">Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_0" xml:lang="en-US">Number of ordinary shares and warrants issued due to a private placement net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_0" xml:lang="en-US">Number of shares issuued due to the At The Market program, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_1" xml:lang="en-US">Issuance Of Shares Due To At Market Program, Net Of Issuance Costs, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_2" xml:lang="en-US">Issuance of shares due to the ATM program, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_0" xml:lang="en-US">Represents the issuance of shares due to at market program, net of issuance costs,.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_1" xml:lang="en-US">Issuance Of Shares Due To At Market Program, Net Of Issuance Costs, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_2" xml:lang="en-US">Issuance of shares due to the ATM program, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_JointVentureAgreementMember_0" xml:lang="en-US">Represents the information regarding the joint venture agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_JointVentureAgreementMember_1" xml:lang="en-US">Joint Venture Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_JointVentureAgreementMember_2" xml:lang="en-US">Joint Venture Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LaboratoryEquipmentMember_0" xml:lang="en-US">Tangible personal property used in laboratory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LaboratoryEquipmentMember_1" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_LaboratoryEquipmentMember_2" xml:lang="en-US">Laboratory equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LeaseArrangementAxis_0" xml:lang="en-US">Information of lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LeaseArrangementAxis_1" xml:lang="en-US">Lease Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LeaseArrangementDomain_0" xml:lang="en-US">Name of the lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LeaseArrangementDomain_1" xml:lang="en-US">Lease Arrangement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_LiabilityForEmployeeRightsUponRetirement_0" xml:lang="en-US">Information about liability for employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_LiabilityForEmployeeRightsUponRetirement_1" xml:lang="en-US">Liability For Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_LiabilityForEmployeeRightsUponRetirement_2" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ManagementAndConsultingFees_0" xml:lang="en-US">The amount of management and consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ManagementAndConsultingFees_1" xml:lang="en-US">Management And Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ManagementAndConsultingFees_2" xml:lang="en-US">Management and consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NetProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Represents the net cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NetProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NetProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Net proceeds from share issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonExecutiveBoardMember_0" xml:lang="en-US">This member is stand for Non Executive Board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonExecutiveBoardMember_1" xml:lang="en-US">Non Executive Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonExecutiveDirectorMember_0" xml:lang="en-US">Non-executive director.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonExecutiveDirectorMember_1" xml:lang="en-US">Non Executive Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_NonExecutiveDirectorMember_2" xml:lang="en-US">Non-executive director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NonExecutiveDirectorMember_3" xml:lang="en-US">Non-executive board members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonExecutiveDirectorsMember_0" xml:lang="en-US">Non executive directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonExecutiveDirectorsMember_1" xml:lang="en-US">Non Executive Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NonExecutiveDirectorsMember_2" xml:lang="en-US">Non-executive directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_0" xml:lang="en-US">Represents the value of non-refundable and non-creditable initial technology access fee payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_1" xml:lang="en-US">Non Refundable And Non Creditable Initial Technology Access Fee Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_2" xml:lang="en-US">Non-refundable and non-creditable initial technology access fee payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_3" xml:lang="en-US">Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NumberOfNonExecutiveBoardMembers_0" xml:lang="en-US">Represents the number of non executive board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NumberOfNonExecutiveBoardMembers_1" xml:lang="en-US">Number Of Non Executive Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NumberOfNonExecutiveBoardMembers_2" xml:lang="en-US">Number of non executive board members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_0" xml:lang="en-US">Represents the number of shares issued under private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_1" xml:lang="en-US">Number Of Shares Issued Under Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_2" xml:lang="en-US">Number of shares issued under private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OfficeLeaseAgreementMember_0" xml:lang="en-US">This member represents about office lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OfficeLeaseAgreementMember_1" xml:lang="en-US">Office Lease Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OneTimeTerminationPayment_0" xml:lang="en-US">Represents a lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OneTimeTerminationPayment_1" xml:lang="en-US">One Time Termination Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OneTimeTerminationPayment_2" xml:lang="en-US">One-time cash termination payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_0" xml:lang="en-US">Represents the operating lease agreements for office and research and development space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1" xml:lang="en-US">Operating Lease Agreements For Office And Research And Development Space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_2" xml:lang="en-US">Operating lease agreements for office and research and development space [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_0" xml:lang="en-US">Represents the operating lease agreements for vehicles for employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_1" xml:lang="en-US">Operating Lease Agreements For Vehicles For Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2" xml:lang="en-US">Operating lease agreements for vehicles for employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_0" xml:lang="en-US">The tabular disclosure of operating lease liability and operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_1" xml:lang="en-US">Operating Lease Liability And Operating Lease Right Of Use Asset [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_2" xml:lang="en-US">Schedule of operating lease liability and operating lease right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_0" xml:lang="en-US">The tabular disclosure of operating lease supplemental cash flow information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_1" xml:lang="en-US">Operating Lease Supplemental Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_2" xml:lang="en-US">Schedule of operating lease cashflow information</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OptionToIssueVestingPercentage_0" xml:lang="en-US">Represents about option to issue vesting percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OptionToIssueVestingPercentage_1" xml:lang="en-US">Option To Issue Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_OptionToIssueVestingPercentage_2" xml:lang="en-US">Option to issue vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_OramedLtdMember_0" xml:lang="en-US">Represents the information regarding one of the related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_OramedLtdMember_1" xml:lang="en-US">Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_OramedLtdMember_2" xml:lang="en-US">Oramed Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PatentCostsPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PatentCostsPolicyTextBlock_1" xml:lang="en-US">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PatentCostsPolicyTextBlock_2" xml:lang="en-US">Patent Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PatentTransferAgreementMember_0" xml:lang="en-US">Represents the information regarding the patent transfer agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PatentTransferAgreementMember_1" xml:lang="en-US">Patent Transfer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PatentTransferAgreementMember_2" xml:lang="en-US">Patent Transfer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_0" xml:lang="en-US">Represents the amount paid for royalty to IIA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_1" xml:lang="en-US">Payment Of Royalty Guarantees Commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_2" xml:lang="en-US">Royalty amount paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_0" xml:lang="en-US">Represents the information regarding Placement Agency Agreement With Gp Numenkari Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_1" xml:lang="en-US">Placement Agency Agreement With Gp Numenkari Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_2" xml:lang="en-US">Placement Agency agreement with GP Numenkari Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_PresidentOfResearchAndDevelopmentMember_0" xml:lang="en-US">President Of Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_PresidentOfResearchAndDevelopmentMember_1" xml:lang="en-US">President Of Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_PresidentOfResearchAndDevelopmentMember_2" xml:lang="en-US">President of R&amp;D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_0" xml:lang="en-US">The cash inflow from issuance of shares and warrants, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds From Issuance Of Shares And Warrants, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from issuance of shares and warrants, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_0" xml:lang="en-US">The cash inflow from issuance of shares through ATM programs, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds From Issuance Of Shares Through Atm Programs, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_2" xml:lang="en-US">Proceeds from issuance of shares through ATM programs, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromOptionsAndWarrantExercises_0" xml:lang="en-US">The cash inflow from exercise of options and warrants into shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromOptionsAndWarrantExercises_1" xml:lang="en-US">Proceeds From Options And Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ProceedsFromOptionsAndWarrantExercises_2" xml:lang="en-US">Exercise of options and warrants into shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_0" xml:lang="en-US">The amount o f proceeds from short term bank deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_2" xml:lang="en-US">Proceeds From Short Term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_3" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ProceedsFromShortTermBankDeposits_4" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_0" xml:lang="en-US">Reconciliation In Amounts On Consolidated Balance Sheets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_1" xml:lang="en-US">Reconciliation in amounts on consolidated balance sheets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_0" xml:lang="en-US">It represents related party transaction of compensation of executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_1" xml:lang="en-US">Related Party Transaction Of Compensation Of Executive Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_2" xml:lang="en-US">Compensation of executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_0" xml:lang="en-US">It represents related party transaction of management and consulting fees to Board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_1" xml:lang="en-US">Related Party Transaction Of Management And Consulting Fees To Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_2" xml:lang="en-US">Management and consulting fees to Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_0" xml:lang="en-US">It represents related party transaction of stock-based compensation expenses to board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_1" xml:lang="en-US">Related Party Transaction Of Stock Based Compensation Expenses To Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_2" xml:lang="en-US">Stock-based compensation expenses to Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_0" xml:lang="en-US">It represents related party transaction of stock-based compensation expenses to executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_1" xml:lang="en-US">Related Party Transaction Of Stock Based Compensation Expenses To Executive Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_2" xml:lang="en-US">Stock-based compensation expenses to executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_0" xml:lang="en-US">It represents related party transaction with executive officers payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_1" xml:lang="en-US">Related Party Transaction With Executive Officers Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_2" xml:lang="en-US">Executive officers&#8217; payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_0" xml:lang="en-US">It represents related party transaction with non executive directors payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_1" xml:lang="en-US">Related Party Transaction With Non Executive Directors Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_2" xml:lang="en-US">Non-executive directors&#8217; payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ResearchAndDevelopmentServiceExpense_0" xml:lang="en-US">It represents research and development service expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ResearchAndDevelopmentServiceExpense_1" xml:lang="en-US">Research And Development Service Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ResearchAndDevelopmentServiceExpense_2" xml:lang="en-US">Research and development service expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ResearchCollaborationAndLicenseAgreementMember_0" xml:lang="en-US">Represents the detail of research collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ResearchCollaborationAndLicenseAgreementMember_1" xml:lang="en-US">Research Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ResearchCollaborationAndLicenseAgreementMember_2" xml:lang="en-US">Research Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_0" xml:lang="en-US">Reversal of expenses upon forfeiture of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_1" xml:lang="en-US">Reversal Of Expenses Upon Forfeiture Of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_2" xml:lang="en-US">Reversal of expenses upon forfeiture of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_0" xml:lang="en-US">Amount of right of use assets obtained in exchange for new operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_1" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_2" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RightToUseIntellectualProperty_0" xml:lang="en-US">Represents the value of right to use the intellectual property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RightToUseIntellectualProperty_1" xml:lang="en-US">Right To Use Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RightToUseIntellectualProperty_2" xml:lang="en-US">Right to use intellectual property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_0" xml:lang="en-US">Represents the percentage of each payment received from Amgen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_1" xml:lang="en-US">Royalty Guarantees Commitments Percentage Of Each Payment Received From Amgen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_2" xml:lang="en-US">Percentage of each payment received from Amgen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_0" xml:lang="en-US">Represents the percentage of net revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_1" xml:lang="en-US">Royalty Guarantees Commitments Percentage Of Net Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_2" xml:lang="en-US">Percentage of net revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_0" xml:lang="en-US">Represents the percentage sales of products developed from projects commencing the seventh year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_1" xml:lang="en-US">Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects Commencing Seventh Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_2" xml:lang="en-US">Percentage sales of products developed from projects commencing the seventh year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_0" xml:lang="en-US">Represents the percentage sales of products developed from projects in first three years, from commencement of revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_1" xml:lang="en-US">Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects In First Three Years, From Commencement Of Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_2" xml:lang="en-US">Percentage sales of products developed from projects in first three years, from commencement of revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_0" xml:lang="en-US">Represents the percentage sales of products developed from projects subsequent three years.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_1" xml:lang="en-US">Royalty Guarantees Commitments Percentage Sales Of Products Developed From Projects Subsequent Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_2" xml:lang="en-US">Percentage sales of products developed from projects subsequent three years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SaleOfStockAmountOfInvestment_0" xml:lang="en-US">Represents the amount invested in the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SaleOfStockAmountOfInvestment_1" xml:lang="en-US">Sale Of Stock, Amount Of Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SaleOfStockAmountOfInvestment_2" xml:lang="en-US">Amount of investment in entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_0" xml:lang="en-US">Represents the percentage of ownership of entity acquired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_1" xml:lang="en-US">Sale Of Stock, Percentage Of Ownership Of Entity Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_2" xml:lang="en-US">Percentage of ownership of entity acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the estimated useful life used to calculate depreciation of assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_1" xml:lang="en-US">Schedule Of Estimated Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_2" xml:lang="en-US">Schedule of estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_0" xml:lang="en-US">Tabular disclosure of related party transaction reported in consolidated statements of comprehensive loss.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_1" xml:lang="en-US">Schedule Of Related Party Transaction Reported In Consolidated Statements Of Comprehensive Loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_2" xml:lang="en-US">Schedule of related parties of consolidated statements of comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_0" xml:lang="en-US">Tabular disclosure of related party transactions reported in consolidated balance sheets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_1" xml:lang="en-US">Schedule Of Related Party Transactions Reported In Consolidated Balance Sheets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_2" xml:lang="en-US">Schedule of related party transaction of consolidated balance sheets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SecondAnniversaryMember_0" xml:lang="en-US">This member represents about second anniversary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SecondAnniversaryMember_1" xml:lang="en-US">Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_0" xml:lang="en-US">Selling price of preclinical Research and Development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_1" xml:lang="en-US">Selling Price Of Preclinical Research And Development Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_2" xml:lang="en-US">Selling price of preclinical R&amp;D services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ServiceProviderMember_0" xml:lang="en-US">Information of service provider.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ServiceProviderMember_1" xml:lang="en-US">Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ServiceProviderMember_2" xml:lang="en-US">Service Provider [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SeveralEmployeesAndServiceProvidersMember_0" xml:lang="en-US">Represents the information regarding two related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SeveralEmployeesAndServiceProvidersMember_1" xml:lang="en-US">Several Employees And Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SeveralEmployeesAndServiceProvidersMember_2" xml:lang="en-US">Several employees and service providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SeveranceExpenses_0" xml:lang="en-US">It represents severance expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SeveranceExpenses_1" xml:lang="en-US">Severance Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SeveranceExpenses_2" xml:lang="en-US">Severance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SeverancePayPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SeverancePayPolicyTextBlock_1" xml:lang="en-US">Severance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SeverancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_0" xml:lang="en-US">Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_1" xml:lang="en-US">Share Based Payment Arrangement Tranche Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_2" xml:lang="en-US">Vest over twelve equal quarterly instalments starting on January 1, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_0" xml:lang="en-US">Forth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_1" xml:lang="en-US">Share Based Payment Arrangement Tranche Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_2" xml:lang="en-US">Vest in three equal installments until January 8, 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_0" xml:lang="en-US">Seventh portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_1" xml:lang="en-US">Share Based Payment Arrangement Tranche Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_0" xml:lang="en-US">Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_1" xml:lang="en-US">Share Based Payment Arrangement Tranche Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_2" xml:lang="en-US">Vest over four equal quarterly instalments starting on January 1, 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareIncentivePlan2013Member_0" xml:lang="en-US">Share Incentive Plan 2013.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareIncentivePlan2013Member_1" xml:lang="en-US">Share Incentive Plan 2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareIncentivePlan2013Member_2" xml:lang="en-US">2013 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_ShareIncentivePlan2018Member_0" xml:lang="en-US">Share Incentive Plan 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_ShareIncentivePlan2018Member_1" xml:lang="en-US">Share Incentive Plan 2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_ShareIncentivePlan2018Member_2" xml:lang="en-US">2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SharesGrantedInPercentage_0" xml:lang="en-US">Represents the percentage of he number of shares issued to subscribers invested through the Broker.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SharesGrantedInPercentage_1" xml:lang="en-US">Shares Granted In Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SharesGrantedInPercentage_2" xml:lang="en-US">Shares granted in percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SharesIssuedWeightedAveragePricePerShare_0" xml:lang="en-US">Represents the weighted average price per share or per unit of equity securities issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SharesIssuedWeightedAveragePricePerShare_1" xml:lang="en-US">Shares Issued Weighted Average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_SharesIssuedWeightedAveragePricePerShare_2" xml:lang="en-US">Weighted average price of share issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SignificantAccountingPoliciesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SignificantAccountingPoliciesLineItems_1" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SignificantAccountingPoliciesTable_0" xml:lang="en-US">This table may contain information related to significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SignificantAccountingPoliciesTable_1" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SixNonExecutiveBoardMembersMember_0" xml:lang="en-US">Information about six non-executive board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SixNonExecutiveBoardMembersMember_1" xml:lang="en-US">Six Non Executive Board Members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_SixNonExecutiveBoardMembersMember_2" xml:lang="en-US">Six non-executive board members [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_StockholdersEquityNoteLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_StockholdersEquityNoteLineItems_1" xml:lang="en-US">Stockholders Equity Note [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_StockholdersEquityNoteTable_0" xml:lang="en-US">Schedule of information regarding the share capital of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_StockholdersEquityNoteTable_1" xml:lang="en-US">Stockholders Equity Note [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SupplementaryFinancialStatementInformationAbstract_0" xml:lang="en-US">Supplementary Financial Statement Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_SupplementaryFinancialStatementInformationTextBlock_0" xml:lang="en-US">The entire disclosure for supplementary financial statement information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_SupplementaryFinancialStatementInformationTextBlock_1" xml:lang="en-US">Supplementary Financial Statement Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_SupplementaryFinancialStatementInformationTextBlock_2" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TransactionCosts_0" xml:lang="en-US">It represents transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TransactionCosts_1" xml:lang="en-US">Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_TransactionCosts_2" xml:lang="en-US">Transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TriggeringEventAxis_0" xml:lang="en-US">Information by triggering event of options under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TriggeringEventAxis_1" xml:lang="en-US">Triggering Event [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TriggeringEventDomain_0" xml:lang="en-US">Triggering event of options under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TriggeringEventDomain_1" xml:lang="en-US">Triggering Event [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TriggeringEventMember_0" xml:lang="en-US">Represents the information of triggering event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TriggeringEventMember_1" xml:lang="en-US">Triggering Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_TriggeringEventMember_2" xml:lang="en-US">Triggering event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TwentySeventeenMemberMember_0" xml:lang="en-US">Twenty Seventeen Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TwentySeventeenMemberMember_1" xml:lang="en-US">Twenty Seventeen Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_TwentySeventeenMemberMember_2" xml:lang="en-US">2017 Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_TwentyTwentyOneGrantMember_0" xml:lang="en-US">Twenty Twenty One Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_TwentyTwentyOneGrantMember_1" xml:lang="en-US">Twenty Twenty One Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_TwentyTwentyOneGrantMember_2" xml:lang="en-US">2021 Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_VestedRestrictedSharesUnits_0" xml:lang="en-US">Value of vested restricted shares units in noncash transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_VestedRestrictedSharesUnits_1" xml:lang="en-US">Vested Restricted Shares Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_VestedRestrictedSharesUnits_2" xml:lang="en-US">Vested restricted shares units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_VestedRestrictedShareUnitsShares_0" xml:lang="en-US">Number of shares vested restricted share units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_VestedRestrictedShareUnitsShares_1" xml:lang="en-US">Vested Restricted Share Units Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_entx_VestedRestrictedShareUnitsShares_2" xml:lang="en-US">Vested restricted share units (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_entx_WarrantToPurchaseOrdinaryShare_0" xml:lang="en-US">It represents warrant to purchase ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_entx_WarrantToPurchaseOrdinaryShare_1" xml:lang="en-US">Warrant To Purchase Ordinary Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_entx_WarrantToPurchaseOrdinaryShare_2" xml:lang="en-US">Warrant to purchase ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefExecutiveOfficerMember_0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefExecutiveOfficerMember_2" xml:lang="en-US">New CEO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis_0" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain_0" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsAxis_0" xml:lang="en-US">Consolidation Items [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidationItemsDomain_0" xml:lang="en-US">Consolidation Items [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember_0" xml:lang="en-US">Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember_1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis_0" xml:lang="en-US">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain_0" xml:lang="en-US">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SubsidiariesMember_0" xml:lang="en-US">Subsidiaries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SubsidiariesMember_1" xml:lang="en-US">Subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_SubsidiariesMember_2" xml:lang="en-US">Entera Bio Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_0" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1" xml:lang="en-US">Schedule of accounts payable - other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1" xml:lang="en-US">Total Accounts payable and Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1" xml:lang="en-US">Accounts payable - other:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2" xml:lang="en-US">Accrued expenses and other payables:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_1" xml:lang="en-US">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_0" xml:lang="en-US">Employees and employees related</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_1" xml:lang="en-US">Employees and employees related</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1" xml:lang="en-US">Accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2" xml:lang="en-US">Accrued expenses and other payables, total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3" xml:lang="en-US">Accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued liabilities and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedVacationCurrent_0" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedVacationCurrent_1" xml:lang="en-US">Provision for vacation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US">Accumulated other Comprehensive income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_0" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1" xml:lang="en-US">Amount transferred from Other Reserves to Additional paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1" xml:lang="en-US">Vested restricted share units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Number of antidilutive securities excluded from computation of earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of presentation of the financial statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1" xml:lang="en-US">Restricted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash and cash equivalents and restricted deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US">DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Exercise price of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US">Number of ordinary shares will be purchased by exercising warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1" xml:lang="en-US">Legal and other contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary share, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Ordinary shares, authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Ordinary shares, issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Ordinary shares, outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_2" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_3" xml:lang="en-US">Ordinary Shares, NIS 0.0000769 par value: Authorized - as of June 30, 2023 and December 31, 2022, 140,010,000 shares; issued and outstanding - as of June 30, 2023 and December 31, 2022, 28,813,952 and 28,809,922 shares, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue_4" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_5" xml:lang="en-US">Value of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValueOutstanding_0" xml:lang="en-US">Common Stock, Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValueOutstanding_1" xml:lang="en-US">Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2021 and December 31, 2020, 140,010,000 shares; issued and outstanding: as of December 31, 2021, and December 31, 2020 28,804,411 and 21,057,922 shares, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights_0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights_1" xml:lang="en-US">Voting rights of ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_0" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_1" xml:lang="en-US">Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember_1" xml:lang="en-US">Computer equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1" xml:lang="en-US">Principles of consolidation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability_0" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability_1" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1" xml:lang="en-US">Milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue_1" xml:lang="en-US">COST OF REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesMember_0" xml:lang="en-US">Cost of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesMember_1" xml:lang="en-US">Cost of revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1" xml:lang="en-US">Current:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1" xml:lang="en-US">Total current income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0" xml:lang="en-US">Losses and benefits for tax purposes for the year, for which deferred taxes were recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_1" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2" xml:lang="en-US">Losses and benefits for tax purposes for the year, for which deferred taxes were recorded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1" xml:lang="en-US">Deferred:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_1" xml:lang="en-US">Deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0" xml:lang="en-US">Total deferred income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2" xml:lang="en-US">Deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3" xml:lang="en-US">Total deferred income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Net deferred tax assets before valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_2" xml:lang="en-US">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1" xml:lang="en-US">Deferred tax assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" xml:lang="en-US">Net operating loss carry forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_1" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Less - valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Closing balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Opening balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5" xml:lang="en-US">valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6" xml:lang="en-US">Less - valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_1" xml:lang="en-US">Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_0" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_0" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">SHARE-BASED COMPENSATION</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DomesticCountryMember_1" xml:lang="en-US">Israeli tax rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0" xml:lang="en-US">Due to Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">LOSS PER SHARE BASIC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">LOSS PER SHARE DILUTED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1" xml:lang="en-US">Statutory tax rate of Entera Bio Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2" xml:lang="en-US">Income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_0" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1" xml:lang="en-US">Fair value measurement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember_0" xml:lang="en-US">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCountryMember_1" xml:lang="en-US">U.S. tax rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US">Functional currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentMember_0" xml:lang="en-US">Government [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GovernmentMember_1" xml:lang="en-US">Government of Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">GROSS PROFIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1" xml:lang="en-US">Impairment of long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss (income) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">LOSS BEFORE INCOME TAX</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" xml:lang="en-US">Net loss for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" xml:lang="en-US">Comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" xml:lang="en-US">LOSS BEFORE INCOME TAX</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8" xml:lang="en-US">Loss (income) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">LOSS FOR THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">LOSS FOR THE YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_0" xml:lang="en-US">Different tax rate in subsidiary operating outside of Israel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_1" xml:lang="en-US">Income (Loss) from Subsidiaries, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_2" xml:lang="en-US">Different tax rate in subsidiary operating outside of Israel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_0" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_1" xml:lang="en-US">Rollforward of valuation allowance:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US">INCOME TAX</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income taxes paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">TAXES ON INCOME</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Actual income tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_3" xml:lang="en-US">INCOME TAX BENEFIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4" xml:lang="en-US">Actual income tax (benefit) expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5" xml:lang="en-US">Total tax on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Net change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2" xml:lang="en-US">Net change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3" xml:lang="en-US">Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_1" xml:lang="en-US">Non-deductible expenses and other permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_0" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_2" xml:lang="en-US">Computed &#8220;expected&#8221; tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Increase (decrease) in accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Increase (decrease) in accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2" xml:lang="en-US">Increase (decrease)&#160;in accrued expenses and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1" xml:lang="en-US">Decrease in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US">Changes in operating asset and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Increase in other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1" xml:lang="en-US">CHANGES DURING THE YEAR ENDED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember_0" xml:lang="en-US">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember_0" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IPOMember_1" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis_0" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain_0" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_1" xml:lang="en-US">Schedule of lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract_0" xml:lang="en-US">Leases [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_0" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_0" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_0" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescription_0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescription_1" xml:lang="en-US">Agreement expiration date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1" xml:lang="en-US">Lessee&#8217;s incremental borrowing rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of maturity of lease liabilities under our non-cancelable operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2" xml:lang="en-US">Total future minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_0" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less: interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2" xml:lang="en-US">Less: interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_0" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_1" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1" xml:lang="en-US">OPERATING LEASES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1" xml:lang="en-US">Agreement term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">TOTAL LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract_0" xml:lang="en-US">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract_1" xml:lang="en-US">LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">Liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">TOTAL NON-CURRENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">NET LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">FINANCIAL INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">FINANCIAL INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">FINANCE EXPENSES (INCOME), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember_0" xml:lang="en-US">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember_1" xml:lang="en-US">Office furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">OPERATING EXPENSES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">OPERATING LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">OPERATING LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost_0" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost_1" xml:lang="en-US">Operating lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost_2" xml:lang="en-US">Annual lease consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense_0" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense_1" xml:lang="en-US">Monthly lease fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Present value of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Total lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract_0" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract_1" xml:lang="en-US">Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_2" xml:lang="en-US">Current maturities of operating lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_1" xml:lang="en-US">Operating leases cost for rental space and vehicles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments_2" xml:lang="en-US">Operating cash flows from operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Operating lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1" xml:lang="en-US">Net changes in operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1" xml:lang="en-US">Weighted-average discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1" xml:lang="en-US">Weighted-average remaining lease term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards_1" xml:lang="en-US">Carryforward losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_0" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_0" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xml:lang="en-US">DESCRIPTION OF BUSINESS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_2" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonrecurringIncome_0" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonrecurringIncome_1" xml:lang="en-US">Other Nonrecurring Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonrecurringIncome_2" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherOperatingIncome_0" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncome_1" xml:lang="en-US">Other Operating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherOperatingIncome_2" xml:lang="en-US">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_0" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1" xml:lang="en-US">Annual lease consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_1" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Postemployment Benefits Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_1" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2" xml:lang="en-US">Prepaid expenses and other current assets, total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xml:lang="en-US">Prepaid expenses and other current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember_0" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember_1" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Proceeds from issuance of shares under the ATM program, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US">Proceeds from private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense_0" xml:lang="en-US">Professional and Contract Services Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense_1" xml:lang="en-US">Amount to be paid for preclinical services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1" xml:lang="en-US">Estimated useful life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_0" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_0" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1" xml:lang="en-US">Related party transaction with continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2" xml:lang="en-US">Related party transaction with continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_0" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_1" xml:lang="en-US">Restricted deposits included in other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndInvestments_0" xml:lang="en-US">Restricted Cash and Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_1" xml:lang="en-US">Restricted Stock Units (RSUs)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1" xml:lang="en-US">REVENUE FROM COLLABORATION AND LICENSE AGREEMENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_0" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1" xml:lang="en-US">Milestone payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US">Revenue recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_2" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_0" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1" xml:lang="en-US">Total royalty amount payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" xml:lang="en-US">Schedule of tax expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1" xml:lang="en-US">Schedule of rconciliation of statutory tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US">Schedule of of share-based compensation on statements of operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" xml:lang="en-US">Schedule of loss (income) before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_1" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServiceMember_0" xml:lang="en-US">Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeveranceCosts1_1" xml:lang="en-US">Severance payment expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US">Vestion period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1" xml:lang="en-US">Description of terms of share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1" xml:lang="en-US">Exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected life - in years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xml:lang="en-US">Number of options exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Options exercisable, Weighted Average Remaining contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Number of options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1" xml:lang="en-US">Number of unvested options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US">Number of options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3" xml:lang="en-US">Exercise Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US">Weighted Average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Options outstanding, Weighted Average Remaining contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1" xml:lang="en-US">Schedule of outstanding and exercisable options of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1" xml:lang="en-US">Fair value of options at the date of grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1" xml:lang="en-US">Number of shares issued on options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1" xml:lang="en-US">Number of options to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Weighted average exercise rice of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Exercise price of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US">Vest on first anniversary of date of grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding_0" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding_2" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US">BALANCE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">SHARE CAPITAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_0" xml:lang="en-US">Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1" xml:lang="en-US">Issuance of shares under the ATM program, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2" xml:lang="en-US">Exercise of options to ordinary shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3" xml:lang="en-US">Number of options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1" xml:lang="en-US">Issuance of shares under the ATM program, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US">Issuance of ordinary shares and warrants due to a private placement net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1" xml:lang="en-US">Exercise of options to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent Events [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1" xml:lang="en-US">Schedule of rollforward of valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_0" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1" xml:lang="en-US">COVID-19</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of estimates in the preparation of financial statements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1" xml:lang="en-US">Net change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2" xml:lang="en-US">Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis_0" xml:lang="en-US">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_1" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_2" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_3" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_4" xlink:to="lab_dei_CoverAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_5" xlink:to="lab_dei_CoverAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_6" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_7" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_8" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_9" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_10" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_11" xlink:to="lab_dei_DocumentQuarterlyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_12" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_13" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_14" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_15" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_16" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_17" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_18" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_19" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_20" xlink:to="lab_dei_EntityAddressStateOrProvince_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_21" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_22" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_23" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_24" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_25" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_26" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_27" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_28" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_29" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_30" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_31" xlink:to="lab_dei_EntityPublicFloat_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_32" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_33" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_34" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_35" xlink:to="lab_dei_EntityTaxIdentificationNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_36" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_37" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_38" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_39" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_40" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_41" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_42" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_43" xlink:to="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_44" xlink:to="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_45" xlink:to="lab_entx_AccreditedInvestorsIncludingCertainBoardMembersAndTheirAffiliatesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_46" xlink:to="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_47" xlink:to="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_48" xlink:to="lab_entx_AdditionalAmountPaidForServicesToBeRecognized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalCashSeparationPayment_49" xlink:to="lab_entx_AdditionalCashSeparationPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalCashSeparationPayment_50" xlink:to="lab_entx_AdditionalCashSeparationPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdditionalCashSeparationPayment_51" xlink:to="lab_entx_AdditionalCashSeparationPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_52" xlink:to="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_53" xlink:to="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_54" xlink:to="lab_entx_AdjustedExercisePriceUnderAtMarketEquityProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementAxis_55" xlink:to="lab_entx_AgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementAxis_56" xlink:to="lab_entx_AgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementDomain_57" xlink:to="lab_entx_AgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementDomain_58" xlink:to="lab_entx_AgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementsTypeAxis_59" xlink:to="lab_entx_AgreementsTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementsTypeAxis_60" xlink:to="lab_entx_AgreementsTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementsTypeDomain_61" xlink:to="lab_entx_AgreementsTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AgreementsTypeDomain_62" xlink:to="lab_entx_AgreementsTypeDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_63" xlink:to="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_64" xlink:to="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_65" xlink:to="lab_entx_AmendmentToBusinessDevelopmentServicesAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_66" xlink:to="lab_entx_AmgenIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_67" xlink:to="lab_entx_AmgenIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AmgenIncMember_68" xlink:to="lab_entx_AmgenIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2020Member_69" xlink:to="lab_entx_AtmEquityProgram2020Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2020Member_70" xlink:to="lab_entx_AtmEquityProgram2020Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2020Member_71" xlink:to="lab_entx_AtmEquityProgram2020Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2021Member_72" xlink:to="lab_entx_AtmEquityProgram2021Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2021Member_73" xlink:to="lab_entx_AtmEquityProgram2021Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_AtmEquityProgram2021Member_74" xlink:to="lab_entx_AtmEquityProgram2021Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BankGuarantees_75" xlink:to="lab_entx_BankGuarantees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BankGuarantees_76" xlink:to="lab_entx_BankGuarantees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BankGuarantees_77" xlink:to="lab_entx_BankGuarantees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BoardMembersMember_78" xlink:to="lab_entx_BoardMembersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BoardMembersMember_79" xlink:to="lab_entx_BoardMembersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsMember_80" xlink:to="lab_entx_BrokerWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsMember_81" xlink:to="lab_entx_BrokerWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsMember_82" xlink:to="lab_entx_BrokerWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType1Member_83" xlink:to="lab_entx_BrokerWarrantsType1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType1Member_84" xlink:to="lab_entx_BrokerWarrantsType1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType1Member_85" xlink:to="lab_entx_BrokerWarrantsType1Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType2Member_86" xlink:to="lab_entx_BrokerWarrantsType2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType2Member_87" xlink:to="lab_entx_BrokerWarrantsType2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_BrokerWarrantsType2Member_88" xlink:to="lab_entx_BrokerWarrantsType2Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashFeesInPercentage_89" xlink:to="lab_entx_CashFeesInPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashFeesInPercentage_90" xlink:to="lab_entx_CashFeesInPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashFeesInPercentage_91" xlink:to="lab_entx_CashFeesInPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashlessExerciseOfWarrants_92" xlink:to="lab_entx_CashlessExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashlessExerciseOfWarrants_93" xlink:to="lab_entx_CashlessExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashlessExerciseOfWarrants_94" xlink:to="lab_entx_CashlessExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashSeparationPayment_95" xlink:to="lab_entx_CashSeparationPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashSeparationPayment_96" xlink:to="lab_entx_CashSeparationPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CashSeparationPayment_97" xlink:to="lab_entx_CashSeparationPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChairmanOfBoardAndDnaMember_98" xlink:to="lab_entx_ChairmanOfBoardAndDnaMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChairmanOfBoardAndDnaMember_99" xlink:to="lab_entx_ChairmanOfBoardAndDnaMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ChairmanOfBoardAndDnaMember_100" xlink:to="lab_entx_ChairmanOfBoardAndDnaMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightExerciseTerm_101" xlink:to="lab_entx_ClassOfWarrantOrRightExerciseTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightExerciseTerm_102" xlink:to="lab_entx_ClassOfWarrantOrRightExerciseTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightExerciseTerm_103" xlink:to="lab_entx_ClassOfWarrantOrRightExerciseTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightIssued_104" xlink:to="lab_entx_ClassOfWarrantOrRightIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightIssued_105" xlink:to="lab_entx_ClassOfWarrantOrRightIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightIssued_106" xlink:to="lab_entx_ClassOfWarrantOrRightIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_107" xlink:to="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_108" xlink:to="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_109" xlink:to="lab_entx_ClassOfWarrantOrRightPercentageOfIpoPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_110" xlink:to="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_111" xlink:to="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightReducedExercisePrice_112" xlink:to="lab_entx_ClassOfWarrantOrRightReducedExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_113" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_114" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_115" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdConsecutiveTradingDays_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_116" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_117" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_118" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfLastReportedSalePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_119" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_120" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_121" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfPeriodForReductionInExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_122" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_123" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_124" xlink:to="lab_entx_ClassOfWarrantOrRightThresholdLimitOfReductionInExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsAndContingenciesTable_125" xlink:to="lab_entx_CommitmentsAndContingenciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsAndContingenciesTable_126" xlink:to="lab_entx_CommitmentsAndContingenciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsLineItems_127" xlink:to="lab_entx_CommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_CommitmentsLineItems_128" xlink:to="lab_entx_CommitmentsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ConsultantMember_129" xlink:to="lab_entx_ConsultantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ConsultantMember_130" xlink:to="lab_entx_ConsultantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ConsultantMember_131" xlink:to="lab_entx_ConsultantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DecreaseIncreaseInTaxRefundAbstract_132" xlink:to="lab_entx_DecreaseIncreaseInTaxRefundAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DecreaseIncreaseInTaxRefundAbstract_133" xlink:to="lab_entx_DecreaseIncreaseInTaxRefundAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DecreaseIncreaseInTaxRefundAbstract_134" xlink:to="lab_entx_DecreaseIncreaseInTaxRefundAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_135" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_136" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_137" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdAndOramedLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdMember_138" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdMember_139" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_DnaBiomedicalSolutionsLtdMember_140" xlink:to="lab_entx_DnaBiomedicalSolutionsLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EffectOfDownRoundTriggerAmount_141" xlink:to="lab_entx_EffectOfDownRoundTriggerAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EffectOfDownRoundTriggerAmount_142" xlink:to="lab_entx_EffectOfDownRoundTriggerAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EffectOfDownRoundTriggerAmount_143" xlink:to="lab_entx_EffectOfDownRoundTriggerAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeMember_144" xlink:to="lab_entx_EmployeeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeMember_145" xlink:to="lab_entx_EmployeeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeMember_146" xlink:to="lab_entx_EmployeeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_147" xlink:to="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_148" xlink:to="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_149" xlink:to="lab_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_150" xlink:to="lab_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_151" xlink:to="lab_entx_EmployeesExecutiveOfficersAndServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesMember_152" xlink:to="lab_entx_EmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesMember_153" xlink:to="lab_entx_EmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EmployeesMember_154" xlink:to="lab_entx_EmployeesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EnteraBioLtdMember_155" xlink:to="lab_entx_EnteraBioLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EnteraBioLtdMember_156" xlink:to="lab_entx_EnteraBioLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EnteraBioLtdMember_157" xlink:to="lab_entx_EnteraBioLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramAxis_158" xlink:to="lab_entx_EquityProgramAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramAxis_159" xlink:to="lab_entx_EquityProgramAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramDomain_160" xlink:to="lab_entx_EquityProgramDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EquityProgramDomain_161" xlink:to="lab_entx_EquityProgramDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodAbstract_162" xlink:to="lab_entx_EventsDuringPeriodAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodLineItems_163" xlink:to="lab_entx_EventsDuringPeriodLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodLineItems_164" xlink:to="lab_entx_EventsDuringPeriodLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodTable_165" xlink:to="lab_entx_EventsDuringPeriodTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodTable_166" xlink:to="lab_entx_EventsDuringPeriodTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodTextBlock_167" xlink:to="lab_entx_EventsDuringPeriodTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodTextBlock_168" xlink:to="lab_entx_EventsDuringPeriodTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_EventsDuringPeriodTextBlock_169" xlink:to="lab_entx_EventsDuringPeriodTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExecutiveOfficerAndServiceProviderMember_170" xlink:to="lab_entx_ExecutiveOfficerAndServiceProviderMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExecutiveOfficerAndServiceProviderMember_171" xlink:to="lab_entx_ExecutiveOfficerAndServiceProviderMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExecutiveOfficerAndServiceProviderMember_172" xlink:to="lab_entx_ExecutiveOfficerAndServiceProviderMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsShares_173" xlink:to="lab_entx_ExerciseOfWarrantsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsShares_174" xlink:to="lab_entx_ExerciseOfWarrantsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsShares_175" xlink:to="lab_entx_ExerciseOfWarrantsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsValue_176" xlink:to="lab_entx_ExerciseOfWarrantsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsValue_177" xlink:to="lab_entx_ExerciseOfWarrantsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExerciseOfWarrantsValue_178" xlink:to="lab_entx_ExerciseOfWarrantsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointTwoFourMember_179" xlink:to="lab_entx_ExercisePricePerShareOnePointTwoFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointTwoFourMember_180" xlink:to="lab_entx_ExercisePricePerShareOnePointTwoFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointTwoFourMember_181" xlink:to="lab_entx_ExercisePricePerShareOnePointTwoFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointZeroSixMember_182" xlink:to="lab_entx_ExercisePricePerShareOnePointZeroSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointZeroSixMember_183" xlink:to="lab_entx_ExercisePricePerShareOnePointZeroSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareOnePointZeroSixMember_184" xlink:to="lab_entx_ExercisePricePerShareOnePointZeroSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_185" xlink:to="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_186" xlink:to="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSevenPointFiveFourMember_187" xlink:to="lab_entx_ExercisePricePerShareSevenPointFiveFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSixPointThreeOneMember_188" xlink:to="lab_entx_ExercisePricePerShareSixPointThreeOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSixPointThreeOneMember_189" xlink:to="lab_entx_ExercisePricePerShareSixPointThreeOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareSixPointThreeOneMember_190" xlink:to="lab_entx_ExercisePricePerShareSixPointThreeOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointNineSevenMember_191" xlink:to="lab_entx_ExercisePricePerShareThreePointNineSevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointNineSevenMember_192" xlink:to="lab_entx_ExercisePricePerShareThreePointNineSevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointNineSevenMember_193" xlink:to="lab_entx_ExercisePricePerShareThreePointNineSevenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointOneFiveMember_194" xlink:to="lab_entx_ExercisePricePerShareThreePointOneFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointOneFiveMember_195" xlink:to="lab_entx_ExercisePricePerShareThreePointOneFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointOneFiveMember_196" xlink:to="lab_entx_ExercisePricePerShareThreePointOneFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixEightMember_197" xlink:to="lab_entx_ExercisePricePerShareThreePointSixEightMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixEightMember_198" xlink:to="lab_entx_ExercisePricePerShareThreePointSixEightMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixEightMember_199" xlink:to="lab_entx_ExercisePricePerShareThreePointSixEightMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixOneMember_200" xlink:to="lab_entx_ExercisePricePerShareThreePointSixOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixOneMember_201" xlink:to="lab_entx_ExercisePricePerShareThreePointSixOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareThreePointSixOneMember_202" xlink:to="lab_entx_ExercisePricePerShareThreePointSixOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_203" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_204" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointFiveThreeMember_205" xlink:to="lab_entx_ExercisePricePerShareTwoPointFiveThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointOneFourMember_206" xlink:to="lab_entx_ExercisePricePerShareTwoPointOneFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointOneFourMember_207" xlink:to="lab_entx_ExercisePricePerShareTwoPointOneFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareTwoPointOneFourMember_208" xlink:to="lab_entx_ExercisePricePerShareTwoPointOneFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareZeroMember_209" xlink:to="lab_entx_ExercisePricePerShareZeroMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareZeroMember_210" xlink:to="lab_entx_ExercisePricePerShareZeroMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ExercisePricePerShareZeroMember_211" xlink:to="lab_entx_ExercisePricePerShareZeroMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FinanceExpensesNet_212" xlink:to="lab_entx_FinanceExpensesNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FinanceExpensesNet_213" xlink:to="lab_entx_FinanceExpensesNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FinanceExpensesNet_214" xlink:to="lab_entx_FinanceExpensesNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FirstAnniversaryMember_215" xlink:to="lab_entx_FirstAnniversaryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FirstAnniversaryMember_216" xlink:to="lab_entx_FirstAnniversaryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FormerChiefExecutiveOfficerMember_217" xlink:to="lab_entx_FormerChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FormerChiefExecutiveOfficerMember_218" xlink:to="lab_entx_FormerChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FormerChiefExecutiveOfficerMember_219" xlink:to="lab_entx_FormerChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_220" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_221" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_222" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_FundsInRespectOfEmployeeRightsUponRetirement_223" xlink:to="lab_entx_FundsInRespectOfEmployeeRightsUponRetirement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralLineItems_224" xlink:to="lab_entx_GeneralLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralLineItems_225" xlink:to="lab_entx_GeneralLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralTable_226" xlink:to="lab_entx_GeneralTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_GeneralTable_227" xlink:to="lab_entx_GeneralTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_InvestorRelationsServicesAgreementMember_228" xlink:to="lab_entx_InvestorRelationsServicesAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_InvestorRelationsServicesAgreementMember_229" xlink:to="lab_entx_InvestorRelationsServicesAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_InvestorRelationsServicesAgreementMember_230" xlink:to="lab_entx_InvestorRelationsServicesAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_231" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_232" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_233" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_234" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_235" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_236" xlink:to="lab_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_237" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_238" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_239" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_240" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_241" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_242" xlink:to="lab_entx_IssuanceOfSharesDueToAtMarketProgramNetOfIssuanceCostsValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_JointVentureAgreementMember_243" xlink:to="lab_entx_JointVentureAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_JointVentureAgreementMember_244" xlink:to="lab_entx_JointVentureAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_JointVentureAgreementMember_245" xlink:to="lab_entx_JointVentureAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LaboratoryEquipmentMember_246" xlink:to="lab_entx_LaboratoryEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LaboratoryEquipmentMember_247" xlink:to="lab_entx_LaboratoryEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LaboratoryEquipmentMember_248" xlink:to="lab_entx_LaboratoryEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementAxis_249" xlink:to="lab_entx_LeaseArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementAxis_250" xlink:to="lab_entx_LeaseArrangementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementDomain_251" xlink:to="lab_entx_LeaseArrangementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LeaseArrangementDomain_252" xlink:to="lab_entx_LeaseArrangementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LiabilityForEmployeeRightsUponRetirement_253" xlink:to="lab_entx_LiabilityForEmployeeRightsUponRetirement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LiabilityForEmployeeRightsUponRetirement_254" xlink:to="lab_entx_LiabilityForEmployeeRightsUponRetirement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_LiabilityForEmployeeRightsUponRetirement_255" xlink:to="lab_entx_LiabilityForEmployeeRightsUponRetirement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ManagementAndConsultingFees_256" xlink:to="lab_entx_ManagementAndConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ManagementAndConsultingFees_257" xlink:to="lab_entx_ManagementAndConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ManagementAndConsultingFees_258" xlink:to="lab_entx_ManagementAndConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NetProceedsFromIssuanceOfCommonStock_259" xlink:to="lab_entx_NetProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NetProceedsFromIssuanceOfCommonStock_260" xlink:to="lab_entx_NetProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NetProceedsFromIssuanceOfCommonStock_261" xlink:to="lab_entx_NetProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveBoardMember_262" xlink:to="lab_entx_NonExecutiveBoardMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveBoardMember_263" xlink:to="lab_entx_NonExecutiveBoardMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_264" xlink:to="lab_entx_NonExecutiveDirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_265" xlink:to="lab_entx_NonExecutiveDirectorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_266" xlink:to="lab_entx_NonExecutiveDirectorMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorMember_267" xlink:to="lab_entx_NonExecutiveDirectorMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorsMember_268" xlink:to="lab_entx_NonExecutiveDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorsMember_269" xlink:to="lab_entx_NonExecutiveDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonExecutiveDirectorsMember_270" xlink:to="lab_entx_NonExecutiveDirectorsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_271" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_272" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_273" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_274" xlink:to="lab_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfNonExecutiveBoardMembers_275" xlink:to="lab_entx_NumberOfNonExecutiveBoardMembers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfNonExecutiveBoardMembers_276" xlink:to="lab_entx_NumberOfNonExecutiveBoardMembers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfNonExecutiveBoardMembers_277" xlink:to="lab_entx_NumberOfNonExecutiveBoardMembers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_278" xlink:to="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_279" xlink:to="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_NumberOfSharesIssuedUnderPrivatePlacement_280" xlink:to="lab_entx_NumberOfSharesIssuedUnderPrivatePlacement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OfficeLeaseAgreementMember_281" xlink:to="lab_entx_OfficeLeaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OfficeLeaseAgreementMember_282" xlink:to="lab_entx_OfficeLeaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OneTimeTerminationPayment_283" xlink:to="lab_entx_OneTimeTerminationPayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OneTimeTerminationPayment_284" xlink:to="lab_entx_OneTimeTerminationPayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OneTimeTerminationPayment_285" xlink:to="lab_entx_OneTimeTerminationPayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_286" xlink:to="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_287" xlink:to="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_288" xlink:to="lab_entx_OperatingLeaseAgreementsForOfficeAndResearchAndDevelopmentSpaceMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_289" xlink:to="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_290" xlink:to="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_291" xlink:to="lab_entx_OperatingLeaseAgreementsForVehiclesForEmployeesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_292" xlink:to="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_293" xlink:to="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_294" xlink:to="lab_entx_OperatingLeaseLiabilityAndOperatingLeaseRightOfUseAssetTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_295" xlink:to="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_296" xlink:to="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_297" xlink:to="lab_entx_OperatingLeaseSupplementalCashFlowInformationTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OptionToIssueVestingPercentage_298" xlink:to="lab_entx_OptionToIssueVestingPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OptionToIssueVestingPercentage_299" xlink:to="lab_entx_OptionToIssueVestingPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OptionToIssueVestingPercentage_300" xlink:to="lab_entx_OptionToIssueVestingPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OramedLtdMember_301" xlink:to="lab_entx_OramedLtdMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OramedLtdMember_302" xlink:to="lab_entx_OramedLtdMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_OramedLtdMember_303" xlink:to="lab_entx_OramedLtdMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentCostsPolicyTextBlock_304" xlink:to="lab_entx_PatentCostsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentCostsPolicyTextBlock_305" xlink:to="lab_entx_PatentCostsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentCostsPolicyTextBlock_306" xlink:to="lab_entx_PatentCostsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentTransferAgreementMember_307" xlink:to="lab_entx_PatentTransferAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentTransferAgreementMember_308" xlink:to="lab_entx_PatentTransferAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PatentTransferAgreementMember_309" xlink:to="lab_entx_PatentTransferAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_310" xlink:to="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_311" xlink:to="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PaymentOfRoyaltyGuaranteesCommitments_312" xlink:to="lab_entx_PaymentOfRoyaltyGuaranteesCommitments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_313" xlink:to="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_314" xlink:to="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_315" xlink:to="lab_entx_PlacementAgencyAgreementWithGpNumenkariIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PresidentOfResearchAndDevelopmentMember_316" xlink:to="lab_entx_PresidentOfResearchAndDevelopmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PresidentOfResearchAndDevelopmentMember_317" xlink:to="lab_entx_PresidentOfResearchAndDevelopmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_PresidentOfResearchAndDevelopmentMember_318" xlink:to="lab_entx_PresidentOfResearchAndDevelopmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_319" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_320" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_321" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesAndWarrantsNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_322" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_323" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_324" xlink:to="lab_entx_ProceedsFromIssuanceOfSharesThroughAtmProgramsNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromOptionsAndWarrantExercises_325" xlink:to="lab_entx_ProceedsFromOptionsAndWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromOptionsAndWarrantExercises_326" xlink:to="lab_entx_ProceedsFromOptionsAndWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromOptionsAndWarrantExercises_327" xlink:to="lab_entx_ProceedsFromOptionsAndWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_328" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_329" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_330" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_331" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ProceedsFromShortTermBankDeposits_332" xlink:to="lab_entx_ProceedsFromShortTermBankDeposits_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_333" xlink:to="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_334" xlink:to="lab_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_335" xlink:to="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_336" xlink:to="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_337" xlink:to="lab_entx_RelatedPartyTransactionOfCompensationOfExecutiveOfficers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_338" xlink:to="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_339" xlink:to="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_340" xlink:to="lab_entx_RelatedPartyTransactionOfManagementAndConsultingFeesToBoardMembers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_341" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_342" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_343" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToBoardMembers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_344" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_345" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_346" xlink:to="lab_entx_RelatedPartyTransactionOfStockBasedCompensationExpensesToExecutiveOfficers_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_347" xlink:to="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_348" xlink:to="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_349" xlink:to="lab_entx_RelatedPartyTransactionWithExecutiveOfficersPayables_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_350" xlink:to="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_351" xlink:to="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_352" xlink:to="lab_entx_RelatedPartyTransactionWithNonExecutiveDirectorsPayable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchAndDevelopmentServiceExpense_353" xlink:to="lab_entx_ResearchAndDevelopmentServiceExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchAndDevelopmentServiceExpense_354" xlink:to="lab_entx_ResearchAndDevelopmentServiceExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchAndDevelopmentServiceExpense_355" xlink:to="lab_entx_ResearchAndDevelopmentServiceExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchCollaborationAndLicenseAgreementMember_356" xlink:to="lab_entx_ResearchCollaborationAndLicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchCollaborationAndLicenseAgreementMember_357" xlink:to="lab_entx_ResearchCollaborationAndLicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ResearchCollaborationAndLicenseAgreementMember_358" xlink:to="lab_entx_ResearchCollaborationAndLicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_359" xlink:to="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_360" xlink:to="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ReversalOfExpensesUponForfeitureOfOptions_361" xlink:to="lab_entx_ReversalOfExpensesUponForfeitureOfOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_362" xlink:to="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_363" xlink:to="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_364" xlink:to="lab_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightToUseIntellectualProperty_365" xlink:to="lab_entx_RightToUseIntellectualProperty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightToUseIntellectualProperty_366" xlink:to="lab_entx_RightToUseIntellectualProperty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RightToUseIntellectualProperty_367" xlink:to="lab_entx_RightToUseIntellectualProperty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_368" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_369" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_370" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfEachPaymentReceivedFromAmgen_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_371" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_372" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_373" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageOfNetRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_374" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_375" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_376" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsCommencingSeventhYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_377" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_378" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_379" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsInFirstThreeYearsFromCommencementOfRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_380" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_381" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_382" xlink:to="lab_entx_RoyaltyGuaranteesCommitmentsPercentageSalesOfProductsDevelopedFromProjectsSubsequentThreeYears_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockAmountOfInvestment_383" xlink:to="lab_entx_SaleOfStockAmountOfInvestment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockAmountOfInvestment_384" xlink:to="lab_entx_SaleOfStockAmountOfInvestment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockAmountOfInvestment_385" xlink:to="lab_entx_SaleOfStockAmountOfInvestment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_386" xlink:to="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_387" xlink:to="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_388" xlink:to="lab_entx_SaleOfStockPercentageOfOwnershipOfEntityAcquired_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_389" xlink:to="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_390" xlink:to="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_391" xlink:to="lab_entx_ScheduleOfEstimatedUsefulLifeTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_392" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_393" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_394" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionReportedInConsolidatedStatementsOfComprehensiveLossTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_395" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_396" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_397" xlink:to="lab_entx_ScheduleOfRelatedPartyTransactionsReportedInConsolidatedBalanceSheetsTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SecondAnniversaryMember_398" xlink:to="lab_entx_SecondAnniversaryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SecondAnniversaryMember_399" xlink:to="lab_entx_SecondAnniversaryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_400" xlink:to="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_401" xlink:to="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_402" xlink:to="lab_entx_SellingPriceOfPreclinicalResearchAndDevelopmentServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ServiceProviderMember_403" xlink:to="lab_entx_ServiceProviderMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ServiceProviderMember_404" xlink:to="lab_entx_ServiceProviderMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ServiceProviderMember_405" xlink:to="lab_entx_ServiceProviderMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveralEmployeesAndServiceProvidersMember_406" xlink:to="lab_entx_SeveralEmployeesAndServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveralEmployeesAndServiceProvidersMember_407" xlink:to="lab_entx_SeveralEmployeesAndServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveralEmployeesAndServiceProvidersMember_408" xlink:to="lab_entx_SeveralEmployeesAndServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveranceExpenses_409" xlink:to="lab_entx_SeveranceExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveranceExpenses_410" xlink:to="lab_entx_SeveranceExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeveranceExpenses_411" xlink:to="lab_entx_SeveranceExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeverancePayPolicyTextBlock_412" xlink:to="lab_entx_SeverancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeverancePayPolicyTextBlock_413" xlink:to="lab_entx_SeverancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SeverancePayPolicyTextBlock_414" xlink:to="lab_entx_SeverancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_415" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_416" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFiveMember_417" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFiveMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_418" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_419" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheFourMember_420" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheFourMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_421" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSevenMember_422" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSevenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_423" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_424" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareBasedPaymentArrangementTrancheSixMember_425" xlink:to="lab_entx_ShareBasedPaymentArrangementTrancheSixMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2013Member_426" xlink:to="lab_entx_ShareIncentivePlan2013Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2013Member_427" xlink:to="lab_entx_ShareIncentivePlan2013Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2013Member_428" xlink:to="lab_entx_ShareIncentivePlan2013Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2018Member_429" xlink:to="lab_entx_ShareIncentivePlan2018Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2018Member_430" xlink:to="lab_entx_ShareIncentivePlan2018Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_ShareIncentivePlan2018Member_431" xlink:to="lab_entx_ShareIncentivePlan2018Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesGrantedInPercentage_432" xlink:to="lab_entx_SharesGrantedInPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesGrantedInPercentage_433" xlink:to="lab_entx_SharesGrantedInPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesGrantedInPercentage_434" xlink:to="lab_entx_SharesGrantedInPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesIssuedWeightedAveragePricePerShare_435" xlink:to="lab_entx_SharesIssuedWeightedAveragePricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesIssuedWeightedAveragePricePerShare_436" xlink:to="lab_entx_SharesIssuedWeightedAveragePricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SharesIssuedWeightedAveragePricePerShare_437" xlink:to="lab_entx_SharesIssuedWeightedAveragePricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_438" xlink:to="lab_entx_SignificantAccountingPoliciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_439" xlink:to="lab_entx_SignificantAccountingPoliciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesTable_440" xlink:to="lab_entx_SignificantAccountingPoliciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SignificantAccountingPoliciesTable_441" xlink:to="lab_entx_SignificantAccountingPoliciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SixNonExecutiveBoardMembersMember_442" xlink:to="lab_entx_SixNonExecutiveBoardMembersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SixNonExecutiveBoardMembersMember_443" xlink:to="lab_entx_SixNonExecutiveBoardMembersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SixNonExecutiveBoardMembersMember_444" xlink:to="lab_entx_SixNonExecutiveBoardMembersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteLineItems_445" xlink:to="lab_entx_StockholdersEquityNoteLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteLineItems_446" xlink:to="lab_entx_StockholdersEquityNoteLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteTable_447" xlink:to="lab_entx_StockholdersEquityNoteTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_StockholdersEquityNoteTable_448" xlink:to="lab_entx_StockholdersEquityNoteTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_449" xlink:to="lab_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationTextBlock_450" xlink:to="lab_entx_SupplementaryFinancialStatementInformationTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationTextBlock_451" xlink:to="lab_entx_SupplementaryFinancialStatementInformationTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_SupplementaryFinancialStatementInformationTextBlock_452" xlink:to="lab_entx_SupplementaryFinancialStatementInformationTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TransactionCosts_453" xlink:to="lab_entx_TransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TransactionCosts_454" xlink:to="lab_entx_TransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TransactionCosts_455" xlink:to="lab_entx_TransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventAxis_456" xlink:to="lab_entx_TriggeringEventAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventAxis_457" xlink:to="lab_entx_TriggeringEventAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventDomain_458" xlink:to="lab_entx_TriggeringEventDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventDomain_459" xlink:to="lab_entx_TriggeringEventDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventMember_460" xlink:to="lab_entx_TriggeringEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventMember_461" xlink:to="lab_entx_TriggeringEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TriggeringEventMember_462" xlink:to="lab_entx_TriggeringEventMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentySeventeenMemberMember_463" xlink:to="lab_entx_TwentySeventeenMemberMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentySeventeenMemberMember_464" xlink:to="lab_entx_TwentySeventeenMemberMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentySeventeenMemberMember_465" xlink:to="lab_entx_TwentySeventeenMemberMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentyTwentyOneGrantMember_466" xlink:to="lab_entx_TwentyTwentyOneGrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentyTwentyOneGrantMember_467" xlink:to="lab_entx_TwentyTwentyOneGrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_TwentyTwentyOneGrantMember_468" xlink:to="lab_entx_TwentyTwentyOneGrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedSharesUnits_469" xlink:to="lab_entx_VestedRestrictedSharesUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedSharesUnits_470" xlink:to="lab_entx_VestedRestrictedSharesUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedSharesUnits_471" xlink:to="lab_entx_VestedRestrictedSharesUnits_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedShareUnitsShares_472" xlink:to="lab_entx_VestedRestrictedShareUnitsShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedShareUnitsShares_473" xlink:to="lab_entx_VestedRestrictedShareUnitsShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_VestedRestrictedShareUnitsShares_474" xlink:to="lab_entx_VestedRestrictedShareUnitsShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_WarrantToPurchaseOrdinaryShare_475" xlink:to="lab_entx_WarrantToPurchaseOrdinaryShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_WarrantToPurchaseOrdinaryShare_476" xlink:to="lab_entx_WarrantToPurchaseOrdinaryShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_entx_WarrantToPurchaseOrdinaryShare_477" xlink:to="lab_entx_WarrantToPurchaseOrdinaryShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_478" xlink:to="lab_srt_ChiefExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_479" xlink:to="lab_srt_ChiefExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_480" xlink:to="lab_srt_ChiefExecutiveOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis_481" xlink:to="lab_srt_ConsolidatedEntitiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain_482" xlink:to="lab_srt_ConsolidatedEntitiesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis_483" xlink:to="lab_srt_ConsolidationItemsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain_484" xlink:to="lab_srt_ConsolidationItemsDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember_485" xlink:to="lab_srt_ExecutiveOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember_486" xlink:to="lab_srt_ExecutiveOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_487" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_488" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_489" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_490" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_491" xlink:to="lab_srt_ProductOrServiceAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_492" xlink:to="lab_srt_ProductsAndServicesDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_493" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_494" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_495" xlink:to="lab_srt_SubsidiariesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_496" xlink:to="lab_srt_SubsidiariesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember_497" xlink:to="lab_srt_SubsidiariesMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_498" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_499" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_500" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_501" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_502" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_503" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_504" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_505" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_506" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_507" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_508" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_509" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_510" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_511" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_512" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_513" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_514" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_515" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_516" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_517" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_518" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_519" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_520" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_521" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_522" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent_523" xlink:to="lab_us-gaap_AccruedVacationCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent_524" xlink:to="lab_us-gaap_AccruedVacationCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_525" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_526" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_527" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_528" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_529" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_530" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_531" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_532" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_533" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_534" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_535" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_536" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_537" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_538" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_539" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_540" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_541" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_542" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_543" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_544" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_545" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_546" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_547" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_548" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_549" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_550" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_551" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_552" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_553" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_554" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_555" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_556" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_557" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_558" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_559" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_560" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_561" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_562" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_563" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_564" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_565" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_566" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_567" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_568" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_569" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_570" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_571" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_572" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_573" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_574" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_575" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_576" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_577" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_578" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_579" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_580" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_581" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_582" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_583" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_584" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_585" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_586" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_587" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_588" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_589" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_590" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_591" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_592" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_593" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_594" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_595" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_596" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_597" xlink:to="lab_us-gaap_CommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_598" xlink:to="lab_us-gaap_CommonStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_599" xlink:to="lab_us-gaap_CommonStockValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_600" xlink:to="lab_us-gaap_CommonStockValue_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_601" xlink:to="lab_us-gaap_CommonStockValueOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding_602" xlink:to="lab_us-gaap_CommonStockValueOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights_603" xlink:to="lab_us-gaap_CommonStockVotingRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights_604" xlink:to="lab_us-gaap_CommonStockVotingRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_605" xlink:to="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_606" xlink:to="lab_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_607" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_608" xlink:to="lab_us-gaap_ComputerEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_609" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_610" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_611" xlink:to="lab_us-gaap_ContractWithCustomerLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_612" xlink:to="lab_us-gaap_ContractWithCustomerLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_613" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_614" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_615" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_616" xlink:to="lab_us-gaap_CostOfRevenue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_617" xlink:to="lab_us-gaap_CostOfSalesMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_618" xlink:to="lab_us-gaap_CostOfSalesMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_619" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_620" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_621" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_622" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_623" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_624" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_625" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_626" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_627" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_628" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_629" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_630" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_631" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_632" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_633" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_634" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_635" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_636" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_637" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_639" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_640" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_641" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_642" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_643" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_644" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_645" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_646" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_647" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_648" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_649" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_650" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_651" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_652" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_653" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_654" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_655" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_656" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_657" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_658" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_659" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_660" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_661" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_662" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_663" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_664" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_665" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_666" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_667" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_668" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_669" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_670" xlink:to="lab_us-gaap_DomesticCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_671" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_672" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_673" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_674" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_675" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_676" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_677" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_678" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_679" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_680" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_681" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_682" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_683" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_684" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_685" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_686" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_687" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_688" xlink:to="lab_us-gaap_ForeignCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_689" xlink:to="lab_us-gaap_ForeignCountryMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_690" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_691" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_692" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_693" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_694" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_695" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_696" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember_697" xlink:to="lab_us-gaap_GovernmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember_698" xlink:to="lab_us-gaap_GovernmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_699" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_700" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_701" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_702" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_703" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_704" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_705" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_706" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_707" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_708" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_709" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_710" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_711" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_712" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_713" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_714" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_715" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_716" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_717" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_718" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_719" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_720" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_721" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_722" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_723" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_724" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_725" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_726" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_727" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_728" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_729" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_730" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_731" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_732" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_733" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_734" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_735" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_736" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_737" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_738" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_739" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_740" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_741" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_742" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_743" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_744" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_745" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_746" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_747" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_748" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_749" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_750" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_751" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_752" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_753" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_754" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_755" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_756" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_757" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_758" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_759" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_760" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_761" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_762" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_763" xlink:to="lab_us-gaap_IntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_764" xlink:to="lab_us-gaap_IPOMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_765" xlink:to="lab_us-gaap_IPOMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis_766" xlink:to="lab_us-gaap_LeaseContractualTermAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain_767" xlink:to="lab_us-gaap_LeaseContractualTermDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_768" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_769" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_770" xlink:to="lab_us-gaap_LeasesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_771" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_772" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_773" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_774" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_775" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_776" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescription_777" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescription_778" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_779" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_780" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_781" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_782" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_784" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_785" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_786" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_787" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_788" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_789" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_790" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_791" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_792" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_793" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_794" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_795" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_796" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_797" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_798" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_799" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_800" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_801" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_802" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_803" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_804" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_805" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_806" xlink:to="lab_us-gaap_LiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_807" xlink:to="lab_us-gaap_LiabilitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_808" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_809" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_810" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_811" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_812" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_813" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_814" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_815" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_816" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_817" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_818" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_819" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_820" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_821" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_823" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_824" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_825" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_826" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_827" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_828" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_829" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_830" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_831" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_832" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_833" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_834" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_835" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_836" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_837" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_838" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_839" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_840" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_841" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_842" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_843" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_844" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_845" xlink:to="lab_us-gaap_OfficeEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_846" xlink:to="lab_us-gaap_OfficeEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_847" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_848" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_849" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_850" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_851" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_852" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_853" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_854" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_855" xlink:to="lab_us-gaap_OperatingLeaseCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_856" xlink:to="lab_us-gaap_OperatingLeaseCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_857" xlink:to="lab_us-gaap_OperatingLeaseCost_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_858" xlink:to="lab_us-gaap_OperatingLeaseExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_859" xlink:to="lab_us-gaap_OperatingLeaseExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_860" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_861" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_862" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_863" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_864" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_865" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_866" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_867" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_868" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_869" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_870" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_871" xlink:to="lab_us-gaap_OperatingLeasePayments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_872" xlink:to="lab_us-gaap_OperatingLeasePayments_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_873" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_874" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_875" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_876" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_877" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_878" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_879" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_880" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_881" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_882" xlink:to="lab_us-gaap_OperatingLossCarryforwards_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_883" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_884" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_885" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_886" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_887" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_888" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_889" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_890" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_891" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_892" xlink:to="lab_us-gaap_OtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_893" xlink:to="lab_us-gaap_OtherAssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_894" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_895" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncome_896" xlink:to="lab_us-gaap_OtherNonrecurringIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncome_897" xlink:to="lab_us-gaap_OtherNonrecurringIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringIncome_898" xlink:to="lab_us-gaap_OtherNonrecurringIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome_899" xlink:to="lab_us-gaap_OtherOperatingIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome_900" xlink:to="lab_us-gaap_OtherOperatingIncome_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome_901" xlink:to="lab_us-gaap_OtherOperatingIncome_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_902" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_903" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_904" xlink:to="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_905" xlink:to="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_906" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_907" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_908" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_909" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_910" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_911" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_912" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_913" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_914" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_915" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_916" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_917" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_918" xlink:to="lab_us-gaap_PrivatePlacementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_919" xlink:to="lab_us-gaap_PrivatePlacementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_920" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_921" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_922" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_923" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_924" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_925" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense_926" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense_927" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_928" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_929" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_930" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_931" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_932" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_933" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_934" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_935" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_936" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_937" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_938" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_939" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_940" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_941" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_942" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_943" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_944" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_945" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_946" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_947" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_948" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_949" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_950" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_951" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_952" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_953" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_954" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_955" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments_956" xlink:to="lab_us-gaap_RestrictedCashAndInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_957" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_958" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_959" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_960" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_961" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_962" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_963" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_964" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_965" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_966" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_967" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_968" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_969" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_970" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_971" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_972" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_973" xlink:to="lab_us-gaap_Revenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_974" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_975" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_976" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_977" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_978" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_979" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_980" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_981" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_982" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_983" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_984" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_985" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_986" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_987" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_988" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_989" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_990" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_991" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_992" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_993" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_994" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_995" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_996" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_997" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_998" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_999" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_1000" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_1001" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_1002" xlink:to="lab_us-gaap_ServiceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_1003" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_1004" xlink:to="lab_us-gaap_SeveranceCosts1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1005" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1006" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1007" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1008" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1009" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1010" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1011" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1012" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1013" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1014" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1015" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1016" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1017" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1018" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1019" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1020" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1021" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1022" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1023" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1024" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1025" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1026" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1027" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1028" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1029" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1030" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1031" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1032" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1033" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1034" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1035" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1036" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1037" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1038" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1039" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1040" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1041" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1042" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1043" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1044" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1045" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1046" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1047" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1048" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1049" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1050" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1051" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1052" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1053" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1054" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1055" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1056" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1057" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1058" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1059" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1060" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1061" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1062" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1063" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1064" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1065" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1066" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1067" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1068" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1069" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1070" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1071" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1072" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1073" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1074" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1075" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1076" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1077" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1078" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1079" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1080" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1081" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1082" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1083" xlink:to="lab_us-gaap_SharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1084" xlink:to="lab_us-gaap_SharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_1085" xlink:to="lab_us-gaap_SharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1086" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1087" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1088" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1089" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_1090" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1091" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1092" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1093" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1094" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1095" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1096" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1097" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1098" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1099" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1100" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1101" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1102" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1103" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1104" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1105" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1106" xlink:to="lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1107" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1108" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1109" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1110" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1111" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1112" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1113" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1114" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1115" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1116" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1117" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1118" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1119" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1120" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_1121" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_1122" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_1123" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1124" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1125" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_1126" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_1127" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1128" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1129" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1130" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1131" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_1132" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1133" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1134" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1135" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_1136" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1137" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1138" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1139" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_1140" xlink:to="lab_us-gaap_VestingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_1141" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1142" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_1143" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1144" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1145" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1146" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1147" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>entx-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals" roleURI="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SHAREBASEDCOMPENSATION" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATION"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SHAREBASEDCOMPENSATIONTables" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SHAREBASEDCOMPENSATIONDetails" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SHAREBASEDCOMPENSATIONDetailTextuals" roleURI="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#GENERAL" roleURI="http://www.enterabio.com/role/GENERAL"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#GENERALDetailTextuals" roleURI="http://www.enterabio.com/role/GENERALDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDBALANCESHEETS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#DocumentAndEntityInformation" roleURI="http://www.enterabio.com/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable" roleURI="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUBSEQUENTEVENT" roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENT"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#SUBSEQUENTEVENTSNarrative" roleURI="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#EVENTSDURINGTHEPERIODNarrativeDetails" roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#EVENTSDURINGTHEPERIOD" roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#EVENTSDURINGTHEPERIODTables" roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables"/>
  <roleRef xlink:type="simple" xlink:href="entx-20230630.xsd#EVENTSDURINGTHEPERIODDetails" roleURI="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock" xlink:label="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesTable" xlink:label="loc_entx_SignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AmgenIncMember" xlink:label="loc_entx_AmgenIncMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SignificantAccountingPoliciesLineItems" xlink:label="loc_entx_SignificantAccountingPoliciesLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_4"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SeveranceExpenses" xlink:label="loc_entx_SeveranceExpenses_5"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment" xlink:label="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_6"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_AdditionalAmountPaidForServicesToBeRecognized" xlink:label="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_7"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightToUseIntellectualProperty" xlink:label="loc_entx_RightToUseIntellectualProperty_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_entx_SignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="loc_us-gaap_RelatedPartyDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1" xlink:to="loc_entx_AmgenIncMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesTable_1" xlink:to="loc_entx_SignificantAccountingPoliciesLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_us-gaap_SeveranceCosts1_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_SeveranceExpenses_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_AdditionalAmountPaidForServicesToBeRecognized_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_entx_RightToUseIntellectualProperty_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SignificantAccountingPoliciesLineItems_4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATION">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1" xlink:to="loc_srt_RangeMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MinimumMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1" xlink:to="loc_srt_MaximumMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SixNonExecutiveBoardMembersMember" xlink:label="loc_entx_SixNonExecutiveBoardMembersMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_NonExecutiveDirectorMember" xlink:label="loc_entx_NonExecutiveDirectorMember_2"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExecutiveOfficerAndServiceProviderMember" xlink:label="loc_entx_ExecutiveOfficerAndServiceProviderMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_16"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_entx_SixNonExecutiveBoardMembersMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_entx_NonExecutiveDirectorMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_entx_ExecutiveOfficerAndServiceProviderMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:to="loc_srt_ExecutiveOfficerMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_VestingAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7" xlink:to="loc_us-gaap_VestingDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/GENERAL">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/GENERALDetailTextuals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralTable" xlink:label="loc_entx_GeneralTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_GeneralLineItems" xlink:label="loc_entx_GeneralLineItems_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_entx_GeneralTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7" xlink:to="loc_us-gaap_CommonStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralTable_1" xlink:to="loc_entx_GeneralLineItems_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_10" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_GeneralLineItems_10" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="loc_us-gaap_OtherNonrecurringIncome_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OtherNonrecurringIncome_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_10"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares" xlink:label="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsValue" xlink:label="loc_entx_ExerciseOfWarrantsValue_16"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ExerciseOfWarrantsShares" xlink:label="loc_entx_ExerciseOfWarrantsShares_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_19"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_VestedRestrictedShareUnitsShares" xlink:label="loc_entx_VestedRestrictedShareUnitsShares_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockholdersEquity_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_SharesOutstanding_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_ExerciseOfWarrantsValue_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_ExerciseOfWarrantsShares_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_entx_VestedRestrictedShareUnitsShares_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_StockholdersEquity_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7" xlink:to="loc_us-gaap_SharesOutstanding_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_6" xlink:to="loc_us-gaap_AssetsNoncurrent_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_LiabilitiesAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_19" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_19" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14" xlink:to="loc_us-gaap_Liabilities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_FinanceExpensesNet" xlink:label="loc_entx_FinanceExpensesNet_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ProceedsFromOptionsAndWarrantExercises" xlink:label="loc_entx_ProceedsFromOptionsAndWarrantExercises_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract" xlink:label="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_29"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities" xlink:label="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_29"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_entx_FinanceExpensesNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_entx_ProceedsFromOptionsAndWarrantExercises_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_25" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract_25" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_29" xlink:to="loc_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_38"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityPublicFloat_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentType_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFilerCategory_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentFlag_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityShellCompany_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityExTransitionPeriod_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine1_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine2_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressAddressLine3_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressStateOrProvince_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCityOrTown_23" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressPostalZipCode_24" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityAddressCountry_25" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_CityAreaCode_26" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_LocalPhoneNumber_27" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentQuarterlyReport_28" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentTransitionReport_29" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityFileNumber_30" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityTaxIdentificationNumber_31" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_TradingSymbol_32" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_SecurityExchangeName_33" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_Security12bTitle_34" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_DocumentAnnualReport_37" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_dei_AmendmentDescription_38" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationTextBlock" xlink:label="loc_entx_SupplementaryFinancialStatementInformationTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_entx_SupplementaryFinancialStatementInformationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaap_AccruedVacationCurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_us-gaap_AccruedVacationCurrent_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_SupplementaryFinancialStatementInformationAbstract" xlink:label="loc_entx_SupplementaryFinancialStatementInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_SupplementaryFinancialStatementInformationAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUBSEQUENTEVENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_10"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightIssued" xlink:label="loc_entx_ClassOfWarrantOrRightIssued_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_ClassOfWarrantOrRightExerciseTerm" xlink:label="loc_entx_ClassOfWarrantOrRightExerciseTerm_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7" xlink:to="loc_us-gaap_SubsequentEventMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_10" xlink:to="loc_entx_ClassOfWarrantOrRightIssued_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_10" xlink:to="loc_entx_ClassOfWarrantOrRightExerciseTerm_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodAbstract" xlink:label="loc_entx_EventsDuringPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTable" xlink:label="loc_entx_EventsDuringPeriodTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_OfficeLeaseAgreementMember" xlink:label="loc_entx_OfficeLeaseAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodLineItems" xlink:label="loc_entx_EventsDuringPeriodLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_entx_EventsDuringPeriodTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodTable_1" xlink:to="loc_us-gaap_LeaseContractualTermAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_1" xlink:to="loc_us-gaap_LeaseContractualTermDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_1" xlink:to="loc_entx_OfficeLeaseAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodTable_1" xlink:to="loc_entx_EventsDuringPeriodLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescription_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodLineItems_4" xlink:to="loc_us-gaap_OperatingLeaseExpense_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodLineItems_4" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodAbstract" xlink:label="loc_entx_EventsDuringPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodTextBlock" xlink:label="loc_entx_EventsDuringPeriodTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_entx_EventsDuringPeriodTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodAbstract" xlink:label="loc_entx_EventsDuringPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails">
    <loc xlink:type="locator" xlink:href="entx-20230630.xsd#entx_EventsDuringPeriodAbstract" xlink:label="loc_entx_EventsDuringPeriodAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_entx_EventsDuringPeriodAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880799216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENTERA
BIO LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,813,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Kiryat
        Hadassah<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Minrav
        Building &#8211; Fifth Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jerusalem<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9112002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">2-532-7151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary
        Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880511632">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,135<span></span>
</td>
<td class="nump">$ 12,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">650<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,814<span></span>
</td>
<td class="nump">12,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">460<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">631<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,445<span></span>
</td>
<td class="nump">13,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">240<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,865<span></span>
</td>
<td class="nump">1,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">316<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL NON-CURRENT LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">348<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares, NIS 0.0000769 par value: Authorized - as of June 30, 2023 and December 31, 2022, 140,010,000 shares; issued and outstanding - as of June 30, 2023 and December 31, 2022, 28,813,952 and 28,809,922 shares, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108,203<span></span>
</td>
<td class="nump">107,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,012)<span></span>
</td>
<td class="num">(95,497)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,232<span></span>
</td>
<td class="nump">11,754<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,445<span></span>
</td>
<td class="nump">$ 13,127<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than one thousand US dollars</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480535/715-20-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481179/712-10-25-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481179/712-10-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880770320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary share, par value</a></td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized</a></td>
<td class="nump">140,010,000<span></span>
</td>
<td class="nump">140,010,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">28,813,952<span></span>
</td>
<td class="nump">28,809,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">28,813,952<span></span>
</td>
<td class="nump">28,809,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795879375392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">3,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncome', window );">Other income</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">3,260<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">3,249<span></span>
</td>
<td class="nump">4,542<span></span>
</td>
<td class="nump">7,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME, NET</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAX</a></td>
<td class="nump">2,325<span></span>
</td>
<td class="nump">3,189<span></span>
</td>
<td class="nump">4,515<span></span>
</td>
<td class="nump">6,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX BENEFIT</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="nump">$ 2,325<span></span>
</td>
<td class="nump">$ 3,185<span></span>
</td>
<td class="nump">$ 4,515<span></span>
</td>
<td class="nump">$ 6,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE BASIC</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE DILUTED</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE</a></td>
<td class="nump">28,812,375<span></span>
</td>
<td class="nump">28,808,023<span></span>
</td>
<td class="nump">28,811,162<span></span>
</td>
<td class="nump">28,806,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE</a></td>
<td class="nump">28,812,375<span></span>
</td>
<td class="nump">28,808,023<span></span>
</td>
<td class="nump">28,811,162<span></span>
</td>
<td class="nump">28,806,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483613/220-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880847904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated other Comprehensive income [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 104,950<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (82,426)<span></span>
</td>
<td class="nump">$ 22,565<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">28,804,411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE YEAR ENDED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,969)<span></span>
</td>
<td class="num">(6,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to ordinary shares (in shares)</a></td>
<td class="nump">5,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,660<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">106,623<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(89,395)<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">105,914<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(86,210)<span></span>
</td>
<td class="nump">19,745<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">28,804,411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE YEAR ENDED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,185)<span></span>
</td>
<td class="num">(3,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to ordinary shares (in shares)</a></td>
<td class="nump">5,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">696<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">106,623<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(89,395)<span></span>
</td>
<td class="nump">17,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">107,210<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(95,497)<span></span>
</td>
<td class="nump">11,754<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE YEAR ENDED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,515)<span></span>
</td>
<td class="num">(4,515)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares under the ATM program, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares under the ATM program, net of issuance costs (in shares)</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">988<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">108,203<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(100,012)<span></span>
</td>
<td class="nump">8,232<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">28,813,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">107,726<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(97,687)<span></span>
</td>
<td class="nump">10,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">28,809,922<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CHANGES DURING THE YEAR ENDED</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(2,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares under the ATM program, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares under the ATM program, net of issuance costs (in shares)</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">472<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 108,203<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="num">$ (100,012)<span></span>
</td>
<td class="nump">$ 8,232<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">28,813,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than one thousand U.S. dollars.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795879478576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,325)<span></span>
</td>
<td class="num">$ (3,185)<span></span>
</td>
<td class="num">$ (4,515)<span></span>
</td>
<td class="num">$ (6,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_FinanceExpensesNet', window );">Finance income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating asset and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Increase in other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(356)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Increase (decrease)&#160;in accrued expenses and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="num">(1,390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,168)<span></span>
</td>
<td class="num">(7,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares under the ATM program, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ProceedsFromOptionsAndWarrantExercises', window );">Exercise of options and warrants into shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,175)<span></span>
</td>
<td class="num">(7,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE PERIOD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,376<span></span>
</td>
<td class="nump">24,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE PERIOD</a></td>
<td class="nump">9,201<span></span>
</td>
<td class="nump">17,316<span></span>
</td>
<td class="nump">9,201<span></span>
</td>
<td class="nump">17,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract', window );"><strong>Reconciliation in amounts on consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">9,135<span></span>
</td>
<td class="nump">17,279<span></span>
</td>
<td class="nump">9,135<span></span>
</td>
<td class="nump">17,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted deposits included in other current assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted deposits</a></td>
<td class="nump">$ 9,201<span></span>
</td>
<td class="nump">$ 17,316<span></span>
</td>
<td class="nump">9,201<span></span>
</td>
<td class="nump">17,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_FinanceExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance expenses, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_FinanceExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ProceedsFromOptionsAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from exercise of options and warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ProceedsFromOptionsAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right of use assets obtained in exchange for new operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795877966096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
1 - DESCRIPTION OF BUSINESS</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Entera Bio Ltd. (collectively with its subsidiary,
        the "Company") was incorporated on September 30, 2009 under the laws of the State of Israel and commenced operation on June 1, 2010. On
        January 8, 2018, the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware United States. The Company
        is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant
        unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
        The Company&#8217;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism,
        are based on its proprietary technology platform and are both in clinical development. Additionally, the Company intends to license its
        oral delivery technology to biopharmaceutical companies for use with their proprietary compounds. &#160;&#160; &#160;</span></span></div>
        </td> </tr>
  </table> </div>

<p style="margin-top:0pt;margin-bottom:0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's ordinary shares, NIS 0.0000769
        par value per share (&#8220;ordinary shares&#8221;), have been listed on the Nasdaq Capital Market since July 2018 under the symbol &#8220;ENTX&#8221;.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because the Company is engaged in research and
        development activities, it has not derived significant income from its activities and has incurred an accumulated deficit in the amount
        of $100.0
        million as of June 30, 2023 and negative cash flows from operating activities. The Company's management is of the opinion that its available
        funds as of June 30, 2023 will allow the Company to operate under its current plans into the third quarter of 2024. This assumes the use
        of the Company&#8217;s capital to fund its ongoing operations, including R&amp;D and the completion of the Phase 1 study related to the
        new formulation EB612. This does not include the capital required to fund the Company's proposed Phase 3 study for EB613 in osteoporosis
        and the related comparative study. These factors raise substantial doubt as to the Company's ability to continue as a going concern. Management
        is in the process of evaluating various financing alternatives in the public or private equity markets, debt financing and strategic collaborations,
        as the Company will need to finance future research and development activities, general and administrative expenses and working capital
        through fund raising. However, there is no certainty about the Company's ability to obtain such funding. These condensed consolidated
        financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</span></span></div>
        <div>&#160;</div> </td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795876707664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">

<div>

<div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES</span></span></div>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold">&#160;</div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis
        of presentation of the financial statements</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:44pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These
unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all the information and
notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial
statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s
consolidated financial position as of June 30, 2023, the consolidated results of operations and statements of changes in shareholders'
equity for the three and six-month periods ended June 30, 2023 and 2022 and cash flows for the six-month periods ended June 30, 2023 and
2022.<br/>&#160;</span></span></span></div>

<div style="margin-right:1.95pt;margin-left:44pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
consolidated results for the three and six-month periods ended June 30, 2023 are not necessarily indicative of the results to be expected
for the year ending December 31, 2023.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:44pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the
Company for the year ended December 31, 2022, as filed with the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March 31, 2023. The comparative balance sheet at December 31, 2022 has been derived
from the audited annual financial statements at that date but does not include all disclosures required by U.S. GAAP for annual financial
statements.</span></span></div> </div>

<div style="line-height:1.25">&#160;</div>

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        per share</span></span></div> </td> </tr>
  </table>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic
loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares
during the period.</span></span></span></span></div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:36pt;text-align:justify">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-align:justify"><span><span><span>Diluted
loss per share is based upon the weighted average number of ordinary shares and outstanding stock options and warrants, which are included
under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants, exercisable
into 7,360,374
shares and 6,326,180
shares for the six months ended June 30, 2023 and 2022, respectively and 7,604,195
shares and 6,473,863
shares for the three months ended June 30, 2023 and 2022, respectively, because the effect would have been anti-dilutive.</span></span></span></span></span></span></span></div>
</div>

<div style="line-height:1.25">&#160;</div>

<div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Newly
        issued and recently adopted accounting pronouncements:</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:44pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently
issued accounting pronouncements adopted</span></span></div>

<div style="margin-left:72pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:44pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2016, the FASB issued ASU 2016-13 &#8220;Financial
        Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current
        incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range
        of reasonable and supportable information to inform credit loss estimates. The guidance is effective for smaller reporting companies (as
        defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The adoption of this
        guidance did not have material impact on the Company&#8217;s consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p> </div> </td> </tr>
  </table> </div>  </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795964205376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">

<div>

<div style="line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
3 - SHARE-BASED COMPENSATION</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On January 2, 2023,
        options to purchase an aggregate of 534,246
        ordinary shares were granted to six non-executive board members with an exercise price of&#8201;$0.73
        per share which was the share price on the grant date. The
        options vest over one
        year in four equal quarterly installments starting on the date of grant. This grant was approved by the shareholders of
        the Company on October 4, 2021. The fair value of the options at January 2, 2023 was $253.</span></span></div>
        </td> </tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 24, 2023<span style="font-weight:bold">,
        </span>options to purchase an aggregate of<span style="font-weight:bold">&#160;</span>881,000
        ordinary shares were granted to employees, executive officers and service providers with an exercise price of&#8201;$0.795
        per share which was the share price on the grant date. These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The
        fair value of the options at the date of grant was $485.</span></span></div>
        <div>&#160;</div>
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The fair value of each
        option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following assumptions:</span></span></div>
        </td> </tr>
  </table>

<div>

<div style="margin-left:63.8pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt">&#160;</div>

<div style="margin-left:54pt">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td style="vertical-align:top;font-family:'Times New Roman';border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-indent:0.05pt;line-height:1.25;font-weight:bold;text-align:center">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>Six months</strong></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>ended June 30, 2023</strong></p>
        </div> </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.73-$0.79</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility </span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">74%-76%</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate
        </span></span></div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.58%-3.98%</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life - in years
        </span></span></div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.3-6.11</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table>  </div> </div>

<div style="line-height:1.25;font-family:'Times New Roman';clear:both">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        April 24, 2023<span style="font-weight:bold">, </span>options to purchase an aggregate of<span style="font-weight:bold">&#160;</span>350,000
        ordinary shares were granted to the Company&#8217;s Chief Executive Officer with an exercise price of&#8201;$0.795
        per share which was the share price on that day. These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. This
        grant is subject to the Company's shareholders' approval.</span></span></div> </div> </td> </tr>
  </table>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="font-family:'Times New Roman',Times,serif">
        <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        June 4, 2023, options to purchase an aggregate of 33,638
        ordinary shares were granted to non-executive board member with an exercise price of&#8201;$0.89
        per share which was the share price on that day. The
        options will vest over three
        years in 12 equal quarterly installments starting on the date of grant. This grant is subject to the Company's
        shareholders' approval.</span></span></div> </div> </td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795878096048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SupplementaryFinancialStatementInformationAbstract', window );"><strong>Supplementary Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SupplementaryFinancialStatementInformationTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text">

<div>

<div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NOTE
4 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</span></span></span></span></strong></div>

<div style="line-height:1.25">&#160;</div>

<div style="line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Balance
sheets:</span></span></span></span></strong></div>

<div>

<div style="line-height:1.25">

<div style="margin-left:31.2pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June&#160;30,</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>December&#160;31,</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2023</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2022</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Prepaid
        expenses and other current assets:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="margin-left:16pt;text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Prepaid
        expenses</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>296</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>86</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-left:16pt;text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Other
        current assets</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>354</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>208</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>650</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>294</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  </table>  </div> </div> </div>

<div>

<div style="margin-left:31.2pt;line-height:1.25">&#160;</div>

<div style="margin-left:45pt">

<div style="margin-bottom:10pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June&#160;30,</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Accrued
        expenses and other payables:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees
        and employees related</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>170</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>154</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Provision
        for vacation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>193</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>146</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued
        expenses</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,122</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>933</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,485</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,233</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> </div>  </div> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SupplementaryFinancialStatementInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplementary financial statement information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SupplementaryFinancialStatementInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795964128272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENTS DURING THE PERIOD<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EventsDuringPeriodAbstract', window );"><strong>Events During Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EventsDuringPeriodTextBlock', window );">EVENTS DURING THE PERIOD</a></td>
<td class="text">

<div>

<div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman';font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
5 - EVENTS DURING THE PERIOD</span></span></div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In April 2023, the
        Company entered into an amendment to its office lease agreement from 2014 to extend the period of the lease agreement for additional five
        years, expiring on June
        30, 2028, with two
        options for early termination by the Company subject to a notice period. The monthly lease fee is a total of $15.<br/>&#160;<br/>As
        of June 30,2023, the Company recorded the related asset and obligation at the present value of lease payments over the expected terms,
        discounted using the lessee&#8217;s incremental borrowing rate, which was 13.84%.
        The Company lease agreements do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing
        rate to discount the lease payments based on information available at lease commencement.</span></span></div>
        <div>&#160;</div>
        <div>
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As
        of June 30, 2023, the maturity of lease liabilities under our non-cancelable operating leases were as follows:</span></span></div> </div>
        </td> </tr>
  </table>

<p>&#160;</p> </div>

<div>

<div style="line-height:1.25">

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">96</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">180</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">180</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        future minimum lease payments</span></span></div> </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">542</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less:
        interest</span></span></div> </td>
    <td style="width:10%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(86)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present
        value of operating lease liabilities</span></span></div> </td>
    <td style="width:10%;vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">456</span></span></div>
        </div> </td> </tr>
  </table> </div> </div> </div>  </div>

<div style="line-height:1.25;clear:both">&#160;</div>

<div style="line-height:1.25">

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">
        <div style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On December 10, 2018,
        the Company entered into a research collaboration and license agreement with Amgen (the &#8220;Amgen Agreement&#8221;) for the use of
        the Company&#8217;s oral delivery platform in the field of inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement,
        the Company and Amgen had agreed to use the Company&#8217;s proprietary drug delivery platform to develop oral formulations for one preclinical
        large molecule program that Amgen had selected. Additionally, the Company had granted Amgen an exclusive, worldwide, sublicensable license
        under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable
        products.</span></span></div>
        <div>&#160;</div>
        <div>
        <div style="line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On
        May 2, 2023, the Company and Amgen agreed to terminate the Amgen Agreement in accordance with its terms, effective on such date. Neither
        party incurred any termination penalty or fees in connection with the termination of the Amgen Agreement.</span></span></div> </div> </td>
        </tr>
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:36pt">&#160;</td>
    <td style="vertical-align:top;font-family:Times New Roman;width:auto">&#160;</td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EventsDuringPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EventsDuringPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EventsDuringPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the entire disclosure for events during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EventsDuringPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880711248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">

<div>

<div style="margin-right:36pt;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">NOTE
6 - SUBSEQUENT EVENTS</span></span></div>

<div>

<div>

<div style="line-height:1.25;font-family:'Times New Roman'">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="font-family:Times New Roman;width:8pt">&#160;</td>
    <td style="width:36pt;vertical-align:top"><span style="font-family:'Times New Roman'">a.</span></td>
    <td style="vertical-align:top;text-align:justify;font-family:Times New Roman;width:auto">
        <div>In connection with the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in July 2018, the Company issued 1,400,000
        IPO warrants to purchase 700,000
        ordinary shares, and these warrants were listed for trading on Nasdaq Capital Market (&#8220;Nasdaq&#8221;) since August
        12, 2018. The IPO warrants were immediately exercisable at an initial exercise price of $8.40
        per ordinary share for a period of five
        years, unless earlier repurchased by the Company as described in the warrant agreement. These IPO warrants expired on
        July 2, 2023, in accordance with their original terms, and Nasdaq removed them from listing.</div> </td> </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880788256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation of the financial statements</a></td>
<td class="text">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">a.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basis
        of presentation of the financial statements</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:44pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>These
unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all the information and
notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial
statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s
consolidated financial position as of June 30, 2023, the consolidated results of operations and statements of changes in shareholders'
equity for the three and six-month periods ended June 30, 2023 and 2022 and cash flows for the six-month periods ended June 30, 2023 and
2022.<br/>&#160;</span></span></span></div>

<div style="margin-right:1.95pt;margin-left:44pt;line-height:1.25;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The
consolidated results for the three and six-month periods ended June 30, 2023 are not necessarily indicative of the results to be expected
for the year ending December 31, 2023.</span></span></div>

<div style="line-height:1.25">&#160;</div>

<div style="text-align:justify;margin-left:44pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the
Company for the year ended December 31, 2022, as filed with the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (the &#8220;SEC&#8221;) on March 31, 2023. The comparative balance sheet at December 31, 2022 has been derived
from the audited annual financial statements at that date but does not include all disclosures required by U.S. GAAP for annual financial
statements.</span></span></div> </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text">

<div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss
        per share</span></span></div> </td> </tr>
  </table>

<div style="text-indent:-36pt;margin-left:36pt;line-height:1.25">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Basic
loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares
during the period.</span></span></span></span></div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:36pt;text-align:justify">&#160;</div>

<div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span style="text-align:justify"><span><span><span>Diluted
loss per share is based upon the weighted average number of ordinary shares and outstanding stock options and warrants, which are included
under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants, exercisable
into 7,360,374
shares and 6,326,180
shares for the six months ended June 30, 2023 and 2022, respectively and 7,604,195
shares and 6,473,863
shares for the three months ended June 30, 2023 and 2022, respectively, because the effect would have been anti-dilutive.</span></span></span></span></span></span></span></div>
</div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text">

<div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="vertical-align:top;width:8pt">&#160;</td>
    <td style="vertical-align:top;width:36pt">
        <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></div>
        </td>
    <td style="vertical-align:top;width:auto">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Newly
        issued and recently adopted accounting pronouncements:</span></span></div> </td> </tr>
  </table>

<div style="line-height:1.25">&#160;</div>

<div style="margin-left:44pt;line-height:1.25;font-style:italic;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Recently
issued accounting pronouncements adopted</span></span></div>

<div style="margin-left:72pt;line-height:1.25">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">
  <tr>
    <td style="width:44pt">&#160;</td>
    <td style="vertical-align:top;font-weight:bold;width:45pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1)</span></span></td>
    <td style="vertical-align:top;text-align:justify;width:auto">
        <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In June 2016, the FASB issued ASU 2016-13 &#8220;Financial
        Instruments&#8212;Credit Losses&#8212;Measurement of Credit Losses on Financial Instruments.&#8221; This guidance replaces the current
        incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range
        of reasonable and supportable information to inform credit loss estimates. The guidance is effective for smaller reporting companies (as
        defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The adoption of this
        guidance did not have material impact on the Company&#8217;s consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p> </div> </td> </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795881639360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td style="vertical-align:top;font-family:'Times New Roman';border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-indent:0.05pt;line-height:1.25;font-weight:bold;text-align:center">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>Six months</strong></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>ended June 30, 2023</strong></p>
        </div> </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise price</span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$0.73-$0.79</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected volatility </span></span></div>
        </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">74%-76%</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate
        </span></span></div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.58%-3.98%</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0)">&#160;</div> </div> </td> </tr>
  <tr>
    <td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected life - in years
        </span></span></div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.3-6.11</span></span></div>
        </div> </td>
    <td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
        </tr>
  </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795878115024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Table)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SupplementaryFinancialStatementInformationAbstract', window );"><strong>Supplementary Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text">

<table border="0" cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>June&#160;30,</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>December&#160;31,</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2023</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2022</span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Prepaid
        expenses and other current assets:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="margin-left:16pt;text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Prepaid
        expenses</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>296</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>86</span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="margin-left:16pt;text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Other
        current assets</span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>354</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>208</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>650</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>294</span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text">

<div style="margin-bottom:10pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="vertical-align:top;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>June&#160;30,</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December&#160;31,</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr>
    <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
        <div style="line-height:1.25">&#160;</div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2023</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
        <div style="line-height:1.25">
        <div style="text-align:center;line-height:1.25"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></strong></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td> </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Accrued
        expenses and other payables:</span></strong></p> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Employees
        and employees related</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>170</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>154</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Provision
        for vacation</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>193</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>146</span></span></span></span></div>
        </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(255, 255, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="text-align:justify;line-height:1.25;margin-left:16pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued
        expenses</span></span></span></span></div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,122</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>933</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom">&#160;</td>
        </tr>
  <tr style="background-color:rgb(204, 238, 255)">
    <td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,485</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom">
        <div style="line-height:1.25">
        <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>1,233</span></span></span></span></div>
        </div> </td>
    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
        </tr>
  </table> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SupplementaryFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SupplementaryFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880774496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENTS DURING THE PERIOD (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EventsDuringPeriodAbstract', window );"><strong>Events During Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of lease liabilities under our non-cancelable operating leases</a></td>
<td class="text">

<div>

<div style="line-height:1.25">

<div style="margin-left:45pt">

<table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">96</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">180</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">180</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
        </td>
    <td style="width:10%;vertical-align:top">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total
        future minimum lease payments</span></span></div> </td>
    <td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">542</span></span></div>
        </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less:
        interest</span></span></div> </td>
    <td style="width:10%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(86)</span></span></div>
        </div> </td> </tr>
  <tr>
    <td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present
        value of operating lease liabilities</span></span></div> </td>
    <td style="width:10%;vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)">
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;margin-left:42.55pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">456</span></span></div>
        </div> </td> </tr>
  </table> </div> </div> </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EventsDuringPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EventsDuringPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880700816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Detail Textuals)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary share, par value | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.0000769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_GeneralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_GeneralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795879471552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">7,604,195<span></span>
</td>
<td class="nump">6,473,863<span></span>
</td>
<td class="nump">7,360,374<span></span>
</td>
<td class="nump">6,326,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795871604416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Detail Textuals) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 04, 2023</div></th>
<th class="th"><div>Jan. 02, 2023</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_SixNonExecutiveBoardMembersMember', window );">Six non-executive board members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
        options vest over one
        year in four equal quarterly installments starting on the date of grant. This grant was approved by the shareholders of
        the Company on October 4, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember', window );">Non-executive director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="nump">33,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">e
        options will vest over three
        years in 12 equal quarterly installments starting on the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember', window );">Executive Officer and Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options at the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember', window );">Executive Officer and Service Provider [Member] | Vest on first anniversary of date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember', window );">Executive Officer and Service Provider [Member] | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vestion period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of terms of share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Vest on first anniversary of date of grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_SixNonExecutiveBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_SixNonExecutiveBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_NonExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=entx_ExecutiveOfficerAndServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880491824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.58%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life - in years</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life - in years</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880696288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets, total</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other payables:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employees and employees related</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other payables, total</a></td>
<td class="nump">$ 1,485<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880612736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENTS DURING THE PERIOD (Detail Textuals) - Office Lease Agreement [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EventsDuringPeriodLineItems', window );"><strong>Events During Period [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Agreement termination description</a></td>
<td class="text">two
        options for early termination by the Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Agreement expiration date</a></td>
<td class="text">June
        30, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly lease fee</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee&#8217;s incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.84%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EventsDuringPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EventsDuringPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=entx_OfficeLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=entx_OfficeLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795871589936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EVENTS DURING THE PERIOD (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_EventsDuringPeriodAbstract', window );"><strong>Events During Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_EventsDuringPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_EventsDuringPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139795880405696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Detail Textuals) - IPO [Member] - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2018 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightIssued', window );">Number of warrants issued</a></td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of ordinary shares will be purchased by exercising warrants</a></td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants issued | &#8362; / shares</a></td>
<td class="nump">&#8362; 8.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_entx_ClassOfWarrantOrRightExerciseTerm', window );">Term of warrants issued</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightExerciseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise period of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightExerciseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_entx_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">entx_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>entx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>zk2330106_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:entx="http://www.enterabio.com/20230630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="entx-20230630.xsd" xlink:type="simple"/>
    <context id="C_20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">entx:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">entx:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">entx:OfficeLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-04</endDate>
        </period>
    </context>
    <context id="C_20230630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:ExecutiveOfficerAndServiceProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="C_20230630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">entx:SixNonExecutiveBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-02</endDate>
        </period>
    </context>
    <context id="C_20230807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638097</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <unit id="NIS_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_20230101to20230630"
      id="F20230807213857684_19">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808213523162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808214535386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20220808214614689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230430155759086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731140510423_xbrl_20220808213523162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141710655_xbrl_20220808214535386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141713727_xbrl_20220808214535386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141740672_xbrl_20230430155759086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141742631_xbrl_20230430155759086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="C_20230630"
      id="Fxbrl_20220808213249447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      id="Fxbrl_20220808214617486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20230630"
      id="Fxbrl_20230426051024328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20230426051028683"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_20230101to20230630"
      id="Fdei_EntityCentralIndexKey20220219150840900">0001638097</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_20230101to20230630"
      id="Fdei_AmendmentFlag20220219150858854">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_20230101to20230630"
      id="Fdei_DocumentFiscalPeriodFocus20220219151109286">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_20230101to20230630"
      id="Fdei_CurrentFiscalYearEndDate20220506104715921">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="C_20230101to20230630" id="F20230807213857678_0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_20230101to20230630" id="F20230807213857678_1">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_20230101to20230630"
      id="F20230807213857685_25">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_20230101to20230630"
      id="F20230807213857685_26">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_20230101to20230630" id="F20230807213857679_2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_20230101to20230630" id="F20230807213857679_3">001-38556</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_20230101to20230630"
      id="F20230807213857684_20">ENTERA BIO LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20230101to20230630"
      id="F20230807213857684_18">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="C_20230101to20230630" id="F20230807213857679_4">Kiryat         Hadassah</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_20230101to20230630" id="F20230807213857679_5">Minrav         Building &#x2013; Fifth Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_20230101to20230630" id="F20230807213857680_6">Jerusalem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_20230101to20230630"
      id="F20230807213857683_17">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="C_20230101to20230630" id="F20230807213857680_7">9112002</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_20230101to20230630" id="F20230807213857681_8">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_20230101to20230630" id="F20230807213857682_9">2-532-7151</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_20230101to20230630"
      id="F20230807213857682_10">Ordinary         Shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_20230101to20230630"
      id="F20230807213857682_11">ENTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_20230101to20230630"
      id="F20230807213857683_14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_20230101to20230630"
      id="F20230807213857685_24">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_20230101to20230630"
      id="F20230807213857682_12">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_20230101to20230630"
      id="F20230807213857685_23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_20230101to20230630"
      id="F20230807213857682_13">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_20230101to20230630"
      id="F20230807213857683_16">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_20230101to20230630"
      id="F20230807213857684_21">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_20230101to20230630"
      id="F20230807213857685_22">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20230807"
      decimals="INF"
      id="F20230807213857683_15"
      unitRef="shares">28813952</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_33"
      unitRef="USD">9135000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205256_xbrl_20220802012333935_xbrl_20220505162133424_xbrl_20220219060830028_37"
      unitRef="USD">12309000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_43"
      unitRef="USD">29000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205260_xbrl_20220802012333942_xbrl_20220505162133429_xbrl_20220219060830028_47"
      unitRef="USD">246000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_53"
      unitRef="USD">650000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205265_xbrl_20220802012333948_xbrl_20220505162133433_xbrl_20220219060830028_57"
      unitRef="USD">294000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_63"
      unitRef="USD">9814000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205268_xbrl_20220802012333953_xbrl_20220505162133436_xbrl_20220219060830028_67"
      unitRef="USD">12849000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_83"
      unitRef="USD">122000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205274_xbrl_20220802012333958_xbrl_20220505162133439_xbrl_20220219060830028_87"
      unitRef="USD">139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_93"
      unitRef="USD">460000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205277_xbrl_20220802012333963_xbrl_20220505162133441_xbrl_20220219060830028_97"
      unitRef="USD">90000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_93"
      unitRef="USD">43000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205281_xbrl_20220802012333968_xbrl_20220505162133444_xbrl_20220305102200651_xbrl_20220219060830028_97"
      unitRef="USD">43000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_103"
      unitRef="USD">6000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205284_xbrl_20220802012333974_xbrl_20220505162133446_xbrl_20220219060830028_107"
      unitRef="USD">6000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_113"
      unitRef="USD">631000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205287_xbrl_20220802012333980_xbrl_20220505162133448_xbrl_20220219060830028_117"
      unitRef="USD">278000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_123"
      unitRef="USD">10445000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205289_xbrl_20220802012333985_xbrl_20220505162133450_xbrl_20220219060830028_127"
      unitRef="USD">13127000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_153"
      unitRef="USD">240000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205292_xbrl_20220802012333989_xbrl_20220505162133452_xbrl_20220219060830028_157"
      unitRef="USD">17000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_163"
      unitRef="USD">1485000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205294_xbrl_20220802012333994_xbrl_20220505162133454_xbrl_20220219060830028_167"
      unitRef="USD">1233000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_173"
      unitRef="USD">140000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205297_xbrl_20220802012333998_xbrl_20220505162133457_xbrl_20220219060830028_177"
      unitRef="USD">91000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_193"
      unitRef="USD">1865000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205301_xbrl_20220802012334009_xbrl_20220505162133460_xbrl_20220219060830028_197"
      unitRef="USD">1341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230731132348860_xbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_223"
      unitRef="USD">316000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230731132348860_xbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_227"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_223"
      unitRef="USD">32000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205306_xbrl_20220802012334021_xbrl_20220505162133465_xbrl_20220219060830028_227"
      unitRef="USD">32000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_233"
      unitRef="USD">348000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205308_xbrl_20220802012334025_xbrl_20220505162133467_xbrl_20220219060830028_237"
      unitRef="USD">32000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_243"
      unitRef="USD">2213000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205310_xbrl_20220802012334031_xbrl_20220505162133469_xbrl_20220219060830028_247"
      unitRef="USD">1373000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220809034950441"
      unitRef="NIS_per_Share">0.0000769</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20230630"
      decimals="INF"
      id="Fxbrl_20220808214817829"
      unitRef="NIS_per_Share">0.0000769</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20220809035007189"
      unitRef="shares">140010000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20230630"
      decimals="INF"
      id="Fxbrl_20220808214936276"
      unitRef="shares">140010000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20230630"
      decimals="INF"
      id="Fxbrl_20220809035046498"
      unitRef="shares">28813952</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20230630"
      decimals="INF"
      id="Fxbrl_20220808215259598"
      unitRef="shares">28813952</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230731132500229"
      unitRef="shares">28809922</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230731132441499"
      unitRef="shares">28809922</us-gaap:CommonStockSharesIssued>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_283"
      unitRef="USD">108203000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205314_xbrl_20220802012334039_xbrl_20220505162133472_xbrl_20220219060830028_287"
      unitRef="USD">107210000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_293"
      unitRef="USD">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205316_xbrl_20220802012334043_xbrl_20220505162133474_xbrl_20220219060830028_297"
      unitRef="USD">41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230731132604195"
      unitRef="USD">-100012000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205318_xbrl_20220802012334047_xbrl_20220505162133476_xbrl_20220219060830028_307"
      unitRef="USD">-95497000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_313"
      unitRef="USD">8232000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205320_xbrl_20220802012334050_xbrl_20220505162133478_xbrl_20220219060830028_317"
      unitRef="USD">11754000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_323"
      unitRef="USD">10445000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213205323_xbrl_20220802012334055_xbrl_20220505162133480_xbrl_20220219060830028_327"
      unitRef="USD">13127000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133138310"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133144933"
      unitRef="USD">112000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132401520_xbrl_20220218235908029_33"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132401520_xbrl_20220218235908029_37"
      unitRef="USD">44000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133155581"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133201241"
      unitRef="USD">87000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132409409_xbrl_20220218235908029_43"
      unitRef="USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132409409_xbrl_20220218235908029_47"
      unitRef="USD">33000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133206777"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133209449"
      unitRef="USD">25000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132417008_xbrl_20220218235908029_53"
      unitRef="USD">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132417008_xbrl_20220218235908029_57"
      unitRef="USD">11000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133215930"
      unitRef="USD">2140000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133218473"
      unitRef="USD">3084000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132429369_xbrl_20220218235908029_73"
      unitRef="USD">1209000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132429369_xbrl_20220218235908029_77"
      unitRef="USD">1394000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133222993"
      unitRef="USD">2429000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133225481"
      unitRef="USD">4052000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132437400_xbrl_20220218235908029_83"
      unitRef="USD">1135000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132437400_xbrl_20220218235908029_87"
      unitRef="USD">1880000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherNonrecurringIncome
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133230777"
      unitRef="USD">27000</us-gaap:OtherNonrecurringIncome>
    <us-gaap:OtherNonrecurringIncome
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133233321"
      unitRef="USD">27000</us-gaap:OtherNonrecurringIncome>
    <us-gaap:OtherNonrecurringIncome
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132445367_xbrl_20220218235908029_93"
      unitRef="USD">14000</us-gaap:OtherNonrecurringIncome>
    <us-gaap:OtherNonrecurringIncome
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132445367_xbrl_20220218235908029_97"
      unitRef="USD">14000</us-gaap:OtherNonrecurringIncome>
    <us-gaap:OperatingExpenses
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133239257"
      unitRef="USD">4542000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133242049"
      unitRef="USD">7109000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132456989_xbrl_20230426024644129"
      unitRef="USD">2330000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132456989_xbrl_20230426024649896"
      unitRef="USD">3260000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133248337"
      unitRef="USD">-4542000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133250874"
      unitRef="USD">-7084000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132513429_xbrl_20230426024657072"
      unitRef="USD">-2330000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132513429_xbrl_20230426024704447"
      unitRef="USD">-3249000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133257321"
      unitRef="USD">27000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133301376"
      unitRef="USD">104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132528780_xbrl_20220505170035707"
      unitRef="USD">5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132528780_xbrl_20220505170041902"
      unitRef="USD">60000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133306248"
      unitRef="USD">-4515000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133309217"
      unitRef="USD">-6980000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132538804_xbrl_20220218235908029_143"
      unitRef="USD">-2325000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132538804_xbrl_20220218235908029_147"
      unitRef="USD">-3189000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731133319816"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731133316065"
      unitRef="USD">-11000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132548997_xbrl_20230426025507535"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132548997_xbrl_20220218235908029_157"
      unitRef="USD">-4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731134159798"
      unitRef="USD">-4515000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731134202640"
      unitRef="USD">-6969000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731132558977_xbrl_20230426024625121"
      unitRef="USD">-2325000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731132558977_xbrl_20230426024631752"
      unitRef="USD">-3185000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230101to20230630"
      decimals="2"
      id="Fxbrl_s_20230731133332051"
      unitRef="USD_per_Share">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230101to20230630"
      decimals="2"
      id="Fxbrl_20230731133332051"
      unitRef="USD_per_Share">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20220630"
      decimals="2"
      id="Fxbrl_s_20230731133334601"
      unitRef="USD_per_Share">0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20220630"
      decimals="2"
      id="Fxbrl_20230731133334601"
      unitRef="USD_per_Share">0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20230401to20230630"
      decimals="2"
      id="Fxbrl_20220809001710649"
      unitRef="USD_per_Share">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20230401to20230630"
      decimals="2"
      id="Fxbrl_20230731132606945_xbrl_20220218235908029_183"
      unitRef="USD_per_Share">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220401to20220630"
      decimals="2"
      id="Fxbrl_20220809001731689"
      unitRef="USD_per_Share">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220401to20220630"
      decimals="2"
      id="Fxbrl_20230731132606945_xbrl_20220218235908029_187"
      unitRef="USD_per_Share">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_s_20230731133341737"
      unitRef="shares">28811162</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20230731133341738"
      unitRef="shares">28811162</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_s_20230731133344049"
      unitRef="shares">28806217</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20230731133344049"
      unitRef="shares">28806217</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="Fxbrl_s_20230426024815480"
      unitRef="shares">28812375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="Fxbrl_20230731132614577_xbrl_20230426024815480"
      unitRef="shares">28812375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220401to20220630"
      decimals="INF"
      id="Fxbrl_s_20230426024821824"
      unitRef="shares">28808023</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220401to20220630"
      decimals="INF"
      id="Fxbrl_20230731132614577_xbrl_20230426024821824"
      unitRef="shares">28808023</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50"
      unitRef="shares">28809922</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49"
      unitRef="USD">107210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47"
      unitRef="USD">-95497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46"
      unitRef="USD">11754000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010392_20220801223211740_10"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010392_20220801223211740_9"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010392_20220801223211739_8"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010392_20220801223211739_7"
      unitRef="USD">-4515000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220808213010392_20220801223211738_6"
      unitRef="USD">-4515000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50"
      unitRef="shares">4030</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010428_20220801223211758_33"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010428_20220801223211758_32"
      unitRef="USD">988000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010428_20220801223211757_31"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230101to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010428_20220801223211757_30"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220808213010428_20220801223211756_29"
      unitRef="USD">988000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010611_20220801223211822_66"
      unitRef="shares">28813952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010611_20220801223211822_65"
      unitRef="USD">108203000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010611_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010611_20220801223211821_63"
      unitRef="USD">-100012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808213010611_20220801223211821_62"
      unitRef="USD">8232000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211822_66"
      unitRef="shares">28809922</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211822_65"
      unitRef="USD">107726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211821_63"
      unitRef="USD">-97687000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230331"
      decimals="-3"
      id="Fxbrl_20230731141710655_xbrl_20220808213010611_20220801223211821_62"
      unitRef="USD">10080000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211805_56"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211798_55"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211791_54"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211791_53"
      unitRef="USD">-2325000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731150220405_xbrl_20220808213010516_20220801223211791_52"
      unitRef="USD">-2325000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50"
      unitRef="shares">4030</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211758_33"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211758_32"
      unitRef="USD">472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211757_31"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230401to20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211757_30"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20230401to20230630"
      decimals="-3"
      id="Fxbrl_20230731141649287_xbrl_20220808213010428_20220801223211756_29"
      unitRef="USD">472000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211822_66"
      unitRef="shares">28813952</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211822_65"
      unitRef="USD">108203000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211821_63"
      unitRef="USD">-100012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230731141713727_xbrl_20220808213010611_20220801223211821_62"
      unitRef="USD">8232000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213010482_20220801223211790_50"
      unitRef="shares">28804411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010482_20220801223211790_49"
      unitRef="USD">104950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010482_20220801223211789_48"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010482_20220801223211789_47"
      unitRef="USD">-82426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20220808213010482_20220801223211788_46"
      unitRef="USD">22565000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20220808213010516_20220801223211805_56"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213010516_20220801223211798_55"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213010516_20220801223211791_54"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213010516_20220801223211791_53"
      unitRef="USD">-6969000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220808213010516_20220801223211791_52"
      unitRef="USD">-6969000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50"
      unitRef="shares">5511</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49"
      unitRef="USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46"
      unitRef="USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211758_33"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211758_32"
      unitRef="USD">1660000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211757_31"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211757_30"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731141652942_xbrl_20220808213010428_20220801223211756_29"
      unitRef="USD">1660000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20220808213412916_20220801223211822_66"
      unitRef="shares">28809922</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20220808213412916_20220801223211822_65"
      unitRef="USD">106623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20220808213412916_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20220808213412916_20220801223211821_63"
      unitRef="USD">-89395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220808213412916_20220801223211821_62"
      unitRef="USD">17269000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211822_66"
      unitRef="shares">28804411</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211822_65"
      unitRef="USD">105914000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211821_63"
      unitRef="USD">-86210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220331"
      decimals="-3"
      id="Fxbrl_20230731141740672_xbrl_20220808213412916_20220801223211821_62"
      unitRef="USD">19745000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211740_10"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211740_9"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211739_8"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211739_7"
      unitRef="USD">-3185000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731141816894_xbrl_20220808213010392_20220801223211738_6"
      unitRef="USD">-3185000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_50"
      unitRef="shares">5511</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211790_49"
      unitRef="USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_48"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211789_47"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213010689_xbrl_20220802040425371_20220801223211788_46"
      unitRef="USD">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211758_33"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211758_32"
      unitRef="USD">696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211757_31"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220401to20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211757_30"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_20220401to20220630"
      decimals="-3"
      id="Fxbrl_20230731141655838_xbrl_20220808213010428_20220801223211756_29"
      unitRef="USD">696000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211822_66"
      unitRef="shares">28809922</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211822_65"
      unitRef="USD">106623000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapAccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211822_64"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211821_63"
      unitRef="USD">-89395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20230731141742631_xbrl_20220808213412916_20220801223211821_62"
      unitRef="USD">17269000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_33"
      unitRef="USD">-4515000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_37"
      unitRef="USD">-6969000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_63"
      unitRef="USD">29000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_67"
      unitRef="USD">32000</us-gaap:Depreciation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220305111909474_xbrl_20220219041121835_63"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220305111909474_xbrl_20220219041121835_67"
      unitRef="USD">-63000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_83"
      unitRef="USD">988000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_87"
      unitRef="USD">1660000</us-gaap:ShareBasedCompensation>
    <entx:FinanceExpensesNet
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_103"
      unitRef="USD">-6000</entx:FinanceExpensesNet>
    <entx:FinanceExpensesNet
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_107"
      unitRef="USD">-71000</entx:FinanceExpensesNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_123"
      unitRef="USD">-217000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_127"
      unitRef="USD">42000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_133"
      unitRef="USD">356000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_137"
      unitRef="USD">704000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220802102026794"
      unitRef="USD">223000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731140959224"
      unitRef="USD">-57000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_153"
      unitRef="USD">252000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_157"
      unitRef="USD">-1390000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_163"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_167"
      unitRef="USD">-15000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_173"
      unitRef="USD">-3168000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220305111416980"
      unitRef="USD">-7619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20221030215719839_xbrl_20220219041121835_203"
      unitRef="USD">12000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20221030215719839_xbrl_20220219041121835_207"
      unitRef="USD">42000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20221030215741538"
      unitRef="USD">-12000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20221030215753542"
      unitRef="USD">-42000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_203"
      unitRef="USD">5000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_207"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <entx:ProceedsFromOptionsAndWarrantExercises
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731140301139_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_203"
      unitRef="USD">0</entx:ProceedsFromOptionsAndWarrantExercises>
    <entx:ProceedsFromOptionsAndWarrantExercises
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731140301139_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_207"
      unitRef="USD">13000</entx:ProceedsFromOptionsAndWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731140302926_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_203"
      unitRef="USD">5000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731140302926_xbrl_20230731140230697_xbrl_20221030215719839_xbrl_20220219041121835_207"
      unitRef="USD">13000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20220219041121835_313"
      unitRef="USD">-3175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20220219041121835_317"
      unitRef="USD">-7648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230426031113662"
      unitRef="USD">12376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230426031120293"
      unitRef="USD">24964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230426031130941"
      unitRef="USD">9201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20230426031137438"
      unitRef="USD">17316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220505171612811"
      unitRef="USD">9135000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20220505171631694"
      unitRef="USD">17279000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230426031237262"
      unitRef="USD">66000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20230426031246543"
      unitRef="USD">37000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230426031145133"
      unitRef="USD">9201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20220630"
      decimals="-3"
      id="Fxbrl_20230426031152246"
      unitRef="USD">17316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
      contextRef="C_20230101to20230630"
      decimals="-3"
      id="Fxbrl_20230731140755339_xbrl_20230426031237262"
      unitRef="USD">449000</entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities>
    <entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
      contextRef="C_20220101to20220630"
      decimals="-3"
      id="Fxbrl_20230731140755339_xbrl_20230426031246543"
      unitRef="USD">0</entx:RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230430182140649">

&lt;div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
1 - DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Entera Bio Ltd. (collectively with its subsidiary,
        the "Company") was incorporated on September 30, 2009 under the laws of the State of Israel and commenced operation on June 1, 2010. On
        January 8, 2018, the Company incorporated Entera Bio Inc., a wholly owned subsidiary incorporated in Delaware United States. The Company
        is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant
        unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients.
        The Company&#x2019;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism,
        are based on its proprietary technology platform and are both in clinical development. Additionally, the Company intends to license its
        oral delivery technology to biopharmaceutical companies for use with their proprietary compounds. &#160;&#160; &#160;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;

&lt;p style="margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company's ordinary shares, NIS 0.0000769
        par value per share (&#x201c;ordinary shares&#x201d;), have been listed on the Nasdaq Capital Market since July 2018 under the symbol &#x201c;ENTX&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Because the Company is engaged in research and
        development activities, it has not derived significant income from its activities and has incurred an accumulated deficit in the amount
        of $100.0
        million as of June 30, 2023 and negative cash flows from operating activities. The Company's management is of the opinion that its available
        funds as of June 30, 2023 will allow the Company to operate under its current plans into the third quarter of 2024. This assumes the use
        of the Company&#x2019;s capital to fund its ongoing operations, including R&amp;amp;D and the completion of the Phase 1 study related to the
        new formulation EB612. This does not include the capital required to fund the Company's proposed Phase 3 study for EB613 in osteoporosis
        and the related comparative study. These factors raise substantial doubt as to the Company's ability to continue as a going concern. Management
        is in the process of evaluating various financing alternatives in the public or private equity markets, debt financing and strategic collaborations,
        as the Company will need to finance future research and development activities, general and administrative expenses and working capital
        through fund raising. However, there is no certainty about the Company's ability to obtain such funding. These condensed consolidated
        financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;&#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20230630"
      decimals="7"
      id="Fxbrl_20230731131108454"
      unitRef="NIS_per_Share">0.0000769</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20230630"
      decimals="-6"
      id="Fxbrl_20230807123800537"
      unitRef="USD">-100000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230430182410304">

&lt;div&gt;

&lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-indent:-36pt;margin-left:36pt;line-height:1.25;font-weight:bold"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basis
        of presentation of the financial statements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:44pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;These
unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all the information and
notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial
statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#x2019;s
consolidated financial position as of June 30, 2023, the consolidated results of operations and statements of changes in shareholders'
equity for the three and six-month periods ended June 30, 2023 and 2022 and cash flows for the six-month periods ended June 30, 2023 and
2022.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-right:1.95pt;margin-left:44pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
consolidated results for the three and six-month periods ended June 30, 2023 are not necessarily indicative of the results to be expected
for the year ending December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:44pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the
Company for the year ended December 31, 2022, as filed with the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (the &#x201c;SEC&#x201d;) on March 31, 2023. The comparative balance sheet at December 31, 2022 has been derived
from the audited annual financial statements at that date but does not include all disclosures required by U.S. GAAP for annual financial
statements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss
        per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="text-indent:-36pt;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Basic
loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares
during the period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:36pt;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="text-align:justify"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Diluted
loss per share is based upon the weighted average number of ordinary shares and outstanding stock options and warrants, which are included
under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants, exercisable
into 7,360,374
shares and 6,326,180
shares for the six months ended June 30, 2023 and 2022, respectively and 7,604,195
shares and 6,473,863
shares for the three months ended June 30, 2023 and 2022, respectively, because the effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Newly
        issued and recently adopted accounting pronouncements:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:44pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently
issued accounting pronouncements adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:44pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-weight:bold;width:45pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In June 2016, the FASB issued ASU 2016-13 &#x201c;Financial
        Instruments&#x2014;Credit Losses&#x2014;Measurement of Credit Losses on Financial Instruments.&#x201d; This guidance replaces the current
        incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range
        of reasonable and supportable information to inform credit loss estimates. The guidance is effective for smaller reporting companies (as
        defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The adoption of this
        guidance did not have material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/span&gt;
        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230426050128144">

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basis
        of presentation of the financial statements&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:44pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;These
unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles
in the United States of America ("U.S. GAAP") for interim financial statements. Accordingly, they do not include all the information and
notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated financial
statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#x2019;s
consolidated financial position as of June 30, 2023, the consolidated results of operations and statements of changes in shareholders'
equity for the three and six-month periods ended June 30, 2023 and 2022 and cash flows for the six-month periods ended June 30, 2023 and
2022.&lt;br/&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-right:1.95pt;margin-left:44pt;line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The
consolidated results for the three and six-month periods ended June 30, 2023 are not necessarily indicative of the results to be expected
for the year ending December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align:justify;margin-left:44pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;These
unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements of the
Company for the year ended December 31, 2022, as filed with the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (the &#x201c;SEC&#x201d;) on March 31, 2023. The comparative balance sheet at December 31, 2022 has been derived
from the audited annual financial statements at that date but does not include all disclosures required by U.S. GAAP for annual financial
statements.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230426050145564">

&lt;div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Loss
        per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="text-indent:-36pt;margin-left:36pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Basic
loss per share is computed on the basis of net loss for the period divided by the weighted average number of outstanding ordinary shares
during the period.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:36pt;text-align:justify"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-left:44pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span style="text-align:justify"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Diluted
loss per share is based upon the weighted average number of ordinary shares and outstanding stock options and warrants, which are included
under the treasury stock method when dilutive. The calculation of diluted loss per share does not include options and warrants, exercisable
into 7,360,374
shares and 6,326,180
shares for the six months ended June 30, 2023 and 2022, respectively and 7,604,195
shares and 6,473,863
shares for the three months ended June 30, 2023 and 2022, respectively, because the effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;/div&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230101to20230630"
      decimals="INF"
      id="Fxbrl_20230807124230923"
      unitRef="shares">7360374</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20220630"
      decimals="INF"
      id="Fxbrl_20230807124240532"
      unitRef="shares">6326180</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20230401to20230630"
      decimals="INF"
      id="Fxbrl_20230807124247875"
      unitRef="shares">7604195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220401to20220630"
      decimals="INF"
      id="Fxbrl_20230807124253627"
      unitRef="shares">6473863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230426050204421">

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;width:36pt"&gt;
        &lt;div style="line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="vertical-align:top;width:auto"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Newly
        issued and recently adopted accounting pronouncements:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:44pt;line-height:1.25;font-style:italic;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Recently
issued accounting pronouncements adopted&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left:72pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="width:44pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-weight:bold;width:45pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;width:auto"&gt;
        &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In June 2016, the FASB issued ASU 2016-13 &#x201c;Financial
        Instruments&#x2014;Credit Losses&#x2014;Measurement of Credit Losses on Financial Instruments.&#x201d; This guidance replaces the current
        incurred loss impairment methodology with a methodology that reflects expected credit losses and requires consideration of a broader range
        of reasonable and supportable information to inform credit loss estimates. The guidance is effective for smaller reporting companies (as
        defined by the SEC) for the fiscal year beginning on January 1, 2023, including interim periods within that year. The adoption of this
        guidance did not have material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/span&gt;
        &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230807093050751">

&lt;div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman';font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
3 - SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;
        &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On January 2, 2023,
        options to purchase an aggregate of 534,246
        ordinary shares were granted to six non-executive board members with an exercise price of&#x2009;$0.73
        per share which was the share price on the grant date. The
        options vest over one
        year in four equal quarterly installments starting on the date of grant. This grant was approved by the shareholders of
        the Company on October 4, 2021. The fair value of the options at January 2, 2023 was $253.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;
        &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 24, 2023&lt;span style="font-weight:bold"&gt;,
        &lt;/span&gt;options to purchase an aggregate of&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;881,000
        ordinary shares were granted to employees, executive officers and service providers with an exercise price of&#x2009;$0.795
        per share which was the share price on the grant date. These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The
        fair value of the options at the date of grant was $485.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The fair value of each
        option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div&gt;

&lt;div style="margin-left:63.8pt;line-height:1.25;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:54pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-indent:0.05pt;line-height:1.25;font-weight:bold;text-align:center"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;Six months&lt;/strong&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;ended June 30, 2023&lt;/strong&gt;&lt;/p&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$0.73-$0.79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;74%-76%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0)"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate
        &lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.58%-3.98%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0)"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life - in years
        &lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.3-6.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; &lt;/div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman';clear:both"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;
        &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
        April 24, 2023&lt;span style="font-weight:bold"&gt;, &lt;/span&gt;options to purchase an aggregate of&lt;span style="font-weight:bold"&gt;&#160;&lt;/span&gt;350,000
        ordinary shares were granted to the Company&#x2019;s Chief Executive Officer with an exercise price of&#x2009;$0.795
        per share which was the share price on that day. These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. This
        grant is subject to the Company's shareholders' approval.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;
        &lt;div style="font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
        June 4, 2023, options to purchase an aggregate of 33,638
        ordinary shares were granted to non-executive board member with an exercise price of&#x2009;$0.89
        per share which was the share price on that day. The
        options will vest over three
        years in 12 equal quarterly installments starting on the date of grant. This grant is subject to the Company's
        shareholders' approval.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember"
      decimals="INF"
      id="Fxbrl_20230731165113188"
      unitRef="shares">534246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember"
      decimals="2"
      id="Fxbrl_20230731165125485"
      unitRef="USD_per_Share">0.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember"
      id="Fxbrl_20230731165150349">The
        options vest over one
        year in four equal quarterly installments starting on the date of grant. This grant was approved by the shareholders of
        the Company on October 4, 2021.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember"
      id="Fxbrl_20230731165418549">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember"
      decimals="-3"
      id="Fxbrl_20230731165202399"
      unitRef="USD">253000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      decimals="INF"
      id="Fxbrl_20230731142759231"
      unitRef="shares">881000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      decimals="3"
      id="Fxbrl_20230731143006520"
      unitRef="USD_per_Share">0.795</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      id="Fxbrl_20230731142842080">These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      id="Fxbrl_20230731142910794">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fxbrl_20230731143031369"
      unitRef="Percent">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="Fxbrl_20230731143046023"
      unitRef="Percent">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_entxExecutiveOfficerAndServiceProviderMember"
      decimals="-3"
      id="Fxbrl_20230731172321185"
      unitRef="USD">485000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230807093025632">

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-indent:0.05pt;line-height:1.25;font-weight:bold;text-align:center"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;Six months&lt;/strong&gt;&lt;/p&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;ended June 30, 2023&lt;/strong&gt;&lt;/p&gt;
        &lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Exercise price&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$0.73-$0.79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected volatility &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;74%-76%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0)"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate
        &lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.58%-3.98%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0)"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;font-family:'Times New Roman';width:88.91%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected life - in years
        &lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25;color:rgb(0, 0, 0);text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.3-6.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="font-family:'Times New Roman';vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20230630_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20230731142418037"
      unitRef="USD_per_Share">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_20230630_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="Fxbrl_20230731143106069"
      unitRef="USD_per_Share">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20230101to20230630"
      decimals="2"
      id="Fxbrl_20220808220724198"
      unitRef="Percent">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="Fxbrl_20230731142428702"
      unitRef="Percent">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="Fxbrl_20230731143116693"
      unitRef="Percent">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      decimals="4"
      id="Fxbrl_20230731142434996"
      unitRef="Percent">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      decimals="4"
      id="Fxbrl_20230731143130366"
      unitRef="Percent">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_srtRangeAxis_srtMinimumMember"
      id="Fxbrl_20230731142443738">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20230101to20230630_srtRangeAxis_srtMaximumMember"
      id="Fxbrl_20230731143137595">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="INF"
      id="Fxbrl_20230731142052683"
      unitRef="shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      decimals="3"
      id="Fxbrl_20230731142104791"
      unitRef="USD_per_Share">0.795</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      id="Fxbrl_20230731142815988">These
        options vest over four
        years from the date of grant; 25%
        vest on the first anniversary of the date of grant and the remaining 75%
        of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember"
      id="Fxbrl_20230731142214458">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fxbrl_20230731142113252"
      unitRef="Percent">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_20230401to20230424_srtTitleOfIndividualAxis_srtExecutiveOfficerMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember"
      decimals="2"
      id="Fxbrl_20230731142136564"
      unitRef="Percent">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      decimals="INF"
      id="Fxbrl_20230731142803880"
      unitRef="shares">33638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      decimals="2"
      id="Fxbrl_20230731143000644"
      unitRef="USD_per_Share">0.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      id="Fxbrl_20230731142348247">e
        options will vest over three
        years in 12 equal quarterly installments starting on the date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20230601to20230604_srtTitleOfIndividualAxis_entxNonExecutiveDirectorMember"
      id="Fxbrl_20230731142856445">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <entx:SupplementaryFinancialStatementInformationTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230430182915089">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;NOTE
4 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Balance
sheets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="margin-left:31.2pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Prepaid
        expenses and other current assets:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="margin-left:16pt;text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Prepaid
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;296&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-left:16pt;text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Other
        current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;208&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;650&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="margin-left:31.2pt;line-height:1.25"&gt;&#160;&lt;/div&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;div style="margin-bottom:10pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Accrued
        expenses and other payables:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:16pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employees
        and employees related&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:16pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Provision
        for vacation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:16pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,122&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,485&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,233&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt;  &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </entx:SupplementaryFinancialStatementInformationTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230731134500300">

&lt;table border="0" cellpadding="0" cellspacing="0" style="border:0px;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Prepaid
        expenses and other current assets:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="margin-left:16pt;text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Prepaid
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;296&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="margin-left:16pt;text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Other
        current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;208&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;650&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230731132636236_xbrl_20220808200953075_xbrl_20220510112546992"
      unitRef="USD">296000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230731132636236_xbrl_20220808200953075_xbrl_20220510112707928"
      unitRef="USD">86000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230731132644516_xbrl_20220808200953081_xbrl_20220510112644305"
      unitRef="USD">354000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230731132644516_xbrl_20220808200953081_xbrl_20220510112742136"
      unitRef="USD">208000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230731132628506_xbrl_20220808200953083_xbrl_20220510112657784"
      unitRef="USD">650000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230731132628506_xbrl_20220808200953083_xbrl_20220510112751072"
      unitRef="USD">294000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230731144057802">

&lt;div style="margin-bottom:10pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:top;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;June&#160;30,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom:2px solid rgb(0, 0, 0);vertical-align:bottom" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;December&#160;31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="text-align:center;line-height:1.25"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Accrued
        expenses and other payables:&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:16pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Employees
        and employees related&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;154&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:16pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Provision
        for vacation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;193&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="text-align:justify;line-height:1.25;margin-left:16pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Accrued
        expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,122&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(255, 255, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(255, 255, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
    &lt;td style="vertical-align:top;width:76%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,485&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid black;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
        &lt;div style="line-height:1.25"&gt;
        &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;1,233&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt;
    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808200953075_xbrl_20220510112546992"
      unitRef="USD">170000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953075_xbrl_20220510112707928"
      unitRef="USD">154000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808200953079_xbrl_20220510112621448"
      unitRef="USD">193000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953079_xbrl_20220510112732615"
      unitRef="USD">146000</us-gaap:AccruedVacationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808200953081_xbrl_20220510112644305"
      unitRef="USD">1122000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953081_xbrl_20220510112742136"
      unitRef="USD">933000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20220808200953083_xbrl_20220510112657784"
      unitRef="USD">1485000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20220808200953083_xbrl_20220510112751072"
      unitRef="USD">1233000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <entx:EventsDuringPeriodTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230807100531482">

&lt;div&gt;

&lt;div style="margin-right:36pt;line-height:1.25;font-family:'Times New Roman';font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
5 - EVENTS DURING THE PERIOD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;
        &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In April 2023, the
        Company entered into an amendment to its office lease agreement from 2014 to extend the period of the lease agreement for additional five
        years, expiring on June
        30, 2028, with two
        options for early termination by the Company subject to a notice period. The monthly lease fee is a total of $15.&lt;br/&gt;&#160;&lt;br/&gt;As
        of June 30,2023, the Company recorded the related asset and obligation at the present value of lease payments over the expected terms,
        discounted using the lessee&#x2019;s incremental borrowing rate, which was 13.84%.
        The Company lease agreements do not provide a readily determinable implicit rate. Therefore, the Company estimated the incremental borrowing
        rate to discount the lease payments based on information available at lease commencement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As
        of June 30, 2023, the maturity of lease liabilities under our non-cancelable operating leases were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;

&lt;p&gt;&#160;&lt;/p&gt; &lt;/div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        future minimum lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less:
        interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(86)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present
        value of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;  &lt;/div&gt;

&lt;div style="line-height:1.25;clear:both"&gt;&#160;&lt;/div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;
        &lt;div style="text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On December 10, 2018,
        the Company entered into a research collaboration and license agreement with Amgen (the &#x201c;Amgen Agreement&#x201d;) for the use of
        the Company&#x2019;s oral delivery platform in the field of inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement,
        the Company and Amgen had agreed to use the Company&#x2019;s proprietary drug delivery platform to develop oral formulations for one preclinical
        large molecule program that Amgen had selected. Additionally, the Company had granted Amgen an exclusive, worldwide, sublicensable license
        under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable
        products.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div&gt;&#160;&lt;/div&gt;
        &lt;div&gt;
        &lt;div style="line-height:1.25;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On
        May 2, 2023, the Company and Amgen agreed to terminate the Amgen Agreement in accordance with its terms, effective on such date. Neither
        party incurred any termination penalty or fees in connection with the termination of the Amgen Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/div&gt; &lt;/td&gt;
        &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:36pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align:top;font-family:Times New Roman;width:auto"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; </entx:EventsDuringPeriodTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember"
      id="Fxbrl_20230731135831949">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember"
      id="Fxbrl_20230731135844020">June
        30, 2028</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember"
      id="Fxbrl_20230806152330316">two
        options for early termination by the Company</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_20230401to20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember"
      decimals="-3"
      id="Fxbrl_20230731135918668"
      unitRef="USD">15000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_20230630_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember"
      decimals="4"
      id="Fxbrl_20230731143936543"
      unitRef="Percent">0.1384</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230807100517778">

&lt;div&gt;

&lt;div style="line-height:1.25"&gt;

&lt;div style="margin-left:45pt"&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total
        future minimum lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less:
        interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;border-bottom:2px solid rgb(0, 0, 0)"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(86)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width:90%;vertical-align:top;background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present
        value of operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt; &lt;/td&gt;
    &lt;td style="width:10%;vertical-align:top;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)"&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;
        &lt;div style="text-align:right;margin-left:42.55pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095051830"
      unitRef="USD">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095101583"
      unitRef="USD">180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095103582"
      unitRef="USD">180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095105670"
      unitRef="USD">86000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095107790"
      unitRef="USD">542000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095109959"
      unitRef="USD">86000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20230630"
      decimals="-3"
      id="Fxbrl_20230807095112103"
      unitRef="USD">456000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20230101to20230630"
      id="Fxbrl_20230731153001919">

&lt;div&gt;

&lt;div style="margin-right:36pt;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;NOTE
6 - SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;

&lt;div&gt;

&lt;div style="line-height:1.25;font-family:'Times New Roman'"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;
  &lt;tr&gt;
    &lt;td style="font-family:Times New Roman;width:8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width:36pt;vertical-align:top"&gt;&lt;span style="font-family:'Times New Roman'"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align:top;text-align:justify;font-family:Times New Roman;width:auto"&gt;
        &lt;div&gt;In connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in July 2018, the Company issued 1,400,000
        IPO warrants to purchase 700,000
        ordinary shares, and these warrants were listed for trading on Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;) since August
        12, 2018. The IPO warrants were immediately exercisable at an initial exercise price of $8.40
        per ordinary share for a period of five
        years, unless earlier repurchased by the Company as described in the warrant agreement. These IPO warrants expired on
        July 2, 2023, in accordance with their original terms, and Nasdaq removed them from listing.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <entx:ClassOfWarrantOrRightIssued
      contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="Fxbrl_20230731152514160"
      unitRef="shares">1400000</entx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="INF"
      id="Fxbrl_20230731152519079"
      unitRef="shares">700000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      decimals="3"
      id="Fxbrl_20230731152524576"
      unitRef="NIS_per_Share">8.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <entx:ClassOfWarrantOrRightExerciseTerm
      contextRef="C_20180701to20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember"
      id="Fxbrl_20230731152529808">P5Y</entx:ClassOfWarrantOrRightExerciseTerm>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fxbrl_20220808213523162"
          xlink:label="Fxbrl_20220808213523162"
          xlink:type="locator"/>
        <link:footnote id="FN20230430155729802" xlink:label="FN20230430155729802" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount less than one thousand U.S. dollars.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808213523162"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214535386"
          xlink:label="Fxbrl_20220808214535386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214535386"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214614689"
          xlink:label="Fxbrl_20220808214614689"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214614689"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230430155759086"
          xlink:label="Fxbrl_20230430155759086"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230430155759086"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731140510423_xbrl_20220808213523162"
          xlink:label="Fxbrl_20230731140510423_xbrl_20220808213523162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731140510423_xbrl_20220808213523162"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:label="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141710655_xbrl_20220808214535386"
          xlink:label="Fxbrl_20230731141710655_xbrl_20220808214535386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141710655_xbrl_20220808214535386"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141713727_xbrl_20220808214535386"
          xlink:label="Fxbrl_20230731141713727_xbrl_20220808214535386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141713727_xbrl_20220808214535386"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141740672_xbrl_20230430155759086"
          xlink:label="Fxbrl_20230731141740672_xbrl_20230430155759086"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141740672_xbrl_20230430155759086"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141742631_xbrl_20230430155759086"
          xlink:label="Fxbrl_20230731141742631_xbrl_20230430155759086"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141742631_xbrl_20230430155759086"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:label="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:label="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20230731141951647_xbrl_20230731141841214_xbrl_20230731141637538_xbrl_20230731140510423_xbrl_20220808213523162"
          xlink:to="FN20230430155729802"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808213249447"
          xlink:label="Fxbrl_20220808213249447"
          xlink:type="locator"/>
        <link:footnote id="FN20220809041142326" xlink:label="FN20220809041142326" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount less than one thousand US dollars</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808213249447"
          xlink:to="FN20220809041142326"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fxbrl_20220808214617486"
          xlink:label="Fxbrl_20220808214617486"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fxbrl_20220808214617486"
          xlink:to="FN20220809041142326"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>36
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<F'M13CFGL=MZGG:%X3.\+,\&RL84Y,5.^7EUP&;.=;GII^>GS<A75JOLG#
M@H;2UOD3N*XNV)Y7X*/.QWS(/K$U%RJ(EVBJJ$KL/@$G?K5:R 2NJLM)2DYR
M%">/(JU+4\6];R=HFCH3>DB45%JL-+:5%TS^63W(T[IIFK'WYQ$9#+![WB7#
MSK.-L30=#+I%>0W9GWAN])OV;H3#JBX><%G=?BP%!\-F\B-C?KFLIH3COA K
M8Q-R@TN[P;"?Y&-UNM)W36;$KFELG5D/Q%1/.4V(#BY-!\."LL.+J,:[3*3^
M6-K[#LY1(K'C->$WN!0<?)3AW,:*B>SNUUSXZ6Z*M8+"B54S:A..@TO)P;"7
MY)S7$1-+<\%XKQ/4"ARO<&!E?S:A.;CT''R4Z%R_H)F^HY)!>K^=33M62#BM
M^J1L0G!(*3@$]I-BU'I<: 5(GRJ<I!+ $->"QQ,M[.;ZZ5L5]D#ZG?U!0!/J
M0TKU(4>IS]CW=;H\V;U =WH_]!#;.>'(3X'84O4*Y3\?J$^EI"LK?!,^1$H?
M(D?YD!U^MN%6>#CR<Q +^ES 7R9!:)0*O7D](!B_TU?LA9X?;D+.K8(/I]<]
M(*4\$=AW?CP@$[.E1_Z,;V+KP8#C/C*12!JRR(K:A$.1TJ'(44^)"M1'KO4W
M1'\%Z^KS&TX\QY@XCM6EX,JZK*5+D:-<JNS6;"*S,L))MW=6O"9<BI0N16 '
M2D?I6#!:W7-PP'G?WFM-.!0I'8K QG/'4[=?<3T9W2?1W/I(X/) "&EW7=+N
MXZ[UV0E<7)>PM"<"RTYQ'_,EH4*;8KC-[[VMH/7$"2ZKBUB*$X%5IWQ*6WH3
MP%C3F^"ZFI!NZ4WN4=YD'EL!(_5 B./@MCOH=GO6]80F+,DM+<D]RI)F] 7=
M^KHW@T7@96M. "X<Z3AM)_NQ\C8A1FXI1BYL,7JPIM8RW49S'EKI#IC5_>Q/
M*U<3?N/N+8/!0C)E7B*R&QEO1>,EJUP:.A!T/YY>C:WK)W!A7<)2:UQ80F:!
MTB<A7R!,?IG_BG; 5D0XZ4'H(4#%MG#9:=7BZ@1.^EGFSMX*L;FO3A?.)?*,
MM&2+Q<6[Q>+\.%V2[I2[9RO[GZFY+9<H9 M=ZISVM:B(;+$\VU!\G:XWS[E2
M/$I?KACUF3 [Z,\7G*O=AOF"XE\61O\!4$L#!!0    ( '.""U>G2'H9F@8
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MC' G=$WE"O0D0:U82($@CU1/4%8=(:X -,N4$1[0+C0B_))(RE3\*6?45M9
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MP9(E$B!^?XYC_OX@/U">WO?_!5!+ P04    " !S@@M77J3>9G<(  "_/0
M&    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+6;;W.C.!*'OXK*MW4W4[6.
MD008<DFJ,C&07.TD<W%R5UM;]X*QE9A: U[ R=RW/X&)L?X@&9_VS<38K9]:
MW:BE9P07[WGQ>[DBI (_TG567HY65;4YGTS*Q8JD<7F6;TA&?WG)BS2NZ&7Q
M.BDW!8F73:-T/4&6Y4[2.,E&5Q?-=]^*JXM\6ZV3C'PK0+E-T[CX[Q>RSM\O
M1W#T\<5C\KJJZB\F5Q>;^)7,2?6\^5;0J\E>99FD)"N3/ ,%>;D<7</S"/MU
M@\;B7PEY+P\^@WHHW_/\]_KB;GDYLFJ/R)HLJEHBIG_>R U9KVLEZL<?K>AH
MWV?=\/#SAWK8#)X.YGM<DIM\_>]D6:TN1]X(+,E+O%U7C_G[+6D'Y-1ZBWQ=
M-O^"]];6&H'%MJSRM&U,/4B3;/<W_M$&XJ !<GH:H+8!XAI W-, MPTPUP"[
M/0WLMH'--;"]G@9.V\#AQ^#W-'#;!NZQ8YBV#:9-LG;1;5(SBZOXZJ+(WT%1
M6U.U^D.3WZ8US4B2U;?BO"KHKPEM5UW=/-S/@OMY, /TT_SAE[O9]1.]F#_1
M/U^#^Z<Y> C!S>WU?13,P=T]F-]>/P:W#[_,@L?YWT#PS^>[IU_!I^<LWBZ3
MBBP_@S%XGL_ IY\^@Y] DH&G5;XMXVQ97DPJZF[=Z631NO9EYQKJ<>VA6"89
MG1Z@7,4%*<%O7TGZG13_D2C-U$K72^H<O?'C-=C$R7),_5K$FZ2BUPK10".Z
M6&S3[3JFHP9YM2(%N,E36@Y6]3Q](W3PBSPEJ@["XSN@DRM9))5*+5*K/>5T
MN&RS";U7]C<,VM\PJ-&Q>W2^Q.LX6Q 05V!&%F< PY\!LA"4Y5>I5!?9\W(3
M+\CEB(:M),4;&5T!B<Z-VJ/?H/26V#5RFT9U07Z[@I;M.];%Y.TPR:*9#5F3
M4#09>\A&+FL6B68(.:ZSMV+"C??AQD>%^Q.]9W?SX/-1H=^I.H?.>)YEVY ;
MW$S9O3Q'?_T+=*V_RV:,2;'0I%AD2(S)H;W/H=VHX[X:VY;/V?/CW7T$GFX#
M\&MP_0@"6GIGLN39!D<^,RD6F!0+38I%AL28!#O[!#O*27I/MXSKO)2N<8Y0
M%;@*-'.$J<K7**U%*%J,7=_UN0JELV(&[^X'[RH''_P@Q2(I"<A?0+ZIE]D2
M5#G(V=5;%AJE[H#E0>U?S_+@"K& F N[:,*'76L1*;MAXCW=QWMJ(-Z'"X8L
M]E/!+\<1U@:E(T-+ATFQT*189$B,R::WSZ:GS.:\3M&XAJDEH/M%2IAE7.=4
MEC-/6TH\\6YS7;Z:B$;\;:VUB#0=,:'P]Z'PC]U9_F.;T>V-U6QOD"P42J4!
MI4/M44_I\,7!6ZZ+^/(AF@D[2]%D[/G8=[AH2SJ<HKZZ#:T._:Q3]I;:X+>R
M_.;2]VMSYGY4.S"T@AA5"XVJ1:;4V%0>4#P\=NY\C8L]&LC3IY0:,'DT/O7,
MGK85.WT<']K<])'8"?-'8C/V7 3Y<B7KTY_:/6P&.Q:&Q\$P-X/T*4#'XIG:
M@<$SR*1::%0M,J7&IK+C;(C-0AHTR:<SHVJ!4;70J%ID2HW-<\?B4$F"2E9K
MFZIV6*V)BM;T)J'$9(RAQZ_[6C,V!AVN0C6OGHYL:N$A:X?:P[ZU0R18@=HD
M-D+XM2:1NB<V[ATI0Q.HK$,W*#*EA-W4K@PN*";50J-JD2DU-JD=CD,UCP\A
MN%9*66!$,G=]E[_'12/A'M>:1)JNV'AT0 O51#L$X]120\J)VJ>^<B+!6!G)
M2>S$K:AH(V4Y69\*F.O@&1Y'SX-A3H3+/I@[ ;H5%<6D6FA4+3*EQAZP=5R.
MCN-R[IQ'FCZUU) S-K5/?8=LXG\%0&LJ %@@L1./V42;L>_8_I0_9Y/T":>.
M+9]!J&-H=!Q#*X[:Y"D0X;)G!JD=&#J#C*J%1M4B4VIL*@_.J)%9F$,F479F
M5"TPJA8:58M,J;%Y[J =J4_'53#7-E7MM9!X2BX4+JU)*#$9VP[D%WZM&1N#
M#FB1&FCORG+;U"T*%2U ;+,E*4"U(N#ZZ2O8%/EK$:<_@XQ&BQHE'PT6>5G)
M0W?"8:I\45&[WK>HB-CK\&G1,[;>)%)VQ*:C8VND)M?_,QTZ^$,BE]H6%F[L
M$S!=48!,JH5&U2)3:FRV.Z)':J(? G^ME+(@B6CO>QY_[^O/I?4FD:8K-AX=
M#",U#/? 'Y;&XX1S5WF54?O45V5$^H66ARP>_B1VXM95M!E#R[(@XJ,N&GH(
MHYZP=\R-CF-N!?S)4R#"*-VZ0DJMPM;U!%)75!23:J%1M<B4&IO*CN/1T:?@
MA\=(\O29.@;7^-0W@V0'X=,I_V!D(+$39Y#D*-R?NIX ?[(^+:_GT0/<,3<^
MZ2Q<FP)\]%FXVH'!3UH:/0LWJA:94F-3V7$\AF;A#YM$WYE1M<"H6FA4+3*E
MQN:Y@WRL/GQ7P1\6'\;F]UI8/(/GX4]O$DI,QG1!Y^%/:\;&X.#I<#4 _PGP
MI^YQP**B<;UG4<$B)O/P)S$1TJ(UB90=L>GH6!S_J2RN@S\L\JH$_M0^#BY
M1A_Y-JH6F5)CL]VA/E:C_A#XP_KGP+$$[:>(O_?UI]MZDTC3%1N/#H:Q&H:'
MP)]::DB5.>GI;RRRN!3^)';"UE5B(X<_B6$__.&.N?%QS#T4_K#(HCWPIW9@
M<$4Q^B2X4;7(E!J;RIKCV6\Z',1:]'HD35\971_B#,1IOLWHQH>4)5U5Z!=Y
M1NB'W5N6X/EL?@:6^7H=%^69S*7)P:NB*2E>F[> 2UJ^J.CNK;3]M[LWC;_
M\YOFA5SN^VOLG4=T9+)?_(^7DR==%[M7FRE/O2992=U_H=U99U-Z]Q6[MX5W
M%U6^:5Y6_9Y759XV'U<DIDMH;4!_?\GSZN.B[F#_SO;5_P!02P,$%     @
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MEFY>3D\2NE.[<U]HDM"M.MP0'! F#<3W:TJ3'R?R!H<MY,-_ %!+ P04
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MF<!XP VP/C?0OE<?**#Y+>7B7U!+ P04    " !S@@M73W4(_2D$  " "0
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*U62W/B.!"^^U=T>28S%\S#
M!D(R0!5DV)J9JCPJ9'</6WL0=AMK(UL>28;P[[<E&T(VC\U6[06D5O?7ST_R
M>"O5O<X0#3SDHM 3/S.F/.]T=)QASG1;EEC022I5S@QMU;JC2X4L<4:YZ(3=
M[K"3,U[XT[&3W:CI6%9&\ )O%.@JSYG:S5'([<3O^7O!+5]GQ@HZTW')UKA$
M\VMYHVC7.: D/,="<UF PG3BSWKG\[[5=PJ_<=SJHS783%92WMO-]V3B=VU
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M@].SED=5HW.-863EM&4A#2J5VZ[QUP#*!N#Y4DJS,VR!_<]F\!-02P,$%
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MEO3- -4\1%>EH67A(D:@M%QAYB3/!OA>.!=W#[S!?HJ=_@=02P,$%     @
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M,%Y9(QPL+EKC_LNK$>WG#7\H6/FM:T&6S*W]3#?3[*+5(X5 0QH(0>+?'4Q
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M=MRCIBH7V,C0VSPCS&&IC&$BQCR0V+N0ROKU[!E)B)[6\TT]=Y$[^4T#74A
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M#CU884]&)0<B8A)3)LF6\A((5=A3A7GERMR(RB0)*M(HL50L3\B,TW#C((#
MJC8N3B%9:"XS$0$_)?8LG=-B5VR/>-4# /, ")8/VO)9\SW(D"D@)C=8[WO=
M"]\QWROKEFU9A#'DP(!'EH.^!38O0FP%IYIQI@_6Q:#C7(PZUI*IC1-+ ,)0
M)6;71%(-EM\=7G8<OWMUV7F)YRP&XJ G.0"5RAIV?6?4[??)J9JXK[HI YE4
M,T.14)2YKANK/6W'TK3NQA?W>J8]4)DP+ J'&$-1Y- FLIX3]4:+HNK-M=#8
MZ969XF@%:1SP/A9"'S<F03NL@[]02P,$%     @ <X(+5URWD:P  P  _@8
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M@\_YG6ML$VVE>M1K "1/&1=ZZ*P1\X'KZN4:,JHO9 ["O$FERBB:KEJY.E=
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M75.1J@[4JH,R+P^QA41S));-M?D'@;(#S/M42GSIV'.Q_JO%?P!02P,$%
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MKIQ/3=/3#9VUNH"PBUR;RXU@'(NY$<"P/)@#C&-96)[_:3X#=#X6P[P-G,@
MY0Q0CF6YD(GY8'G<G%A?[IG&<1A&$;:BDXG3P01;MRB"'[<:Y@T86![(]'=K
MC>\V7B'[ZP#;TWT5@LT4KT1LIOA: ^)>-V#$L7NWL3S P'8!JQW([\X#->7F
MA"'L*N8->X)Q)(XQ!&K17:-1A*Q.!!_W_F!/21C&L1L!S.T@##$$GD8<P1R
M!PP)0_,>W'D?!9OW5-#\-W'\!U!+ P04    " !S@@M7EXJ[',     3 @
M"P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%
MBD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L
M'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+
M,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO
M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( '.""U>^#JWC
MR0(   D1   /    >&PO=V]R:V)O;VLN>&ULQ9A;;YLP%(#_BL737C8";=.+
MFDH$2&LI!19(I3U-#CB-5; CX[1=?_U,&*K3K4=[L?)D?)'Y?*SC#W/](N33
M2H@G]-K4O)TX&Z6V5Z[;EAO:D/:;V%*N>]9"-D3IJGQTVZVDI&HWE*JF=OW1
M:.PVA''GYGJ8*Y.N61&*EHH)KAN[A@=&7]KW_JZ*GEG+5JQFZM?$V3_7U$$-
MXZQA;[2:.",'M1OQ<B<D>Q-<D3HOI:CKB>/U'0]4*E;^U9QWD 59M?L6158+
MHD$FSGBD)UPSV:K]B/W\1#,^4SVXK^V4F+%:41D116^EV&T9?^RFT:MPC67L
MXS"4?1"OY/^$4:S7K*21*'<-Y:J/HZ1U!\C;#=NV#N*DH1-G&(((KU#,E0X2
MPKR?2H_M5JI?C:M^U4KC&C&45TQW2%SMP>U!AFD2Q4D>1T@_Y>D<1T&A*]-@
M'B1AC Q('X#TCPCYTS<@3P#(DZ- YH4N[N/$@#P%($^/"'D0R3, \NR8D"<&
MY!B '-N%C.(\7."LP&F"TAF:+G.<Q'ENP)T#<.=VX7)\F^ 9#H.D0$$8ILND
MP,DMRG0L0QR;D!< Y(5ER+M@$7^=!OU&WV=ZRX,NG ;=)4!W:9ENF67S+G&+
M8/$#S7"BCQH<S(=\-D_O$71\C^QBQ@^:,$?1<M%M<'$7HRQ>X#0R^4"]6/9+
MOISF\?>EAD0]J@D&*<6S[!0P10Y.0@^2BF?9*I\E"?JBOW@ZDG=,2"N>9:^
MV7(834@LGF6S?)8M_X@FI!;O.&Y!7R*J"*M-3$@RWC$M<^!I#]*,=R3/_ FG
MB0GYQK,M' CS((5\2#B^9>' F6YNN@]YQ[?LG<\S_>.F^^#%QK*%0,S#38<L
MY-NVT$>+#T<1*NBKVIF8D(7\O87<X>I=T37CM$KT*UK=7I*ZS"3JBO[KX/2L
M2\CUKJY#W9;RN2#5<),?_D+<_ 902P,$%     @ <X(+5Z_LDZ4X 0  'P\
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M?M"!!1WB!T'*94P%)"VP%J U<*Y!@-? P08!8@,G&P28#1QM$* V<+9!@-O
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !S@@M7;:/$HNX    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !S@@M7
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( '.""U<C,60/$@8  +X@   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !S@@M7
MITAZ&9H&  "V&P  &               @(%5#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ <X(+5\ME5!RJ @  .@<  !@
M     ("!)14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M '.""U?A*GN[8 4  ,D7   8              " @048  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !S@@M77J3>9G<(  "_/0  &
M            @(&;'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ <X(+5RHL!/ /"   3BX  !@              ("!2"8  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( '.""U?;2C<X^@8  #T/
M   8              " @8TN  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !S@@M7:20A=?(&  !7$0  &               @(&]-0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ <X(+5T]U"/TI
M!   @ D  !@              ("!Y3P  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( '.""U>_64!<WP(  '@&   9              "
M@41!  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ <X(+
M5T_.8I8,!0  T0H  !D              ("!6D0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !S@@M72['V$EP#   :!P  &0
M        @(&=20  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( '.""U<P8I^?$@<  'P2   9              " @3!-  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ <X(+5QZ(>D?! @  N 4
M !D              ("!>50  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !S@@M77+>1K  #  #^!@  &0              @(%Q5P
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( '.""U<^ H'%
MDP(  &\%   9              " @:A:  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ <X(+5T7)M>ZR @  G@@  !D
M ("!<ET  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !S
M@@M7TM%S-]L"   :"   &0              @(%;8   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( '.""U>Q6%WE<P<  ,@Y   9
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M970R,RYX;6Q02P$"% ,4    " !S@@M7XKA^5[8"  "R!@  &0
M    @($U>   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M '.""U=[GM@)5@,  %H4   -              "  2)[  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ <X(+5Y>*NQS     $P(   L              ( !
MHWX  %]R96QS+RYR96QS4$L! A0#%     @ <X(+5[X.K>/) @  "1$   \
M             ( !C'\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( '."
M"U>O[).E. $  !\/   :              "  8*"  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '.""U?^WU#H;P$  !80   3
M          "  ?*#  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     @ "
*EP@  )*%      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>68</ContextCount>
  <ElementCount>147</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>15</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/GENERAL</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - EVENTS DURING THE PERIOD</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD</Role>
      <ShortName>EVENTS DURING THE PERIOD</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - EVENTS DURING THE PERIOD (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables</Role>
      <ShortName>EVENTS DURING THE PERIOD (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - DESCRIPTION OF BUSINESS (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/GENERALDetailTextuals</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/GENERAL</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - SHARE-BASED COMPENSATION (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals</Role>
      <ShortName>SHARE-BASED COMPENSATION (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - EVENTS DURING THE PERIOD (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails</Role>
      <ShortName>EVENTS DURING THE PERIOD (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - EVENTS DURING THE PERIOD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails</Role>
      <ShortName>EVENTS DURING THE PERIOD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2330106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.enterabio.com/role/SUBSEQUENTEVENT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="zk2330106.htm">zk2330106.htm</File>
    <File>entx-20230630.xsd</File>
    <File>entx-20230630_cal.xml</File>
    <File>entx-20230630_def.xml</File>
    <File>entx-20230630_lab.xml</File>
    <File>entx-20230630_pre.xml</File>
    <File>exhibit_31-1.htm</File>
    <File>exhibit_31-2.htm</File>
    <File>exhibit_32-1.htm</File>
    <File>exhibit_32-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="350">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>41
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2330106.htm": {
   "axisCustom": 0,
   "axisStandard": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 350,
    "http://xbrl.sec.gov/dei/2023": 31
   },
   "contextCount": 68,
   "dts": {
    "calculationLink": {
     "local": [
      "entx-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "entx-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2330106.htm"
     ]
    },
    "labelLink": {
     "local": [
      "entx-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "entx-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "entx-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 264,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 16,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 21
   },
   "keyCustom": 7,
   "keyStandard": 140,
   "memberCustom": 4,
   "memberStandard": 11,
   "nsprefix": "entx",
   "nsuri": "http://www.enterabio.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.enterabio.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:SupplementaryFinancialStatementInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:SupplementaryFinancialStatementInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:EventsDuringPeriodTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - EVENTS DURING THE PERIOD",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD",
     "shortName": "EVENTS DURING THE PERIOD",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "entx:EventsDuringPeriodTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.enterabio.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "13",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "14",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Table)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "entx:EventsDuringPeriodTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - EVENTS DURING THE PERIOD (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables",
     "shortName": "EVENTS DURING THE PERIOD (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "entx:EventsDuringPeriodTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "NIS_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - DESCRIPTION OF BUSINESS (Detail Textuals)",
     "menuCat": "Details",
     "order": "17",
     "role": "http://www.enterabio.com/role/GENERALDetailTextuals",
     "shortName": "DESCRIPTION OF BUSINESS (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230401to20230630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)",
     "menuCat": "Details",
     "order": "18",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230401to20230630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - SHARE-BASED COMPENSATION (Detail Textuals)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
     "shortName": "SHARE-BASED COMPENSATION (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230102_srtTitleOfIndividualAxis_entxSixNonExecutiveBoardMembersMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "entx:SupplementaryFinancialStatementInformationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "entx:EventsDuringPeriodTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0022 - Disclosure - EVENTS DURING THE PERIOD (Detail Textuals)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails",
     "shortName": "EVENTS DURING THE PERIOD (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "entx:EventsDuringPeriodTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230430_usgaapLeaseContractualTermAxis_entxOfficeLeaseAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "entx:EventsDuringPeriodTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - EVENTS DURING THE PERIOD (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails",
     "shortName": "EVENTS DURING THE PERIOD (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "entx:EventsDuringPeriodTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "entx:ClassOfWarrantOrRightIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative",
     "shortName": "SUBSEQUENT EVENTS (Detail Textuals)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20180731_usgaapClassOfWarrantOrRightAxis_usgaapWarrantMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "entx:ClassOfWarrantOrRightIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "NIS_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230630",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230401to20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230401to20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230401to20230630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.enterabio.com/role/GENERAL",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.enterabio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2330106.htm",
      "contextRef": "C_20230101to20230630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 15,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r409",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.enterabio.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "entx_AdditionalAmountPaidForServicesToBeRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional amount paid for services to be recognized.",
        "label": "Additional Amount Paid For Services To Be Recognized",
        "verboseLabel": "Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services"
       }
      }
     },
     "localname": "AdditionalAmountPaidForServicesToBeRecognized",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents one of the related party.",
        "label": "Amgen Inc [Member]",
        "verboseLabel": "Amgen Inc [Member]"
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ClassOfWarrantOrRightExerciseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise period of warrants or rights.",
        "label": "Class Of Warrant Or Right, Exercise Term",
        "verboseLabel": "Term of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExerciseTerm",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "entx_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights issued.",
        "label": "Class Of Warrant Or Right, Issued",
        "verboseLabel": "Number of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_EmployeeSeveranceBenefitsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for employee severance benefits.",
        "label": "Employee Severance Benefits Policy [Policy Text Block]",
        "verboseLabel": "Employee severance benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceBenefitsPolicyPolicyTextBlock",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_EventsDuringPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events During Period [Abstract]"
       }
      }
     },
     "localname": "EventsDuringPeriodAbstract",
     "nsuri": "http://www.enterabio.com/20230630",
     "xbrltype": "stringItemType"
    },
    "entx_EventsDuringPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Events During Period [Line Items]"
       }
      }
     },
     "localname": "EventsDuringPeriodLineItems",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_EventsDuringPeriodTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the disclosure of events during the period.",
        "label": "Events During Period [Table]"
       }
      }
     },
     "localname": "EventsDuringPeriodTable",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_EventsDuringPeriodTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the entire disclosure for events during the period.",
        "label": "Events During Period [Text Block]",
        "terseLabel": "EVENTS DURING THE PERIOD"
       }
      }
     },
     "localname": "EventsDuringPeriodTextBlock",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIOD"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_ExecutiveOfficerAndServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about executive officer and service provider.",
        "label": "Executive Officer And Service Provider [Member]",
        "terseLabel": "Executive Officer and Service Provider [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerAndServiceProviderMember",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercise.",
        "label": "Exercise Of Warrants Shares",
        "terseLabel": "Exercise of warrants to ordinary shares (in shares)"
       }
      }
     },
     "localname": "ExerciseOfWarrantsShares",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_ExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercise of warrants.",
        "label": "Exercise Of Warrants Value",
        "terseLabel": "Exercise of warrants to ordinary shares"
       }
      }
     },
     "localname": "ExerciseOfWarrantsValue",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_FinanceExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of finance expenses, net.",
        "label": "Finance Expenses, Net",
        "terseLabel": "Finance income, net"
       }
      }
     },
     "localname": "FinanceExpensesNet",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_GeneralLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "General [Line Items]"
       }
      }
     },
     "localname": "GeneralLineItems",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_GeneralTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about general information of the entity.",
        "label": "General [Table]"
       }
      }
     },
     "localname": "GeneralTable",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of issuance of ordinary shares and warrants due to a private placement net of issuance costs.",
        "label": "Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs",
        "verboseLabel": "Issuance of ordinary shares and warrants due to a private placement net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCosts",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares and warrants issued due to a private placement net of issuance costs.",
        "label": "Issuance Of Ordinary Shares And Warrants Due To Private Placement Net Of Issuance Costs Shares",
        "terseLabel": "Issuance of ordinary shares and warrants due to a private placement net of issuance costs (in shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesAndWarrantsDueToPrivatePlacementNetOfIssuanceCostsShares",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "entx_NonExecutiveDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-executive director.",
        "label": "Non Executive Director [Member]",
        "terseLabel": "Non-executive director [Member]",
        "verboseLabel": "Non-executive board members [Member]"
       }
      }
     },
     "localname": "NonExecutiveDirectorMember",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of non-refundable and non-creditable initial technology access fee payment.",
        "label": "Non Refundable And Non Creditable Initial Technology Access Fee Payment",
        "terseLabel": "Non-refundable and non-creditable initial technology access fee payment",
        "verboseLabel": "Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services"
       }
      }
     },
     "localname": "NonRefundableAndNonCreditableInitialTechnologyAccessFeePayment",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_OfficeLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represents about office lease agreement.",
        "label": "Office Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeLeaseAgreementMember",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_ProceedsFromOptionsAndWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from exercise of options and warrants into shares.",
        "label": "Proceeds From Options And Warrant Exercises",
        "terseLabel": "Exercise of options and warrants into shares"
       }
      }
     },
     "localname": "ProceedsFromOptionsAndWarrantExercises",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation In Amounts On Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Reconciliation in amounts on consolidated balance sheets:"
       }
      }
     },
     "localname": "ReconciliationInAmountsOnConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right of use assets obtained in exchange for new operating lease liabilities.",
        "label": "Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_RightToUseIntellectualProperty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of right to use the intellectual property.",
        "label": "Right To Use Intellectual Property",
        "verboseLabel": "Right to use intellectual property"
       }
      }
     },
     "localname": "RightToUseIntellectualProperty",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_SeveranceExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents severance expenses.",
        "label": "Severance Expenses",
        "verboseLabel": "Severance expenses"
       }
      }
     },
     "localname": "SeveranceExpenses",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "entx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table may contain information related to significant accounting policies.",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "entx_SixNonExecutiveBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about six non-executive board members.",
        "label": "Six Non Executive Board Members [Member]",
        "terseLabel": "Six non-executive board members [Member]"
       }
      }
     },
     "localname": "SixNonExecutiveBoardMembersMember",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "entx_SupplementaryFinancialStatementInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplementary Financial Statement Information [Abstract]"
       }
      }
     },
     "localname": "SupplementaryFinancialStatementInformationAbstract",
     "nsuri": "http://www.enterabio.com/20230630",
     "xbrltype": "stringItemType"
    },
    "entx_SupplementaryFinancialStatementInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplementary financial statement information.",
        "label": "Supplementary Financial Statement Information [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "localname": "SupplementaryFinancialStatementInformationTextBlock",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "entx_VestedRestrictedShareUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares vested restricted share units.",
        "label": "Vested Restricted Share Units Shares",
        "terseLabel": "Vested restricted share units (in shares)"
       }
      }
     },
     "localname": "VestedRestrictedShareUnitsShares",
     "nsuri": "http://www.enterabio.com/20230630",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r179",
      "r275",
      "r306",
      "r320",
      "r321",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r388",
      "r389",
      "r391",
      "r395",
      "r437",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r179",
      "r275",
      "r306",
      "r320",
      "r321",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r388",
      "r389",
      "r391",
      "r395",
      "r437",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r177",
      "r179",
      "r210",
      "r211",
      "r212",
      "r274",
      "r275",
      "r306",
      "r320",
      "r321",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r388",
      "r389",
      "r391",
      "r395",
      "r398",
      "r434",
      "r437",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r177",
      "r179",
      "r210",
      "r211",
      "r212",
      "r274",
      "r275",
      "r306",
      "r320",
      "r321",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r388",
      "r389",
      "r391",
      "r395",
      "r398",
      "r434",
      "r437",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r430",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable - other:",
        "verboseLabel": "Accrued expenses and other payables:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r394"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpenseIncludingAssetRetirementObligations": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion expense, which includes, but is not limited to, accretion expense from asset retirement obligations, environmental remediation obligations, and other contingencies."
       }
      }
     },
     "localname": "AccretionExpenseIncludingAssetRetirementObligations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employees and employees related",
        "terseLabel": "Employees and employees related"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other payables",
        "totalLabel": "Accrued expenses and other payables, total",
        "verboseLabel": "Accrued expenses and other payables"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r16",
      "r31"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r57",
      "r97",
      "r297",
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r3",
      "r8",
      "r21",
      "r245",
      "r248",
      "r268",
      "r307",
      "r308",
      "r420",
      "r421",
      "r422",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "verboseLabel": "Accumulated other Comprehensive income [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r318",
      "r427",
      "r428",
      "r429",
      "r466",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional paid-in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "terseLabel": "Vested restricted share units"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r36",
      "r37",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Number of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r96",
      "r112",
      "r137",
      "r143",
      "r147",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r240",
      "r242",
      "r253",
      "r293",
      "r343",
      "r394",
      "r405",
      "r435",
      "r436",
      "r473"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r93",
      "r100",
      "r112",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r240",
      "r242",
      "r253",
      "r394",
      "r435",
      "r436",
      "r473"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r112",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r240",
      "r242",
      "r253",
      "r435",
      "r436",
      "r473"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation of the financial statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22",
      "r95",
      "r381"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r23",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r22",
      "r66",
      "r110"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT END OF THE PERIOD",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS AT BEGINNING OF THE PERIOD",
        "totalLabel": "Total cash and cash equivalents and restricted deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r2",
      "r66"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of ordinary shares will be purchased by exercising warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r43",
      "r294",
      "r329"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "verboseLabel": "Legal and other contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r427",
      "r428",
      "r466",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary share, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r51",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r51",
      "r330",
      "r349",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r51",
      "r296",
      "r394"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Ordinary Shares, NIS 0.0000769 par value: Authorized - as of June 30, 2023 and December 31, 2022, 140,010,000 shares; issued and outstanding - as of June 30, 2023 and December 31, 2022, 28,813,952 and 28,809,922 shares, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Value of shares issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r61",
      "r112",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r253",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "COST OF REVENUES"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r6",
      "r74",
      "r89",
      "r238",
      "r239",
      "r426"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedLabel": "Total deferred income tax",
        "terseLabel": "Deferred income taxes",
        "verboseLabel": "Total deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r77",
      "r174",
      "r175",
      "r176",
      "r342",
      "r390",
      "r482"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r6",
      "r29"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r39",
      "r40",
      "r41",
      "r42",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "verboseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r180",
      "r184",
      "r214",
      "r215",
      "r216",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r108",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r127",
      "r129",
      "r131",
      "r132",
      "r133",
      "r135",
      "r251",
      "r252",
      "r290",
      "r304",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "LOSS PER SHARE BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r108",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r129",
      "r131",
      "r132",
      "r133",
      "r135",
      "r251",
      "r252",
      "r290",
      "r304",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "LOSS PER SHARE DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r24",
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r9",
      "r91",
      "r104",
      "r105",
      "r106",
      "r114",
      "r115",
      "r116",
      "r118",
      "r124",
      "r126",
      "r136",
      "r155",
      "r156",
      "r173",
      "r217",
      "r218",
      "r219",
      "r235",
      "r236",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r307",
      "r308",
      "r309",
      "r318",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "verboseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Functional currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62",
      "r353"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r60",
      "r112",
      "r137",
      "r142",
      "r146",
      "r148",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r253",
      "r387",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS PROFIT"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "verboseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r424",
      "r432"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 60.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r0",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r1",
      "r58",
      "r80",
      "r137",
      "r142",
      "r146",
      "r148",
      "r291",
      "r302",
      "r387"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedLabel": "Loss (income) before income taxes",
        "negatedTerseLabel": "Loss before income taxes",
        "negatedTotalLabel": "LOSS BEFORE INCOME TAX",
        "positiveLabel": "Net loss for the year",
        "positiveVerboseLabel": "Loss before income taxes",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "LOSS BEFORE INCOME TAX",
        "verboseLabel": "Loss (income) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r90",
      "r125",
      "r126",
      "r140",
      "r230",
      "r237",
      "r305"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "positiveTerseLabel": "Actual income tax (benefit) expense",
        "terseLabel": "INCOME TAX BENEFIT",
        "totalLabel": "Actual income tax (benefit) expense",
        "verboseLabel": "Total tax on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r234",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Increase (decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "verboseLabel": "Increase (decrease)\u00a0in accrued expenses and other payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r276",
      "r423"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Decrease in contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating asset and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r418",
      "r423"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 80.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Increase in other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "CHANGES DURING THE YEAR ENDED"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Agreement expiration date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Lessee\u2019s incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of maturity of lease liabilities under our non-cancelable operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "verboseLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest",
        "verboseLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Agreement termination description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r112",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r241",
      "r242",
      "r243",
      "r253",
      "r328",
      "r386",
      "r405",
      "r435",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r56",
      "r79",
      "r299",
      "r394",
      "r425",
      "r431",
      "r467"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r94",
      "r112",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r241",
      "r242",
      "r243",
      "r253",
      "r394",
      "r435",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r46",
      "r47",
      "r48",
      "r49",
      "r112",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r241",
      "r242",
      "r243",
      "r253",
      "r435",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r59",
      "r68",
      "r81",
      "r92",
      "r101",
      "r102",
      "r106",
      "r112",
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r130",
      "r137",
      "r142",
      "r146",
      "r148",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r252",
      "r253",
      "r303",
      "r351",
      "r366",
      "r367",
      "r387",
      "r404",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 90.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTotalLabel": "NET LOSS",
        "positiveLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss) Attributable to Parent, Total"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Newly issued and recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "FINANCIAL INCOME, NET",
        "negatedTerseLabel": "FINANCIAL INCOME, NET",
        "terseLabel": "FINANCE EXPENSES (INCOME), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "TOTAL OPERATING EXPENSES",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r137",
      "r142",
      "r146",
      "r148",
      "r387"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "OPERATING LOSS",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Monthly lease fee"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/EVENTSDURINGTHEPERIODDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current lease liabilities",
        "verboseLabel": "Current maturities of operating lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r45",
      "r75",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS",
        "verboseLabel": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERAL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r99",
      "r394"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonrecurringIncome": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 20.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other income that is infrequent in occurrence or unusual in nature.",
        "label": "Other Nonrecurring Income",
        "negatedLabel": "Other income",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonrecurringIncome",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "auth_ref": [
      "r438",
      "r439"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).",
        "label": "Postemployment Benefits Liability, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets, total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Prepaid expenses and other current assets:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r98",
      "r157",
      "r158",
      "r382"
     ],
     "calculation": {
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of shares under the ATM program, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r292",
      "r301",
      "r394"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r85",
      "r88",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r178",
      "r269",
      "r270",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r348",
      "r350",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r178",
      "r269",
      "r270",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r348",
      "r350",
      "r371",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r44",
      "r225",
      "r481"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r22",
      "r76",
      "r95",
      "r110",
      "r295"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted deposits included in other current assets"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r53",
      "r72",
      "r298",
      "r310",
      "r312",
      "r317",
      "r331",
      "r394"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r91",
      "r114",
      "r115",
      "r116",
      "r118",
      "r124",
      "r126",
      "r155",
      "r156",
      "r217",
      "r218",
      "r219",
      "r235",
      "r236",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r307",
      "r309",
      "r318",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Accumulated Deficit [Member]",
        "verboseLabel": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r352",
      "r380",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r107",
      "r112",
      "r138",
      "r139",
      "r141",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r154",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r253",
      "r291",
      "r435"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "positiveLabel": "REVENUES",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUPPLEMENTARYFINANCIALSTATEMENTINFORMATIONTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of of share-based compensation on statements of operations"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r181",
      "r183",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r11",
      "r12",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Severance payment expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 70.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vestion period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Description of terms of share-based payment arrangement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r181",
      "r183",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals",
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Number of options to purchase ordinary shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of outstanding and exercisable options of ordinary shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "verboseLabel": "Exercise price of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vest on first anniversary of date of grant [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vest in twelve equal quarterly installments following the first anniversary of the applicable grant date [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r180",
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r220",
      "r221",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life - in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options at the date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r9",
      "r19",
      "r91",
      "r104",
      "r105",
      "r106",
      "r114",
      "r115",
      "r116",
      "r118",
      "r124",
      "r126",
      "r136",
      "r155",
      "r156",
      "r173",
      "r217",
      "r218",
      "r219",
      "r235",
      "r236",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r307",
      "r308",
      "r309",
      "r318",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.enterabio.com/role/GENERALDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r136",
      "r277",
      "r315",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r136",
      "r277",
      "r315",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r368",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "verboseLabel": "Issuance of shares under the ATM program, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r50",
      "r51",
      "r72",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of options to ordinary shares (in shares)",
        "verboseLabel": "Number of options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "verboseLabel": "Issuance of shares under the ATM program, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r19",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of options to ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r70",
      "r332",
      "r349",
      "r369",
      "r370",
      "r394",
      "r405",
      "r425",
      "r431",
      "r467",
      "r484"
     ],
     "calculation": {
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [
      "r261",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r261",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r261",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r261",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r261",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r83",
      "r84",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates in the preparation of financial statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/SHAREBASEDCOMPENSATIONDetailTextuals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r396",
      "r397",
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/GENERALDetailTextuals",
      "http://www.enterabio.com/role/SUBSEQUENTEVENTSNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r128",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r127",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.enterabio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org//830/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r409": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r411": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r412": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r413": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r414": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r415": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r416": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481879/410-20-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org//1943274/2147481179/712-10-25-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org//1943274/2147481179/712-10-25-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483613/220-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org//810/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>42
<FILENAME>0001178913-23-002834-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-002834-xbrl.zip
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ME=17,EZR7^HU?UD<% E[;(23RBM/\1/?HPXEHL)4OR/5F^>JYI1O_9 (/L7
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M.UI^HY_66]LD!/:_7BIZ"\2>2C7>;J8DM-[?N^*D&3V^AF/02N?MPDI"ZZ^
M??N7VEKO3$[P9"I#8_VN@&/XA:;:)5I^?_2\J!LG%5"/-#[EH28X4/;,V)8+
M)/QU#" ],.8" =>+B*DW_O)0E <7.$AP:4 [J,Z]6G^3\:?_ 5!+ P04
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MP^F%HX2:B=C#$C43T8@E:IKBDW@%#;%S@:,(8PA,C4 B+R#)U'T6WD93J@<
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M\JW40F%W%2_=A/C5GI,G23Z29QOA0%5/9'$25'5%*"= 55?<TA'-\2ZE=0M
MNN>X9IBD>XY]ADFZU_@(MU .&GUPMWCNJ"T]J2P@TFM<9))(K[&/22*]QC?8
MN/ >;@:@ Q>9N-D'3;E_!D.GUVC%/!U=$8GP+@//R)P-I/78F^L"4%WQ1.]
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MP^TE 0E-/D:YZ>95_?:B9C]HRJ5EG88F/V6;AAY?5CF4)'U68K\< -#CJ8X
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M,;M:!N3@:9Q:E]%0 S"W=!F#P-S2GPP!<]MD&]TP5^Y W>#][( D-?-/67%
MV](':4-;.S>45P#$+9W2D8CQL31<AU;2;K4P(&WIG30A5=3L;G% V])5=4+;
MJIO5]K"6?LLBTI9.K!/2S^Y;L-JLI !WR@ N$_ZK"RX3/NIS$#7CJI8!7";\
M4 =<;9-#=,*5I0V:T.R*D&0D%!4%E"9\3)[<J+S*)!\(:\L#7A,>YA%/ATI4
M6?P>\)CP(ZP]J>U52@ F$]X"<U(%?N!2</]2:(<% :$)+W$<0A/>X3B$)OS$
M-$CQXO\X\H.7P-^XH:17",L"3A-^XZ!M?*Z'I2O _ 3+8#V-6:RZE8X[+:4
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M@'5A/.J(5R1) ^\*,]S3;>.97F%YP&T\>M"#VW@&RFL8#./,'!Y<RC*<94]
ML'>,%&([-0G S704LO_0%#Z?X$F8",L#;M.QAR[<IB..?1S7^":8]'I)30W
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MV[V[(HUC24M)P-5T%'8;4Q(L(M6)N:@XH#8=)^E!;3J2R6&P*3]TX\K+QS!
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MQM$\IBNVYU4>.5-8]6@I";B:CBT>20@QM/\ .+>-W>JP," V'3-404PAZ$Q
M<7A<\"V0!0N26L#!=)10@Z;5!SBH!SQ,QPDU>/*\0#@SJ/PX^35(E]4J[9FJ
M2I[]8CP3X9!U83HV&;(N3$<R-8A59CA-58&-Z1BF!I+*18NFJL#&=/12!^ER
M6_U--]<B$ (,3<<R=>#:'=)O(04XVHQA3'$T'_4DQ*7>$H+D:_)"PIB%R<U+
M/])ZP,-\Y-,/#_.1CP1/XZ:00NW9+\9S09K@9#X2D:#BRQQ=.?':P,E\1-$_
M)_-Q!00!@0<#,+ZK@8O4\ <N![RX8<-AQJ:JP,9\7-$G&_,QQ!XDM4.FLFK
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M,OY W<DJZF1F;9S PX9Z2_S5;4Q'?4T0:II"=9W,C&L8ZAK<_E)M)E7VGRE
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MHL&BFF@('\\EK\[5S<1*),SP5A()W>#V54"2VL6XG61->>D>UZG: I>L4=5
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M]LJA]6<8LWF3\B<X<\:]3;2ZZ3\CH*1[BY/$?=B339JDX*; -[50?J76<+Y
ME8K29XC[9:&^<54RD9QCV/D0K%S>"<Z<&T;"N71#S-]C>\]IGXXPQ)71N22+
M((IZ9M2BJT@.+-33&$+'X,!%NS2[S]3@F;CQD_/^N_?POY]_^J7TT7^N.#OG
MG>.RU:!_WT3$^?#^S+EX?_&!!;G7Q.-/#WXX9S^].'/.?WA_]OX<_O_^?=;C
M_BD;^'A87':^=G(O/IY]//]P]LN/%ZP$_O/]+V>_7%P4_1K^LR9XLX"$O61;
M5MO<V/\*/[3M!5/+J6D.&/PH8% \8)<%WX-P;0Q4.\^6Z7Y@CNV B-2O=>G*
M^QWL7-CMWK?ISG^N$WTFELV[\ ]G/YSSQJ'@^Q]_-MJCV]A6C/-XV9KYKEVQ
MX@-8 J]A(+PDR#%35N)PA=O2!RAN0][PA%?\"A( Q0N>D_FG./;+IR2>XK!V
M,E$(<C))9TXAB]\6!<HH;N>Q"91H]_NU5T!-X&7U=C&_+48H;N6O<7E-OAK%
MRCI%X2$D?ZAC4*=MQH 88="L_,KK56HKMY4*@UVIE9 2)PX+(B]8AX0-;EZU
MNJ6/PC9H\-V(JTV2QJLR^5_-N=2LAO,*59R\SEF11<_&&R-J;,1])&,3]IM$
M\ZCO\(C/F6](=K^^?K6PX</@P2XFR"DE#?5C'5(6OWP%_2B-8>*VYAD:+'T[
M=($9XII/PQU[5L9B=%]%*M[]>YKB4=G'FZ\W]U]L;?@ARB<WE+["E.N4E1O"
M=M$^:/%PPT%3_@GLF"N_/G=+?$+=D&VD0.AV%WMN.'7?LO@N2[$L/P:0/;V0
M23KC>T8L<&72SC!#9![G.G_,1/YI&/DJ.FE!^$FY("O7"[.V>8J- ]C2CY9E
M'1%^(?N?I8Y1_9,HV:70/-=CVD]NTJ8/<DUXAB[LYTF65@>]UP,EF)&K>&&!
M7655/822"V7S0[Q*7LJ%J)A+KKYVE-W=WSF=PIZC&$)&R*,UU/2NT9H+$J6F
MSFW$U9\9XA>N@H@L<%]:50E*HX_X"; XR;D]9]GP6<(IL'L\^[>.\;?L!TOB
M;(D+<2#^ZW49>$O'SPT*2N.900(F@NESJ&]G];2=.H1'Z7-&+7V1Q9&N'6G1
M_L\_K@U(PY*NMC",N*2;'F1]PDIDDC=>./(L>P-I^&:5L*1(F$'L9827T) .
M0V44HCG&[^9GV@2(/)SR#YD,PHS:^ +3(6XWBU(8Z/LWJVYC5!V'^IN9 S.K
MHD-_HN!+Y2-3=4ABQ:WM[M>@%UX4(>F.I\]"7X@7(!(@;&N6[T:Y^?M;@_@<
MX^B!QAY)\$HFQ"T>7L:\)B\DC-DVAOJ'"B(GD^3DHK)]X$+8 /J1,N^:! @E
M+[]?7JT_9*._WW/T.('[6ACEJ$^C;#5:-WK^FHXVG#$"@8M\BT'@7:QG,B_,
MH; &M>A?S;*&%?0K,Y?&/>57M!KZ%V2*#+\X865YF,#YO+K4;^%QR\3'*,39
MD3*D#R?A6C=LE!F)6=)B#RLY6:UA?+_:-QC$G\KR:PLU^(6GUVP]DW: $?Z2
M_RP+IJMG92 ,R&+K1)RD'5=3U;\0_KWX17$.:>=T$@83>9.[N?!WBF&[0_K4
M.M1H[8F$;G/[@ONANQ"O'&,P_*[WT'^7S+13L"5@)/HXAF8QRE<J5'@(S_/#
M^(]NX'D0-RE46 @/]T/GZ)E%Z]%5 %UT(EXX6 YZ.B(@)CHH;ZB'=!VU!2Q^
MLC=RJ1M9$)'<H3P 4D[F-J;XC]S1*&6%9OLR6*OB<S/Y^4_8KVT:7DNRHH'Z
M=A/Y":[)9$?JV4L*V<O<^8GOS3K&WZ<!)?96,=:4>(%;^T!0M8#5?E3!*9X1
M]HNS69$T>&%O1"AE:J@4'^AI7PDAL?Z+XE;4'R3N8D$Q F//HV3G_NZ@)X]3
MLJJ9?>]4JAQ:=/Z*%1U6T\KY\1HZ[&A+6RJLDBT6V9&6R7SWF2WV?BT[%E.^
M\)8]/"9_JZ/AI3++67B4"5]6"<M'BD;&@SCI="1QX3STWT:/-^\N1T\WF)CG
M\\/-_9.U1V^OXQ5)TL"[PJS_="LYJIN7Y'$UOP>8;H=PG4;,0:3Y<4)=$@9L
M<97B<1*;5VFN8=B+,SMZ@+D<YH_+'L5@ST#)(DZHR]^@X^]E9]5ML-A_K@L?
M@_"$F$6/D['2?#,/7^^R>.==S$.8F&GR](09J!W6CQWHQ^.K(6@^TZ"R[GO4
MN&+'K6.@H/7K\=V7Z8V5%.#[J%6B8I'^!QD<-Y$3?AK<\;#ZAA[/SPPA>G&8
M!;,VYP]8\KG3J'I-8)/&=+M36/S9<KG58T@L\?6N;/823";>*>3O5V(IMKV^
MWHQ2&N0TZ$D8T124"\^*KU%& ,IU+H/8N4O][VQ:M0;>HL7><7$ BI&V8OK9
MTDM^:UNX)8)+<EXQX\IOX_$$Z"R$E4\G&U]1SK9I_.P1D\K-ANS=<]O33KQI
MG6Y1)7$$B"79MWE)IRAJ->GVS1M,^?+<"1 5?HDVR<8-F1ZEL\FL(.8 '$=S
M?&&771?">F?XP\LX75J>4MZZ 67923X3%^=7:$GJ#ZMA[2RO8:7^0)VJ.E7A
M@BM29?E7G%59W\HG"Z(@)7<PCOKC* 6,P7-(^!KRY?:S^[>8LCS9M=GY>?UW
M3(!32LCO.CUO'2;$X4G#[67LE_ L6=Z[*R(91^1<SW:8HBBKX\QM3$FPB)H7
M ;*"PUL#$#(0]:8OWSU]-XSY?PZ93?-A$*@\]0Q#/?MGR'RVTKI[_F5R<4Y5
M'O/+58D#'2<[:Z1FHXK5+>Z5>E8R/WTB$4:50&#DKV!00)>+H6@6,PD_9E:'
MO]Z]4RL/M:Q-(9KHB+Y$E8Z[2R>_X&G1ZIH8B0+_>D8#-#')>-YL:/:3,JBQ
M:V=W5KY2# 89-22L*@L-P:L>0!9JN80,DWZ^Q&[5L;*;- \TKKL<QW[O\ +6
MSO9700JU^L@6/!\GM^.I#26.5VN8=^!7G=#K(%G'B1M.YG=QM& A+0]C50*3
M4A!./'-1:"HH+ N0\ZAXD&%))U4(MY\JJI@[(=(/&7WKN0SX0A8NY-[2>,7?
MJM@$T2(["0\1UR6[;%8LB9%D9VV"K2S@GA6F@XI#:&8QQM4_4G.BF2T9_Y'?
M'_Q3?I'-T'U;I6.L?2JD=@W=L!Y4AJD^]2!,AX"CWN7-[>017U2\FGR^<::C
M_^KE%"T^&@J]SZ8&1$=O\38)NT-23?K0IP*^*HZ"/>I!=([72(]0=88]<A<=
M]<WV%?Z(+?[)F4.;3MFH4[::ZZ?<:&+9FW<:<O*6K 7P?6I/=,08U^XI6<+D
M .<QH<U;WGU2_]GJ\*D:._6H@(]#"RST6$3Q O%#3/G&9$J#YTV*IQVG<9L@
M"XT!3($]F?Z7F]'C,(?.3GR%X;7BJ%E<)09SJSYMG;7O5 '@*2N3XZE%$ZH-
MQWHSH6/F*$^;YR3P Y<&A%^TAH]9<X!X_O_*>]<>MY%D3?C[^RN(=X$]W8 ;
MIWUIN[UGL8#JYM%NN:2I4KEW=C\8-)F2>)HBU;R4K?GUFYF\DQG))"56A&J
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M/+/.5\JOV!/SP[WX89%VER+G$\?W0,P=Q0S-9N.@ _%W%+,SLSH0K4<Q0TM
M=AL6S .GP 2$]68K/!=M"@N$]68K/*=J"@L$]68K-#=(=HV$^,VO;WXM! =B
M.TR!YAZP2!^ 6 ]3H+F-!@00^6$*0N[TN@ !9 $P!2%W*D$  1^F(.1.)0@@
M=,,46.YT80=_?DIM^7@NB[]^4 ?>5BLLMVD+JXZHK598[M$65AU16ZW0W*"V
MB5/XL#JJ*EJBN8-":'5$5;1$<XLH_)-%>=6#0IC?U3%4V19-VTK!U7%3V9:6
MQM6Q4MD6K5,VA!%3^"):_*X.DC !#:=I0%"'2)B AOLT( #!$B2@XTAO"@A
M" 4)Z#A2"0$(K" !'4<J(0"A%B3 <B3YEB;/4^;BZH)X]]O>L*^_JV.NLBV6
M^RB%^:B.NLJV6$ZC%EP==95M,5W%9W%9LWNQ+ASYZT=U[-508+H-!$(=@C44
MF"X$@5 '80T%ICMU#TI\5$=@6F=> -'5D9?6^19 ='7$I766Y7)K>]'.#A9K
M.?F;!>Y58.?A\Z,ZWNI(T)Q'!P,(O!H2-$?2R?0K$(<U-&A>E3TZGP^'B^A>
MU$TKALD5BW8<#1"<>RG17,P $Q"Q^RD)8P(">"\E*=_+7DWA:(!(KJ$AY6\E
M#B"BZVA(X@#"NX:&E%]5,XC%>KX/Y2$__K/'P./9R*]  C"4$2D/U",&,H;!
MC,X',9!<#&5$RJOOF9LZK:.K7U]WJ[$-Y$#*CP&, [(2-8<SP#@@2U%R(.6K
MJVW$8O'$]&48Q,Q)1=6$_,;BE7V(.=P!"4P?,U(>W(]\0++3R^R\D ](C_J8
MT?3V6V_G)8OUK1WG)968*YX=*KKX@+3*C"5-S^_1PH#\RY#E.6IA0$YFQI)T
MCR@*\48R=(DEMGG0#H #<K;A[$GW% /M=.L"GI3]N6MG0((XG#WIGJ51RH",
MTI@KZ7ZDT<68=+.7ZYGJ8DP"VL<5K8^$.RZ8O"8T"T2R**I8LL#Q6)P](/JZ
M6Y'1C!#-T_L1 7ED+R$^HMOR]>C7W8*-<&,"MJA+#N1NRL9HD@=QZB>UYZNZ
ME1K5#?%TW9:X6XT1:$A'8B /:3?$&BV+-P^+5Q#GP<K^<<_6:>!6;ZMTBS(:
MTV+YCADN=0Y@1$L:ESJ>F]"B^6%@7WCACKF>8_L/H9_*AQUO$[%/OHAL_@O^
M][)3J0/X$!YH?CD(ISJL#^)Q%CC5@7\(#W)^6V)3IP9]=.3\L\2C3AIZZ:CB
MZ9:K-*+#\K?K]9HY?-IU%7X/[D,^<J\B;[-A4?$.<+>4I0D9EK?UHE$G'GUD
M5-&HTXT>,C1/V^W]\,!8V5'4246K&9HGM:55IPCM9E2D50?Z5C-L3WA@XCU5
MWOZ"!6SM)?$R]#WGD/U_Q7XD%YSD3XY&'<X'LL'V)&.TZ@ _E,VYH%6'_X%L
ML#U97 7(=I 7Z[7G9*5>\X(K\A4EMW:S%BCB.(87MD\/PPVD$F-X8>,N,0$)
M1:L=NIU*>8&4H=V.C+SZ) '["O*U?+&%)_:U"0!02E'1%,TK5%(#&8.B*26I
M@<R@VQ3-0^H%3;*2?D"1Q6Y+-/]0R R$Z6Y+"C(7I?R .HNJMB1T7<H-1$I5
M6RRYG\0NU%4:><$F.]]0+1<#Y18U)&C:[XAT6^VK ;45=30T<0 Q5$=#!D>^
MKPQ4/(3:T[%#(3\07J'V=.2OIFI T4,=#2$[U'  \5='0Q('$),U-&A94&MJ
MUYW9%1D=4"[1F &:QYDC!(*[,0/Z"('X;\H T4M;]1RRYY<Y(B 5@ @0O1!"
M "0!( $]!$ * !'0\:(OMI_RF [48X3:T_&A0GX@_D/MR<D/Q'V@/;;_%-=$
MI3LO K8,O2!9?0]OPK0::8$4P)P%MI>9H 3*/PYA<0XHP;S E 5)C_T_+ H?
MO!\E2C W,&5!TF/;*/7Y@@F+<T"ISRD,6)#R6+'7&$@A;WB2VNB:^M3#C LI
MO]5@U6<IAES.!*L^HS'C0LN'O1]98-A&3/2Y$JD^]S'A0<M_(9P#$B*(QSG@
M!&IS#N%!RF^E;%+*.R_(^EH)=4!>!+,AY;TZM /R(PV;<T$[($^"V1#U9-[5
M1*@HL0[(EB F1+VXC71 N@0R.0^D Y(EB E1[^51XUK<SRVA#LB50"Y$_;>#
M=4"V!',Y$ZP#,B:0"UT?KN4[0!W5(3SH^F\=YZB$J<&#KN_6<8Y*E9H\2.'\
M'I;S2REO"71(E@0PH>6Y(-(A.1+ A);O@DB'Y$@0$XI(17)36QP!"KT.8$'2
M<]LHAR1'2A8DO;:-<DA:I&9!":58BBZA#<B":G2D?+..!ZC9VD='R@L;> ;D
M-'4Z)#PW7B N+5W_V+,@9O$=2S@$=;JB:(KE54JIU;F'HBF6[RBE5N<1JJ9H
M4D=Q,@L"'M*CV(X.I:.K\P*@.9ZG -*KHSW0',UCPFC'HLNMQ];M,VDE$'5
M[Z=$LX@!)G7X[J>D;"=UW#:@Q,*4!FX\#^Y9O)>7](N;;+(67ORX#_FO$B]B
MV>- 0$W.04S0/'(84G6 '\0$S4^'(07R@$%,S@,ID#L,8?(6">DG%K#(]F_+
M*S%O@**6G898_4TAL3J7Z#3$ZC>Y(-F5ES= S<E&(V3=%I*JDX-&(RR=SH,G
M%B>BU+ OWYF+\R/V\6P3,=FEB@ (U)@T9H!EBP$(U<F!,0/Z-@3J5YHSP$(8
MQZF8B2W6B\CED[+HD!W:GP5N<0C[*F4K\53.DYVPI6\[4FP^8UNL"^++,!8O
M;@(5,4_X"31//Z66U%G'"3^!UEM.J25UQG+*3YR]EHKK-4!1T)-_Z/Q[7ZDQ
M=3YV\@^=?T\L-:;."4__(72-98)(J6?)9SOZDR5YH0>-=M1YZ%%,\7O;*$T
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MD'@=RYABSS#4")"C'<N88C\QU B0PQW+F$*OR19M:]V[>(1$X 8R.3-R"CU
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M;%C@\)EMS<O@"N1F#% 1\A21W6891NQ$WEYL1-R6)4H_P+7)^TC)H<J>&OD
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MB1 1'5O4SWF\UKQA"%)1A0)G'S 5&2CY]N]KS4-^*@(ZMI"7X>7!EM>:5_(
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M)AW#.-&S- P93$@&<LH@__=_E_+=<H;_X__C_^!_BO*M_^/_ 5!+ P04
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M5:! L5WJ"0J-63)&)"NI?K%P-<&I,L1J&0U7%RL!$Z^>J>[KX4:U)TL+EM,
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MTV8/@CDT(_3% %@,[/)-FCWIK29GXB-Y[-GW0%Q$@$+2<;-F3VSYY<O?]E8
MY0GW+58?*J3+H]:HL(82DT5V,7-1>=Q<^#UO;2V7.<7'S5#9A_;)6EJOXS4$
MQ=DX-A84.&BD]%G=M'NOP'E#^M_B;?OHNQ0""VU0^8<V"5H >Q]@T3"V,3,,
M>J2FJYMV[XSTFU?7CTLG(N;G(S5;W:BX'[[Z+CSNK2"VZ; 5KZ.VJQL5NLSO
M4!']EP>O]@6P0A_Y$E ><?;&H/19W;1[AQP,_][><KG.P'S3U8TB2]H(A';@
M["B97VE-5S>'6T2Q?VI-\%P<N9\.DU]T),AR)KE=^N>$^"]Y*Z0YT<\!@R/?
MB#37]CGQ?NR D1:_=PX@T+P\TD+OS@$$AA])6LC<.>! =E=)BW8[!PB.?6/2
MPE;.@?D*SUN*Q4\]PJ+"HY="\JD/D#"<A@>AJ7] '+DE,RAZ(4"2_9\9!KT0
M)"E^U@R$'@F2=#=NAD8O),H*-W$&1H_$2K(G.D.B%](EIX<[ Z5'4B?%AYY!
MT2.AD^*ESZ#HA;#)C ,XV*EZ!P4AS"!#HT<2)S&4(0.B1V(G+58BPZ)'TF<Y
M)"-#H1=2YW$$2,9]+\1,4K!)AD OQ$M&0$L&1"]$2E;,3(9$CR3*8GA.AD"/
M!$E&\,_!W]<'.$JA1AG[O9 >:1%-&0J]$!U)P5,9 CT2& DA6AD,O9 8*P/
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M3U#?2NM0#_T0'OQQ/4'G+[!.A):BM#)R0MOUPWT 6.9V64,KMYLM[&>PWKO
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M*7KUBP1]BM'SP),5)6W/#CVZ?)#BT[A\$(^-[)=+1-TC).$?_P]02P,$%
M  @ <X(+5\MH-@C'"0  !S8  !    !E>&AI8FET7S,Q+3$N:'1M[5MK<]NX
M%?W>F?X'5)GN)C.2S:=(^35C.W;7;1I['>],VV\@<2EA0Q%:@+2L_?6]%Z0>
MEN2L(B>V.[4F$Y/ !7 !W(-S )('@W*8'_WY3XP=#( +>X77I2QS.#K8K?\V
MB7_I=-@'F4)A0+!2[;'_=/[!_I:KA.>UA?V]5VDUA*)DJ09>HF5E9-%G)UIQ
MH:7H [NZOLQD#LSS=Z(==R=TN]Y"^5,UFFC9'Y3,[?5"UF&>X_F+Q3N=VM_=
MQN&#1(D)2_JIRI4^;+W)[*_%3#G)X;"5J:+L9'PH\\D>^_%&#L&PCS!FUVK(
MBQ_;S*:TF0$MLWUFK8W\'?:8ZXS*?5;"7=GAN>P7>RR'#%-L.WOLC6-_^ZW:
M&R%OI^,TT,P6.&SA6)6@9ZXD2@O HH4J8)_5=YU$E:4:8G.C.V94+@5+<IY^
MGN67:K3'@N7, = 062?OYB[57<>B:-/7JBI$9SEKL3^U>_MLR'5?%AWJWA[C
M5:EF2;INQ::UIOW#KDY[M%B;M44K=E ='= XWIN!<>-PHG*!1F=W YG(DOGN
MCGNP2Q88;5@NT=-6=A=&E"[9%_*FX6-=2W-NS&'KY/KJ_(KWX2>,$IR#HWF(
M+78@EP5T9H.YXX7H&S;TI>R%BG;O-;Z[XLJ:4?JU,J7,)OMLM6JV;J!.SZYO
M+LXO3H]O+BX_LJM?KC_]<OSQAMU<LD]GIS;-=SQV><YN?CICGXZO3XX_GGUB
ME__Z</9O=GQZ0SF>XW@/.[?B1^OHAS=NU]E_=']:1Q=M]D^I>2$XNU$Y"%ZH
M-D:=IA*L'/!R[_%^E3S!M22%/#<CGN)2<]AR6O9^Q(68WG^;Q6 L13F@&^>O
MFZP,TU!\_^GJ_(,TY0VYVF)2'+9^A]B#!(0CW# (DBCJ=1V>IN!"U_&]((L7
MXVQA=<3^ZJ/%>TH1T^Y-_8M'91W'RZ:[I=BL-+NE64IY/NTA+D-8I;NS417U
M&K*N"K8N=EI+%3:HOF #?@M,PZV$,5'.0!KV<\4U+EKYA%W#2.F2J8*=*SW$
M2>G\C#.FT0Q8)@TVS'ZKC1D4 LO_O2H T=*N&45E[(R6/\Y.I&(?2K&S%%D/
M#!DFZ#5S@\DTN_^/H>QQ3\1^X$0014&60"\)W2 .!/=[:9*$O9<9RMY3AO()
M)\V$H3J<L,^%&N-:V(=V'=&ZCF.A< (+A;H)IXK+@O%BPJJBU!6@2ZBDK*C"
MJ.5(SABW$N,[XRDF:::&2*6EJNU6# I(P1BN)V0RY)_!0F16I\$T@<Y@D[G5
M7=@&&:12HY)#LP*+HR?(HFP\D.F F8K^FY<?@X:F$NS \@ P-I0F1Q8F&3B6
MY0![;$:06H^IH1'ZJ@3V&T<91RF9+([+*RBW Z43\:07<>$DGA] -XGC+ L#
M$21NYH 7OU!0^B\"E,0?!88](6@>YFU$))ICME[(EP5R#N)-8CVR2/.*F :A
MM!#";82A),8:8> 3B G<>3Y':8,'L]0T+@1"4L5MLJAR-$!H*H2+;<Y8?U)N
M!BS+U=A,<:NAC[& JJMDG!*MWZN@1+?;"_ S4^]6W']%X'8(3+G3BQW?3S*4
M>#Z/X\AU_31$G1=ZD1<D+Q.!P5,B\.9>N/[P)O;<:-\T&&OV"<0:*LLDWMJ
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MK.JF^='!KODDR!XTGS?]'U!+ P04    " !S@@M7/\^I4_<$  #Y%   $
M &5X:&EB:71?,S(M,2YH=&WM6%MOVS84?A^P_W"F8&T"6+8DWR\QX+C.FBV+
M4]L%MKU1(F5SI465HAJ[OWZ'DA6[MM.E;=9B0/4B\?#<^1V2.KV%7HK^CS\
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MX-:Y:Z]];OLS_G0QB'>W[J#QTLWX]\M7ZPT/&"\*(GOYV;55TWFQ[*GJ8F+
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MCKPYTAD08J'/P]-HX6DH^+$-\8*;F[KWML?A#28R1[\R=0-3@SW'"Q_,*IA
M=M.BBYO]M&1%4J16XV33$O+9+;F!_VNU3S8M,>/=DG@9\YFB-)4VG^-N]1QG
MCK2;N8T5RGO,EI;V3]68(^_RK64/D?VFCY&S'08RG7M3$@295P1>%J6G(_/E
M04LBY[LD6)(T,?<^L;%2VQ%,RI35@T5H"GQ#459G>VI@RVO+FX+4%)NLS5;,
M:V]EOM$4GXX,@\=']V"V8@,O(QN@3S\;S*BMTWU']EAWD):X& 'PY[4L+5G
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M=F6B\J)CJL:'HU.)$_(<84HO&Y#<\X"<N;%JV52( 05V752Y$A:F*VDS]TG
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MZ_9X/B7@,$947!@^>^D>/FY 4@)MA#ZM,:9O^C",!?,0[#E*/[XDX0AU$%&
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M8B17O,@6'=159E!9@+/=+"H+$I_43$?F^>2$DL;ZL]WQ9F$1-^]1K+A:JU&
MPAM0\AZ@&: 9H/F8T!RSXU)!<Y:!.$FNG/E6W! =$Q4XMO4T*RT\Q,:WFUT:
M*7*?> C89ZGBG 6&7'PHBE"YK6=Z<$"7&7EF\T_?/X7O=;8B[+P\FF-(9F_A
M_>6//FU)B>";?[WXNHADA .GF2R<$:K&J63CK(*N3Q8'=^Q$TSQ(>9-E*/%-
M2<"&H22W6DNV7L1@;"0:C**0;# JZPQ&,5XY=TW@[TAM3R1A>U>T,IF"@"*
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M7;#,\"I@(&!@4=EQ-+$1 EP\_494 Q?I&".YAJ#L'A/HQ8*#^]X<?WJ+>SL
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M R_'Z"/4[ '[KE#V'9S<@_AP^OAPOSL*%X<<XX.C>F5)*%M1A&2L"&G6_-E
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MF;W-&5HT6JHB'N=.35L<#1V\"<3EKAH[^ .+.=69JFMUW2S]/,?J3'?WVT^
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M,!R0C8<CBUAH9,D_I--NM0!L8#@ -@>#3?.)%#HI,MBP$RNJ .)4]=U@_R0
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M0/TP'!"#!XO!-16ZM\7E=I6#Q\AFE&MMA0>Q",,!8#@4&-;7X\X<&%A+2JP
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MS:?#DV)\#KG%?-'SJ7SP<FU-IY8Y=*WQGT?*A=E^U)<]!\Z122W@(W_B #
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M"!,X, $Y<=XUT06FBV#&TYU%ST""GH* M2T3S4-\;;P@Q B-#ZD5P T]RYV
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M1> IR(<)6C/,&^]=[R>!CO$BZ4OPW' X8N3 ,X*K:N(/]QY>Z)&E!$NQ$,%
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M;FD7<BSS-J2&))UJ:..9^WO #?V$%]+RB6^'B9R='AJ#**<<8-UTN991K)\
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M/*$<GE .3TB?6NX_Y?"$-0U/>/K4!%#!&\?-DT:G?AQ5AZ)N\?$FG$QLTFC
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ML4LLVBHLFILWOMU85*:/KRU]7%DF"]/')VS'E(GC99+P*SZ7$B?*Q/&%(K]
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M>T- :+!$ ]U(XY/6'4?>_FXX(2X"<W<K$;AT&RA-D=R$32_>T$O?WXO6KE*
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MT<'0CDR//4W$=J(I9*0G18H;)YNU(^<:\VIVJYG,=E(^KRCJY#K,\%/#?^,
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MU"4?.4:8HK8UE-F&81H,DP&Y6]C$.G)>1J7,VE&;KKC.#TE9 ]U[R>-Y8TG
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M(35:#5+;0+!8N!,75@^OP5E5EA.X^WLY+ZFM'H$WPIRR=R4(/LL3>*;N_AY
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M2\1[8&U@G%2 V4K/M-@N<0F.3)CWAN=%YDMF>427EQX\W_"FX@8M*'C6Q),
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MA\!I7L88$)B-1A!3% CL1U!UPP XI@H?1K([MO9F *,%*5PS!T;J-.B!@S!
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M#3WK\;>?+)+0WQ7M7"L.QUP5*UI1^]][,[8NL+9^+Y+2MK1^DS&L4!_<]KQ
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MKOP ^=+ID^@,)HHC%@?.&/T?GR'^[KF#U]_AS^'XR?F=_0M02P$"% ,4
M" !S@@M7Q$;%N:42  !CR0  $0              @ $     96YT>"TR,#(S
M,#8S,"YX<V102P$"% ,4    " !S@@M7*2-H5&L)  "\>0  %0
M    @ '4$@  96YT>"TR,#(S,#8S,%]C86PN>&UL4$L! A0#%     @ <X(+
M5TL6141+#@  _]$  !4              ( !<AP  &5N='@M,C R,S V,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( '.""U?X<SPB,]   #::"P 5
M  "  ? J  !E;G1X+3(P,C,P-C,P7VQA8BYX;6Q02P$"% ,4    " !S@@M7
MO1^,D7TC  #&5@( %0              @ %6^P  96YT>"TR,#(S,#8S,%]P
M<F4N>&UL4$L! A0#%     @ <X(+5\MH-@C'"0  !S8  !
M ( !!A\! &5X:&EB:71?,S$M,2YH=&U02P$"% ,4    " !S@@M7].E_#J0)
M  #G-   $               @ '[* $ 97AH:6)I=%\S,2TR+FAT;5!+ 0(4
M Q0    ( '.""U<_SZE3]P0  /D4   0              "  <TR 0!E>&AI
M8FET7S,R+3$N:'1M4$L! A0#%     @ <X(+5Y*ZY6,J!0  )18  !
M         ( !\C<! &5X:&EB:71?,S(M,BYH=&U02P$"% ,4    " !S@@M7
M[Q";:)3I   :7 T #0              @ %*/0$ >FLR,S,P,3 V+FAT;5!+
4!08     "@ * 'X"   ))P(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
